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Abstract 
 Histamine is a very important biological amine that plays a key role in several 
biological events such as immune response, gastric system modulation and also as a 
neurotransmitter in the central nervous system. However, there are some disorders 
associated with an overproduction of histamine, and, consequently, several inhibitors for 
histamine action have been studied and developed in order to treat them. Among all 
histamine-related diseases, we can highlight allergies, atopic dermatitis, and cancer. 
Since the in vivo production of histamine is catalyzed by Histidine decarboxylase (HDC), 
in this work, we studied the catalytic mechanism of this enzyme using computational 
means. 
 HDC is an enzyme that requires pyridoxal-5´-phosphate (PLP) as a cofactor. This 
enzyme belongs to the group II of PLP-dependent decarboxylases together with L-DOPA 
and glutamate decarboxylases, and catalyzes the L-histidine decarboxylation from which 
results histamine and carbon dioxide.  
 In this work, we studied the catalytic mechanism of HDC by computational 
approaches using the recent X-ray structure of HDC (PDB code: 4E1O) and an ONIOM 
QM/MM methodology. The QM part was calculated using DFT method (B3LYP with the 
6-31G(d) basis set for geometry optimizations and the M06 functional with the 6-
311++G(3df,2pd) for single point energy calculations), whereas the MM part was 
considered under MM approach using the GAFF and ff99SB force fields amongst other 
parameters determined by us.  
 The results showed that experimental data does not always give accurate and 
full information about the structure of biomolecular complexes. Therefore, computational 
methods are important techniques to test and complement these results. In the particular 
case of this work, an inhibitor was co-crystallized with the enzyme, but, apart from its 
similarity with the natural substrate, several issues were founded in the structure from 
PDB file that prevents the reaction to occur with acceptable energetics. During this work, 
we proved that such orientation of the external aldimine inside the active site is not 
suitable for catalysis under physiological conditions and that a different conformation 
needs to be taken into account. All the obtained results are consistent with the available 
experimental kinetic results. Then, we confirmed a two-step type of mechanism for the 
reaction catalyzed by the HDC. The first step involves a decarboxylation of the external 
aldimine (PLP cofactor bonded to the substrate), and it is followed by the formation of a 
stable carbanion (quinonoid intermediate). This is the rate-limit step, since the activation 
barrier is 12.70 kcal/mol, and it is also an endergonic step (∆Gr = 10.52 kcal/mol). In the 
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second step, the quinonoid intermediated is protonated by Tyr-334B from which results 
histamine. This work proposed for the first time which amino acid residue from the active 
site was the one involved in this protonation stage. This step is faster than the first one 
(Ea= 2.87 kcal/mol) and, in contrast, is a high exothermic step (Er = -26.02 kcal/mol). 
 This work allowed a fully atomistic description of the catalytic mechanism of HDC, 
elucidating about the important role played by several amino acids from the active site, 
namely, Asp-273A, Lys-305A, Tyr-334B, His-194A, Ser-304A, Thr-248A, Asn-302A, Tyr-
80A, Ser-354B. This data can now be useful for the development of new drugs to treat 
histamine-related diseases. Additionally, the importance of the computational means 
was consolidated once again, becoming a stronger approach to test and validate 
experimental data.   
 
Keywords 
Histidine decarboxylase, pyridoxal-5’-phospaphate (PLP), L-histidine, histamine, 
catalytic mechanism, quantum mechanics, hybrid QM/MM methodologies, ONIOM, 
enzymatic catalysis, density functional theory (DFT) 
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Resumo 
 A histamina é uma amina que desempenha um papel importante em diversos 
fenómenos fisiológicos tais como a resposta imunitária, a modulação gástrica, atuando 
também como neurotransmissor no sistema nervoso central. Porém, existem várias 
doenças associadas a uma produção excessiva de histamina e, por isso, são vários os 
inibidores que têm sido estudados para atenuar os efeitos provocados por  estas 
concentrações anormais de histamina nas células. De entre todas as doenças 
associadas a esta disfunção fisiológica, podemos destacar as alergias, a dermatite 
atópica e o cancro, como as mais preocupantes. Como a produção de histamina é  
catalisada pela Histidina descarboxilase (HDC), este trabalho foi focado no estudo do 
mecanismo catalítico desta enzima,.  
 A HDC é uma enzima que usa o piridoxal-5’-fosfato (PLP), a forma ativa da 
vitamine B6, como cofator. Esta enzima pertence ao grupo II das descarboxilases que 
usam o PLP como cofator, juntamente com a L-DOPA e glutamato descarboxilases. A 
HDC é uma enzima muito específica que catalisa a descarboxilação da L-histidina, 
originando histamina e dióxido de carbono. 
 Neste projeto, estudámos o mecanismo catalítico da HDC usando como base a 
única estrutura da HDC disponível experimentalmente (código do PDB: 4E1O). Para 
este efeito foram utilizados métodos computacionais nomeadamente os métodos 
híbridos de QM/MM usando um esquema subtrativo (ONIOM). A parte QM foi calculada 
usando a teoria do funcional de densidade, o funcional B3LYP e a base de funções 6-
31G(d), enquanto que a parte MM foi calculada por mecânica molecular com recurso 
aos campos de forças GAFF e ff99SB, mas também aos parâmetros que foram 
determinados por nós neste trabalho. 
 Os resultados mostraram que os dados experimentais nem sempre são perfeitos 
e podem dar informações incompletas acerca da estrutura de complexos 
biomoleculares. Por isso, as técnicas computacionais são uma excelente ferramenta 
para testar e complementar os resultados experimentais. No caso particular deste 
estudo, um inibidor foi co-cristalizado com a enzima, mas, apesar da sua similaridade 
com o substrato natural, os resultados computacionais mostram que a conformação 
adoptada por este e subsequente modificação pelo substrato natural impossibilitavam a 
reação em meio fisiológico. Consequentemente, durante este trabalho, esta estrutura 
foi sequencialmente modelada de forma a obter um modelo que fosse consistente com 
os dados cinéticos obtidos por técnicas experimentais. Após as devidas correções ao 
modelo, foi possível confirmar um mecanismo catalítico de dois passos para a reação 
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catalisada pela HDC. O primeiro passo envolve a descarboxilação da aldimina externa 
(o cofator de PLP ligado ao substrato), que origina um carbanião altamente estabilizado 
pelo cofator (intermediário quinonóide). Este é o passo limitante da reação, uma vez que 
a barreira de ativação é de 12,70 kcal/mol, e se trata de uma reação endergónica em 
10.52 kcal/mol. Durante o segundo passo, o intermediário quinonóide é protonado pela 
Tyr-334B, formando-se a histamina que é o produto final da reação. Este passo é 
consideravelmente mais rápido que o primeiro (Ea = 2,87 kcal/mol) e, em contraste, é 
altamente exotérmico (Er = -26,02 kcal/mol). 
 Este trabalho permitiu também obter uma descrição atomística do mecanismo 
catalítico da HDC, revelando quais os resíduos do centro ativo que têm um papel 
determinante para a catálise. Estes resultados podem agora ser úteis para o 
desenvolvimento de novos fármacos que possam ser usados na terapêutica de doenças 
relacionadas com a produção de histamina. Além disso, este trabalho corrobora a 
importância dos métodos computacionais, uma vez que se tratam de uma excelente 
ferramenta para complementar os dados experimentais e que permitem também muitas 
vezes corrigir conceções incorretas, promovidas por estes, tal como aconteceu neste 
caso em particular.   
 
 
Palavras-Chave 
Histidina descarboxilase, piridoxal-5’-fosfato (PLP), L-histidina, histamina, mecanismo 
catalítico, mecânica quântica, métodos híbridos QM/MM, ONIOM, catálise enzimática, 
Teoria do Funcional de Densidade (DFT) 
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Preamble 
 
 This dissertation is composed of four major chapters and four appendices: 
 
A. Introduction 
A brief description of Histidine decarboxylase and PLP-dependent enzymes is 
presented. In this chapter, it will be described some available details about the catalytic 
mechanism, the gene regulation, the protein maturation, mutagenesis studies, test of 
inhibitors and biological relevance of Histidine decarboxylase. Additionally, a brief 
description of PLP-dependent enzymes, and PLP as cofactor will be included.  
 
B. Theoretical Background 
A short review of the theoretical methods used during this project is described. 
Particular attention is given to molecular mechanics, quantum mechanics, and hybrid 
methodologies. 
 
C. Results and Discussion 
The obtained results will be chronologically presented in this chapter, as well as, 
some insights about the methodologies that were applied along the work that was done. 
The first section is about the results associated to the molecular dynamic simulations. 
Then, the QM/MM results will be presented, as well as, all the required modification to 
the PDB file, aiming to model, as accurately as possible, the catalytic mechanism of 
mHDC. 
 
D. Conclusions and Future Perspectives 
This final chapter will present the major conclusions of this work, and the relevant 
contributions for the advances in the knowledge provided about Histidine decarboxylase.  
  
E. Bibliography 
List of all bibliographic references used along the dissertation. They are sorted in 
the order they appeared in the text.  
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F. Appendices 
Four appendices were attached to this dissertation: 
 
1. Detailed Information about the molecular dynamics simulations 
In this section, a more detailed information about the methods and the structure 
of Histidine decarboxylase will be presented resorting to the molecular dynamic 
simulation. 
 
2. Book Chapter 
A book chapter about PLP-dependent enzymes and their importance in the 
cancer treatment was written during this project. The book chapter, entitled “Cancer 
therapies based on Enzymatic Amino-Acid Depletion”, was already accepted for 
publication in the multi-volume SET (I-V) “Therapeutic Nanostructures” - Elsevier. 
 
3. Conference Presentations 
This section includes all the contributions of this work to conference presentations 
(posters and oral communications). 
 
4. Non-academic work 
During this project, an education game was developed in order to explain, in a 
playful way, the importance of the drug development in the treatment of different 
diseases. Furthermore, the TCL scripts that were developed to handle with Gaussian 
input and output files will be described.  
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A. Introduction 
 
 
 
 
It is health that is real wealth and not  
pieces of gold and silver. 
Mahatma Gandhi 
  
2 FCUP 
Computational studies addressed to Histidine decarboxylase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This page was intentionally left blank. 
  
FCUP 
Computational studies addressed to Histidine decarboxylase 
3 
 
1. Histamine 
Histamine is a very important biological amine (Fig. 1) that plays an important 
role in a variety of reactions in vivo such as: dilatation in the cardiovascular system, 
contraction of smooth muscle, regulation of gastric acid secretion [1, 2] and a 
neurotransmitter in the nervous system [3, 4]. Moreover, histamine is also important in 
the immune response against pathogens, where it triggers an inflammatory process that 
increases the capillary permeability to leukocytes. [3, 4] 
 
 
Fig. 1 – Structure of histamine. 
 
In mammals, histamine is predominantly produced in the immune system by mast 
cells and basophils. It is also produced in the central nervous system (CNS) by the 
tuberomammillary nucleus of the posterior hypothalamus, and in the stomach by 
enterochromaffin-like cells (ECL). Once produced, it is often stored in fast or slow 
renewal granules. The slower process is generally associated with immune response 
events, where histamine is slowly stored in secretory granules of mast cells and 
basophils. [5, 6] The slower storage prevents exuberant and exaggerated inflammatory 
responses that could injure the tissues.  
The fast renewal occurs in the granules of gastric cells and mainly in the neurons 
because they are frequently stimulated and require a higher supply of histamine. [5, 6] 
Contrarily to what happens in the immune system, the exaggerated histamine release in 
the CNS is not a problem since, once it is released, it is limited to the synaptic cleft where 
it is rapidly degraded. 
The release of the stored histamine occurs through immunological dependent or 
independent processes. The associated immune process is the most relevant one, and 
it is triggered by the antigen-IgE (Immunoglobulin E) interaction, leading to a mast cell 
or basophil degranulation. The independent process, i.e., from a mechanical or chemical 
stimulus, occurs through the degranulation of histaminergic neurons and ECL cells. [7] 
Histamine can also be produced and be rapidly released from the cell in response 
to an extracellular stimulus. This histamine, also called induced or nascent histamine, 
plays an important role in the cell growth [2], in the platelet aggregation [8], and in the 
4 FCUP 
Computational studies addressed to Histidine decarboxylase 
 
gastric acid secretion [2, 9]. Furthermore, this type of histamine is believed to act soon 
after its synthesis at the site or in the cell where it is formed. [2]  
Once released (Fig. 2a), histamine has a limited time of action. It is rapidly 
degraded by histamine N-methyltransferases (HNMT) and diamine oxidase (DAO) (Fig. 
2b) into methylhistamine and imidazole-4-acetic acid, respectively, whose metabolic 
products are excreted in the urine (Fig. 2c). [7] Interestingly, histamine release is 
accompanied by an autacoid effect that not only affects the cell that produces it but also 
the adjacent ones.  
 
 
Fig. 2 – Histamine release, receptors activation, metabolism, and excretion. 
 
 
 
1.1. Histamine Receptors 
Once histamine is released, it triggers a variety of receptors on the neighbor cells. 
There are four G-protein-coupled receptors in the cells, called H1, H2, H3, and H4, that 
are activated depending on histamine availability. The H1 receptor is associated with a 
Gq/11 protein, which activates the phospholipase C (PLC), increasing the intracellular 
concentration of inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). The IP3 binds 
to the calcium channels in the endoplasmic reticulum (ER), increasing by this way the 
calcium concentration in the cytosol. [10] Consequently, the NF-κB transcription factor is 
activated and induces the expression of immune response-related genes [11] and also 
nervous system plasticity related with memory and learning [12]. The consequences of 
this cascade of events, triggered by the H1 receptors activation, are bronchoconstriction, 
capillaries dilatation, an increase of the vascular permeability and afferent neurons 
sensitization. [7] 
The H2 receptor triggers a Gs protein that activates adenylyl cyclase and thereof 
increases the intracellular concentration of cAMP. This process activates several other 
Mast Cell
Target Cell
Granules
Histamine
Imidazoleacetic
acid
Histamine Receptors
HNMT
DAO
Imidazoleacetic
acid riboside
methyl-histamine
methyl-Imidazoleacetic acid
Ribose conjugation
Monoamine Oxidase
Kidney
ⓐ
ⓑ
ⓒ
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enzymes that stimulate the gastric acid secretion, the cytokines production, the T-cell 
proliferation and vasodilatation. [7] 
Both H3 and H4 receptors activate a Gi protein that decreases the intracellular 
concentration of cAMP. This means that their activation inhibits the effects triggered by 
the H2 receptor. [7] Among these two receptors, the H3 receptor plays a major role in the 
CNS since it is essential to control the circadian rhythms. This receptor initiates a 
negative feedback mechanism forcing histamine release reduction. The functional role 
of the H4 receptor is still not clear, although its expression has been reported to be 
specifically associated with the human bone marrow and colon and it could also be 
involved in the immune response. [13] In contrast, the H1, H2, and H3 receptors are 
ubiquitous in different tissues, including the CNS. [13, 14]   
 
 
Fig. 3 – Overview of intracellular pathways triggered by histamine receptors. Red circles represent histamine 
molecules in the extracellular environment. 
 
 
 
2. Histidine Decarboxylase (HDC) 
The production of histamine occurs by decarboxylation of L-histidine, a reaction 
that is catalyzed by the Histidine decarboxylase (HDC) (Fig. 4) [7, 15, 16]. This enzyme 
catalyzes the reaction with a rate of 1.73 ± 0.07 s-1 and has an enzymatic efficiency 
(kcat/Km) of 17.3 ± 1.9 s-1 mM-1. [17] 
HDC activity is dependent on the presence of a cofactor in the active site of the 
enzyme that in mammals (mHDC) is the pyridoxal-5'-phosphate (PLP) and pyruvic acid 
in bacteria (Fig. 5). [18-21] Since in this work we are going to be focused on the mHDC, 
only PLP-dependent enzymes will be described. 
 
H1
H2
H3 H4
Gq/11
Gs Gi
Gi
⬆IP3 AdenylylCyclase
⬆[Ca2+]cytosol ⬆[cAMP]
Adenylyl
Cyclase
⬇[cAMP]
NF-κB
6 FCUP 
Computational studies addressed to Histidine decarboxylase 
 
 
Fig. 4 - Reaction catalyzed by HDC. 
 
PLP is the active form of the vitamin B6 (Fig. 5), and it is used as a cofactor by 
more than 140 distinct enzymes, corresponding to more than 4% of all classified 
enzymatic activities. [22] PLP-dependent enzymes play a crucial role in several 
metabolic pathways involving amino acids, and catalyze a variety of different chemical 
reactions, including α-decarboxylation, transamination, aldol cleavage, racemization, β- 
and γ-eliminations and replacement reactions. [23, 24] 
 
 
Fig. 5 - Wedge-Dash representations of the PLP, vitamin B6, and pyruvic acid. 
 
Among the PLP-dependent decarboxylases, four evolutionary origins are 
distinguished in four different families, according to their divergent evolution. Family I 
includes the glycine decarboxylase that is a component of a multi-enzyme system. [25] 
Family II includes mHDC (EC 4.1.1.22), L-DOPA (L-3,4-dihydroxyphenylalanine) 
decarboxylase, also known as Aromatic-L-amino-acid decarboxylase, (AADC) (EC 
4.1.1.28) and the glutamate decarboxylase (GAD) (EC 4.1.1.15). [26] Family III only 
contemplates prokaryotic decarboxylases, namely the ornithine and lysine 
decarboxylase likewise the biodegradative arginine decarboxylase. Family IV includes 
the eukaryotic arginine and ornithine decarboxylases as well as the prokaryotic 
biosynthetic arginine and diaminopimelate decarboxylases. [25] 
In this work, we will only be focused on family II of the PLP-dependent 
decarboxylase, because it is where mHDC belongs to. From the enzymes present in this 
family, AADC is the most promiscuous enzyme because it can catalyze the 
decarboxylation of L-DOPA, 5-HTP (5-hydroxytryptophan), L-phenylalanine, L-histidine, 
L-tyrosine, and L-tryptophan. Both, the mHDC and the glutamate decarboxylase are 
CO2
Vitamin B6 Pyruvic acidPyridoxal-5'-phosphate (PLP)
C8
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highly specific since they only catalyze the decarboxylation of L-histidine and L-
glutamate, respectively. Moreover, animal models showed that mHDC was the main 
enzyme responsible for histamine biosynthesis in vivo. [27] 
Apart from the different biological roles assigned to these decarboxylases and a 
lower homology between HDC and other enzymes from family II (Table 1), the structure 
of the active site is interestingly similar among these enzymes (Fig. 6). The major 
disparities in their sequences are located in the region of the binding site that interacts 
with the imidazole group of the substrate (Fig. 6 Right Bottom), so those differences 
should be correlated with their specificity. Fig. 6 only shows Tyr-334B and Leu-335B 
from HDC without the correspondent amino acid residues from AADC and GAD. Indeed, 
this tyrosine residue is also present in AADC and GAD, but the its-containing loop was 
not crystallized for AADC, and it is displaced from the active site in the GAD. GAD has 
the tyrosine-containing loop away because the PDB file presents a structure with the 
internal aldimine (IA), and it was described that the flexible loop only approximates to the 
active site when the external aldimine (EA) is formed. This information also explains the 
displacement of Leu-435B from GAD, since it belongs to the same flexible loop.  
In sum, this evidence indicates a possible common catalytic mechanism for all 
PLP-dependent enzymes from family II, pointing the structural differences of the active 
site as specificity regulators. 
 
Table 1– Summary of all PDB structures available for family II of PLP-dependent decarboxylases from 
mammals. Homology percentage of AADC and GAD comparatively to HDC (human sequences). 
 
 Structures 
Homology3 
Enzymes Apoenzyme (open) 
Apoenzyme 
(close) IA 
Gem-
diamine 
EA-
Inhibitor 
HDC - - - - 4E1O[17] N.A. 
AADC 3RBF[28] 3RBL[28] 3RCH[28] 
3RCH[28] 
1JS61[29] - 1JS3
1[29] 52% 
GAD - - 
3VP6[30] 
2OKJ[31] 
2OKK2[31] 
2OKJ[31] - 29% 
 
1 No structural information about the loop (amino acid residues: 327 to 338)  
2 Containing only one subunit 
3 Homology was determined using the amino acid sequence of HDC as a reference. 
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Fig. 6 – Structural comparison between all the PLP-dependent decarboxylases from family II.  
(Left) NewCartoon representation of HDC colored by homology with AADC. VDW representation of the external aldimine 
with an inhibitor (histidine methyl ester). (Right) Overlap of the active site from HDC (gray), AADC (yellow) and GAD 
(green). CPK representation of the external aldimine with the inhibitor. *Amino acid residues are not showed because 
they belong to a flexible loop which was far away from the active site. 
 
Taking into account all the available crystallographic structures of the PLP-
dependent decarboxylases from family II, the only one available for mHDC is the best 
one. It contains the complete structure of the enzyme co-crystallized with the external 
aldimine that involves an imine linkage between the PLP cofactor and an inhibitor 
(Histidine methyl ester - HME). Moreover, HME is a methylated derivative of L-histidine 
(natural substrate), which helps the construction of the model system of the wild-type 
enzyme with the natural substrate. 
 
 
2.1. mHDC Gene 
Structural analysis of the HDC gene revealed that the human gene is composed 
of 12 exons spanning approximately 24 kb (kilobases) [32] and located on chromosome 
15 [33]. Moreover, DNA analysis revealed a unique copy gene for HDC. Exon 1 contains 
the 5’-untranslated region, the translation initiation codon, and the coding region for the 
first ten amino acid residues of HDC, whereas almost half of the enzyme mRNA 
sequence is encoded by the exon 12, including the 248 carboxyl-terminal amino acid 
residues. The heterogeneity of the isoelectric point of the enzyme might be due to post-
translation modification of the enzyme. [32] Four copies of the GATA consensus 
sequence were found in the promoter region of HDC gene. [32] Also four GATA-binding 
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proteins (GATA-1, -2, -3, and -4) have been characterized [34, 35], and GATA binding 
proteins were found to be expressed abundantly in several mast cell lines through an 
electrophoretic gel mobility shift assay. [36] 
cDNA analysis revealed that the calculated molecular weights of the rat, mouse, 
and human histidine decarboxylases (hHDC) deduced from the nucleotide sequences 
are significantly larger than those determined for the purified proteins, suggesting that 
primarily translated products are post-translationally processed to yield mature active 
enzymes. [32] 
Expression of HDC is regulated by several different stimuli, including gastrin [37], 
phorbol ester 12-myristate-13-acetate [37], oxidative stress [38], thrombopoietin [39], 
and Helicobacter pylori infection [40].  
Cell stimulation with either gastrin or phorbol ester 12-myristate-13-acetate is 
known to increase the phosphorylation of extracellular signal-regulated kinases (ERKs) 
and increase ERK activity. Not unexpectedly, the overexpression of Erk-1 and Erk-2, or 
activation of endogenous ERKs using activated MEK-1 (ERK kinase-1), stimulate HDC-
promoter activity. Additionally, gastrin regulates HDC transcription in a Raf-dependent, 
Ras-independent fashion through activation of the ERK-related pathway. [13] 
HDC gene expression varies with time during the day and selectively deleting the 
Bmal1 clock gene from histaminergic neurons removes this variation, producing higher 
HDC expression and brain histamine levels during the day. The consequences include 
more fragmented sleep, prolonged wake at night, shallower sleep depth, increased 
NREM-to-REM (Non-rapid eye movement sleep to rapid eye movement sleep) 
transitions, hindered recovery sleep after sleep deprivation, and impaired memory. The 
local BMAL1-dependent clock directs appropriately timed declines and increases in 
histamine biosynthesis, by HDC gene expression, to produce an appropriate balance of 
wake and sleep within the overall daily cycle of rest and activity specified by the 
suprachiasmatic nucleus. [41, 42] 
Also, epigenetic patterns were described as been an important regulator of HDC 
expression, once DNA demethylation by 5-azacytidine induces high expression of HDC 
mRNA. [13]  
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2.2. mHDC Structure 
The structure and function of mHDC are the less described in the literature 
comparing with the other decarboxylases from family II, such as AADC. Nonetheless, 
some works have reported certain similarities between some of mHDC and AADC motifs. 
[43, 44] 
mHDC is firstly translated into an insoluble form with a size of 74 kDa (Fig. 7a), 
but a 54 kDa form has also been identified. This size difference is caused by a post-
translational process (Fig. 7b) induced by a sequence of amino acids denominated as 
PEST regions that are rich in proline, glutamic acid, serine, and threonine. The PEST 
sequences are intrinsically associated with a short half-life time of proteins, and they act 
as peptide signals for protein degradation. [45, 46] In the case of mHDC, it has two PEST 
regions. One is located near the N-terminus (between the amino acid residues 40 and 
70) and another in the C-terminus region, after the amino acid residue 503. [43] The C-
terminus PEST region triggers the proteolytic activity of this region promoting the 
monomer maturation (Fig. 7b). This proteolytic maturation converts the 74 kDa form into 
the 54 kDa monomer. [43] After this maturation, another PEST sequence remains in the 
protein indicating a short half-life time for this protein, once it can initiate the protein 
degradation (Fig. 7c). In fact, the 54 kDa form of the mHDC indeed has a short half-life 
time of 50 to 100 minutes. [26] 
Both forms of the enzyme possess the same histamine synthesis capability, and 
a hypothesis was described to explain the existence of both forms. Yatsunami’s group 
proposed that the 74 kDa form bind to the cell membrane and promptly responds to 
signals from the extracellular environment, whereas the 54 kDa form is dispersed along 
the cytosol. [47] The Yatsunami’s hypothesis indicates that the 74 kDa form is 
responsible for the newly formed histamine, once it is suitable to respond easily to an 
extracellular stimulus (Fig. 7d). On the other hand, the 54 kDa form is a soluble form that 
produces the stored histamine (Fig. 7e). [47] 
Subsequent studies in RBL-2H3 (basophils cell line) cells demonstrated that the 
degradation of the 74 kDa form of mHDC is an ATP-dependent process, under the 
ubiquitin-conjugated pathway, and it is sensitive to proteasome inhibitors (Fig. 7b). 
These results, together with the significant activity of proteasome in RBL-2H3 cells, 
demonstrated that the 74 kDa form is a short half-life protein because of its rapid 
degradation via the proteasome pathway (Fig. 7b). When compared to the 74 kDa form, 
the 54 kDa form seems to be relatively stable. In contrast with previous studies [47], the 
74 kDa form is localized primarily in the cytosol, whereas the 54 kDa form is mostly 
located in the endoplasmic reticulum, Golgi apparatus, and granules. [48, 49] Tanaka’s 
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work completes Yatsunami’s hypothesis once it revealed that the 74 kDa form may have 
a function in the production of cytosolic histamine that is spontaneously released (Fig. 
7d) or transported to histamine-containing granules for storage (Fig. 7f) Whereas the 54 
kDa form is convenient to synthesize directly granular histamine (Fig. 7e), which is stored 
and released in response, for example, to a receptor-mediated immune reaction (Fig. 
7g). [48] 
 
 
Fig. 7 – Schematic representation of the mHDC synthesis and post-translational processing. 
 
The first and, until now, unique experimental mHDC structure was obtained in 
2012 by Yoshiki Higuchi’s research group. It was necessary to make a double mutation 
at C179S and C417S (PDB equivalent to C180S and C418S) to prevent nonspecific 
protein oligomerization, which was found to turn difficult the structure determination by 
X-ray crystallography. [50] The wild-type enzyme and the double mutated form showed 
similar Km and kcat values, indicating that the mutation of these two cysteine residues on 
the protein sequence did not affect enzyme activity. [17] Structure information was 
deposited into the Protein Data Bank with the PDB code 4E1O, and contains three 
dimers with the PLP cofactor and a histidine derivative inhibitor, the histidine methyl ester 
(HME), bounded in the active site of each monomer. The two active sites are placed in 
the interface of the two subunits, and they are composed of amino acid residues from 
both monomers (Fig. 8). [50]  
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Fig. 8 – Structure of mHDC dimer and the external aldimine of each active site. 
 
Each subunit is composed of 477 amino acid residues comprising the post-
translational form of the mHDC (54 kDa form). The subunit could be divided into three 
structural domains: an N-terminal (2–71), a large (71–371) and a small (372– 477) 
domains. The large domain is connected to the small domain by a long α-helix. The 
dimer interface is formed by the N-terminal and large domains, producing a stable 
dimeric structure. The N-terminal regions of each monomer are mainly hydrophobic and 
are located at the dimer interface. The large domains are exposed to the solvent and 
point to the opposite direction of the dimer interface. [17]  
 
 
2.3. Catalytic Mechanism 
The catalytic mechanism of mHDC can be divided into three main stages: the 
PLP activation, the transimination, and the decarboxylation. The first two stages are 
common among all the PLP-dependent enzymes, and only the last one is specific to 
each enzyme. 
 
2.3.1. PLP Activation and Transimination Mechanisms 
All known PLP-dependent enzymes follow a common set of initial steps which 
activates the enzyme through the formation of an internal aldimine (IA). In such state, 
the PLP cofactor becomes bonded to an active site lysine by a covalent bond (Fig. 9).  
Subunit ASubunit B
Active Site
Active Site
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Fig. 9 – Schematic representation of the currently accepted mechanism for the internal and external aldimines 
formation. [51, 52] 
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The fixation of the cofactor to the enzyme is mediated by an imine bond that is 
established between the ε-amino group of the lysine residue and carbon C8 of PLP (Fig. 
5). In this process, one water molecule is released. [52, 53]  
Once the internal aldimine is formed, the enzyme is activated, and the 
decarboxylation process can take place. If the substrate is available (for example 
histidine), it binds to internal aldimine and forms a gem-diamine structure. Then, one 
proton from the imine group of the substrate migrates to the imine group of the lysine 
leading to the dissociation of the active site lysine. At the end of this process, the 
substrate becomes bonded to the PLP cofactor through an imine bond. This intermediate 
is often called external aldimine (EA), but as in the PLP mechanisms, there are several 
different external aldimine species we will call it EA-S to denote that it is an external 
aldimine with the substrate bonded to it. The EA-S is then ready to undergo a set of 
different reactions as mentioned before. Those reactions are the ones that make the 
PLP-dependent enzymes specific for different reactions. In the case of mHDC, it is a 
decarboxylation process. Once the specific reaction takes place, the external aldimine 
with the product of the reaction (EA-P) is formed, and the enzyme is ready for a new 
turnover, once the product of the reactions dissociates from the PLP cofactor and the 
active site lysine becomes bonded to PLP (IA) (Fig. 9). [51] 
In the case of mHDC, these mechanistic steps that were studied by computational 
means [51, 52] are confirmed by spectrophotometric studies. In the wild-type enzyme, 
the internal aldimine presents a characteristic absorption spectrum with two maximum 
peaks around 335 and 425 nm (Fig. 10 – Blue line), which are generally attributed to the 
enolimine and ketoenamine tautomeric forms (Fig. 11) of the IA, respectively. The 
absorption peak at 335 nm is twice as high as that at 425 nm (Fig. 10 – Blue line), 
indicating a prevalence of the enol form. [54] The predominance of the enol form of the 
IA is considered to reflect the hydrophobic nature of its active site that accepts aromatic 
substrates. [54] This trend was also observed for the AADC, which also catalyzes the 
decarboxylation of aromatic substrates. [55] 
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Fig. 10 – Absorption spectra of HDC in the absence (blue line) and presence (orange line) of 1 mM HME 
(histidine methyl ester).  
The spectra were taken in 50 mM PIPES-NaOH buffer, pH 7, at 25 °C. The enzyme concentration was 8 µM. [54] 
(Adapted)  
 
 
Fig. 11 - Wedge-Dash representations of the internal aldimine in a (Left) ketoenamine form and (Right) 
enolimine form. 
 
These initial steps of the mechanism are also confirmed by a spectroscopic study 
of the wild-type enzyme in the presence of an inhibitor (Histidine methyl ester - HME). In 
this case, it is observed a decrease in the absorbance at both 335 and 425 nm, and a 
significant increase of the absorbance around 388 nm (Fig. 10). [54] This absorption 
band indicates the accumulation of the EA-S that stalls the reaction in this reaction 
intermediate. Similar results have also been observed for rat AADC with DOPA methyl 
ester (similar inhibitor). [55] The same experiment have also detected a low at 425 nm, 
corresponding to the keto form of the EA-S. [54] 
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2.3.2. mHDC mechanism 
Once the EA-S is formed, a certain number of particular chemical reactions 
happen, and they make the difference between all PLP-dependent enzymes. Concerning 
about the mHDC, a decarboxylation takes place, and the resultant quinonoid 
intermediate (QI) is subsequently protonated. 
To evaluate, sequentially, the histidine decarboxylation, a stopped-flow 
spectrophotometer study was done with the natural substrate (L-histidine). In the first 
fast phase, a rapid increase in the absorbance at 425 nm with a concomitant decrease 
in the 335-nm peak was observed within 50 milliseconds, showing a shift from the IA to 
the ketoenamine tautomer of the EA with the substrate (EA-S). [54] These spectral 
changes are also similar to those observed for the reaction of AADC and L-DOPA. [55] 
In a second slower phase, the absorption at 425 nm decreases, and there is the 
concomitant emergence of a new absorption band at around 380 nm within 2.0 seconds, 
indicating that the enolimine tautomer of the EA is formed. However, no distinction 
between the EA-S and the EA-P (external aldimine with the product) could be made. [54] 
Circular dichroism spectroscopy assays have also revealed an inversion of the 
conformation of the Schiff base. This inversion is probably caused by the change in the 
amino moiety of the Schiff base from the IA to the EA-S. Comparing the obtained data, 
the EA of mHDC has a more distorted structure than that of AADC. [54, 55] In this sense, 
it is interesting that the overall rate constant of the steps after the EA-S formation, which 
includes the decarboxylation step, is apparently lower for mHDC than for AADC. Thus, 
we can consider that the distorted conformation of the EA in the mHDC lowers the rate 
of decarboxylation by partially breaking the π-conjugation between the pyridine ring and 
the imine. [54] 
When the α-fluoromethyl-histidine inhibitor (FMH) is used, a similar QI can be 
accumulated in a stable complex. The gel filtration of the complex with the similar 
quinonoid leads to an apparent reduction of the Mr, suggesting a “more closed” structure. 
[56] 
Rodriguez’s group performed temperature denaturation assays that showed 
more evident changes for the free holoenzyme comparatively with the α-FMH-treated 
enzyme sample, indicating that the enzyme that had an EA is more resistant to 
temperature-induced denaturation. However, the observed increasing trend in the 
ellipticity at 222 nm of the HME-treated enzyme preparations suggests that the reversible 
inhibitor is not able to protect the enzyme against thermal denaturation. [56] Those 
results indicate that mHDC adopts at least two well-differentiated conformations during 
the catalytic reaction. One corresponds to the fully active IA of the enzyme, and the 
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second one takes place in the presence of the external aldimine (EA-S or EA-P) in the 
catalytic site. [56]  
Other earlier studies have already shown that histamine is produced with the 
retention of configuration in HDC from Lactobacillus 30a, a pyruvate-dependent 
decarboxylase. [57] The assay was reproduced with a PLP-dependent decarboxylase 
model, and the result was also corroborated for those enzymes. [58] These observations 
indicate a previous decarboxylation, and a subsequent proton addition at the same 
position. Therefore, an SN2 nucleophilic attack is impossible to take place once it would 
add a hydrogen in an anti-position relatively to the liberated carboxylate group. Then, the 
carboxylate group should be released in the first step, and afterward, a proton is added 
to the α-carbon. The first step (decarboxylation) is promoted by the strongly electron-
withdrawing nature of the pyridoxylidene moiety that weakens the bond between the 
carboxyl group and the extended π-system of the Schiff bases formed with the substrate 
(L-histidine) and PLP, resulting in the loss of the carboxylate group. [53, 59] In 1966, 
Dunathan has already proposed that all double bonds of the extended π system should 
be placed on the same plane of the PLP ring to favor the electron displacement and by 
this way stabilize the QI. During the decarboxylation process, the bond that is broken, 
the Cα of PLP-amino acid Schiff’s bases should, however, be held at 90° to the plane in 
the relation the extended conjugated system to promote a faster catalysis. [60, 61] 
In the second step, the QI is protonated. However, the proton donor is not known. 
An earlier computational study has suggested that the lysine residue (Lys-305A) could 
protonate the carbanion formed [62], but recent experimental structural data showed a 
huge impediment for the protonation process by Lys-305A. Additionally, according to the 
crystallographic structure, the Lys-305A is on the opposite face of the carboxylate group 
which does not agree with that computation study. [17] In sum, there are no suggestions 
about which amino acid residue or molecule can protonate QI at the active site.  
 
2.3.3. Mutagenesis studies 
mHDC holoenzyme seems to have a highly restrictive and hydrophobic binding 
pocket. It is only able to bind histidine or imidazole-containing analogs, such as the 
inhibitors FMH and HME. [26] In the following topic, the active site features will be 
depicted to look for hints about the structural arrangement and provide insights into the 
catalytic mechanism of the enzyme. 
As mentioned before, the enzyme activation through the IA formation is mediated 
by a lysine amino acid residue (Fig. 9) and some studies with HDC from Morganella 
morganii and other PLP-dependent enzymes revealed that this lysine residue (Lys-305A) 
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(Fig. 12) is essential for the enzymatic activity. The replacement of this lysine by an 
alanine [63] or an arginine [64] culminates into the full inactivation of the enzyme. The 
substitution of this residue by an arginine residue allows the IA formation, but it does not 
allow the progress of the catalytic reaction, presumably stalling the enzyme in the IA. 
[64, 65] 
 
 
Fig. 12 – (Left) Wedge-Dash representation of the external aldimine (EA-S) and the Asp-273A, Lys-305A, Ser-
304A and Asn-302A residues.  
Blue dashed lines represent relevant non-bonded interactions (Right) CPK and licorice representations of the external 
aldimine (EA-S) and the Asp-273A, Lys-305A, Ser-304A and Asn-302A residues, respectively. 
 
An extensive experimental mutagenesis study, that tested 27 different mutant 
proteins, was done by Flemming and co-workers that studied the role of 34 different 
amino acid residues in the catalysis. These results showed that several amino acid 
residues are indispensable for catalysis. In this study, the importance of the Lys-305A 
(Fig. 12) was confirmed once its substitution by a glycine totally inactivates the enzyme. 
[66] Also, the mutation of the Asp-273A (Fig. 12), an amino acid residue that interacts 
with N4 of PLP-pyridine, by glycine also leads to the inactivation of the enzyme. [66] 
An almost inactivation of the enzyme is also achieved when Ser-304A (Fig. 12) 
is mutated by a glycine. This residue defines together with the Lys-305A a α-helix that 
holds the position of Lys-305A that is essential for the IA formation. This serine residue 
is also involved in a hydrogen bond with the Asn-302A (Fig. 12) that helps the 
stabilization of the phosphate group of the PLP. [66] The same type of inhibition is also 
achieved when His-194A (Fig. 13) is mutated by a glycine. [66] This amino acid residue 
makes a π stacking interaction with the ring of the PLP, and therefore it is expected that 
its mutation might lead to a difference rearrangement of the PLP ring and accordingly 
affect the catalytic process. Additionally, this residue establishes a hydrogen bond with 
the carboxylate group of the substrate, which may be important for the catalytic process 
(Fig. 13). [17] 
LYS305A
SER304A
ASN302A
ASP273A
N4
B
B
A
A
ASP273
THR248
HIS194
LYS305
ASN302
SER304
FCUP 
Computational studies addressed to Histidine decarboxylase 
19 
 
 
 
Fig. 13 - Wedge-Dash representation of the external aldimine (EA-S) and the His-194A, Thr-248A, Tyr-80A, Tyr-
334B, Leu-335B, Phe-104B and Leu-353B residues. 
Blue dashed lines represent relevant non-bonded interactions (Right) CPK and licorice representations of the external 
aldimine (EA-S) and the His-194A, Thr-248A, Tyr-80A, Tyr-334B, Leu-335B, Phe-104B and Leu-353B residues, 
respectively. 
 
The same mutagenesis studies also indicate that the loop containing Tyr-334B is 
essential for catalysis (Fig. 13 and Fig. 14). Indeed, the replacement of Tyr-334B or any 
contiguous amino acid residues of the loop conducts to a total inactivation of the enzyme. 
This loop (Fig. 14) is believed to play a major role in catalysis, as it closes the binding 
pocket when the substrate is accommodated inside the active site. [66]  
Molecular dynamics simulation using a homology model of the mHDC revealed 
a more noticeable motion of this loop (Fig. 14) in HDC with the IA than with the 
correspondent EA. The IA containing structure is more exposed to the solvent comparing 
to the structure with the EA. The exposure of the flexible loop to the solvent over the 
protein surface in IA justifies the more suitability of this portion to be degraded by 
proteases. [67] The most critical residue in this loop is Tyr-334B, which is also highly 
conserved in some PLP-dependent enzymes. [29, 68] In a similar test, the equivalent 
tyrosine residue was replaced by a phenylalanine in the pig AADC, and that substitution 
changes the reaction that is catalyzed by the enzyme, once decarboxylation-dependent 
oxidative deaminase happened instead of a decarboxylation followed by the QI 
protonation. [26] The crystallographic structure obtained in 2012, also indicates that the 
Tyr-334B may play a critical role in catalysis. [17] 
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Fig. 14 – NewCartoon representation of the mHDC dimer.  
The subunit A is blue colored, and the subunit B is orange colored. Zoom at the flexible loop region containing the Tyr-
334B (Licorice representation) near the external aldimine with the substrate (EA-S) (CPK representation). 
 
Other relevant mutagenic studies involved the amino acid residues of the active 
site that establish substrate-specific interactions, i.e., Tyr-83A, Tyr-80A, and Ala-86A. All 
of these mutations revealed a decrease the enzymatic activity of the mutated enzymes. 
[26, 66]  
Based on the new crystallography structure of mHDC, the previous hypothesis 
for the structural rearrangement of the PLP cofactor and substrate inside the active site 
are inaccurate mainly in respect to the N-imine orientation and substrate’s imidazole 
group orientation. Previous studies have presented imidazole group pointed to the His-
194A face [69], but the new X-ray structure revealed an opposite orientation for the 
HME’s imidazole group. In fact, the imidazole ring of HME points toward the si-face of 
the EA. The nitrogen atoms of the imidazole ring appeared to participate in hydrogen-
bonding interactions with the backbone amino group of Tyr-81A and a water molecule. 
Except for two hydrogen bonds, the imidazole ring was surrounded by hydrophobic 
residues (Trp-72A, Tyr-80A, Leu-102A, and Phe-104A). Interestingly, flipping the 
imidazole ring allows the formation of extra hydrogen bonds with Ser-354B (Fig. 15) and 
with the carbonyl group of Tyr-81A, instead of the water molecule and amino group of 
Tyr-81A, respectively. [17] 
TYR334B
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The X-ray orientation for the imidazole group was confirmed with a later work that 
showed an important role of Ser-354B (Fig. 15) for substrate specificity for histidine 
rather than L-DOPA. A mutagenesis study, where the Ser-354B was replaced by a 
glycine, revealed a 10-fold Km increase of the S354G mutant when compared with the 
wild-type enzyme, whereas kcat values for both enzymes were similar, resulting in a 
decrease of kcat/Km values for the S354G mutant. This data indicates that the mutation 
of the Ser-354B decreased the affinity between the enzyme and the histidine. 
Additionally, this mutation increases the binding pocket area nearby the active site which 
makes mHDC available to catalyze the L-DOPA decarboxylation. [17] 
 
 
Fig. 15 – CPK and licorice representations of the external aldimine with the substrate (EA-S) and of the Ser-
354B residue, respectively. 
 
Nevertheless, the N-imine group of the EA is pointing to the phosphate group 
instead of pointing to the enol group of PLP-pyridine as some works have shown before 
(Fig. 15). [26, 54, 56, 62, 69] Additionally, the pyridine ring of the PLP is inserted between 
the methyl group of the Ala-275A and the imidazole ring of His-194A. The Asp-273A and 
Thr-248A residues interact, through hydrogen bonds, with the protonated nitrogen and 
oxygen atoms of the pyridine ring of PLP. The phosphate group of PLP is stabilized by 
a set of hydrogen bonds with the Ser-151A, Asn-302A, and Ser-354B amino acid 
residues. Also, the negative charge of the phosphate group interacts with the dipole of 
helix-5, which was positioned with its N-terminus close to the phosphate group. [17] 
Fig. 16 summarizes all important active site residues at the active site of the 
mHDC, in particular, the red ones, which are preponderant once their mutation 
completely blocks the reaction that is catalyzed by mHDC. 
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Fig. 16 – CPK and licorice representations of the EA-S and important amino acid residues at the active site, 
respectively.  
Red colored amino acid residues are the ones whose mutation completely inactive the mHDC, whereas the blue colored 
residues only decrease the catalytic rate. 
 
 
 
2.4. Biological role of histamine in cells 
As described before, histamine is widely produced by a variety of cells, and 
consequently, several physiological conditions are correlated with the histamine release. 
 
2.4.1. Cell Cycle 
Expression of mammalian HDC (mHDC) induces a cell cycle arrest through the 
alteration of the levels of several proteins such as cyclin cdk6, D1, cdk7 and cyclin A. 
Histamine production, mediated by an increased mHDC gene expression and activity, 
has the ability to regulate caspase-3 and α-synuclein, justifying the relatively reduced 
proliferation rates of mammalian histamine-producing cells. [70] For example, some 
works have shown a histamine role in the proliferation of human adrenocortical cells 
because it causes an inhibition of their proliferation, although no effect has been related 
with steroidogenesis. [71] 
 
2.4.2. Muscle Endurance 
Murine assays revealed an essential role of histamine in the muscle activity 
during physical exercise. Mice practicing prolonged walking revealed an increase of 
mHDC mRNA expression and mHDC activity in quadriceps femurs muscles. 
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Furthermore, mice supplied with antagonists of the H1 or H2 receptors or an irreversible 
mHDC inhibitor displayed less prolonged walking endurance than control group. [72] 
 
2.4.3. Hair growth 
The hair-inducing ability of newborn mice dermal cells was studied and results 
showed a disappearance in the first few days of life, and also an mHDC expression 
decrease during that period. mHDC downregulation in newborn mouse dermal cells 
decreased their hair follicle-inducing ability, indicating a key role of mHDC in the 
maintenance of hair-inducing ability during the first few days of life in mice. [73] 
 
2.4.4. Granule Maturation 
As mentioned before, mHDC is essential for the stored histamine production, 
mainly the 54 kDa form. Additionally, mHDC was also described as having a key role in 
the histamine-containing granules maturation [74], once mHDC-/- mutant mice showed 
an aberrant morphology with severely decreased granule contents. [75] 
 
 
2.5. Drug target 
The role of histamine in diverse physiological events is, unfortunately, associated 
with many diseases. This scenario turns mHDC as an important drug target to treat those 
pathologies. Consequently, the correct understanding of the catalytic mechanism of 
mHDC is crucial to unveil specific features about the enzyme, which could be used in 
the design of new drugs. 
 
2.5.1. Diseases 
Atopic Dermatitis 
Histamine H1 receptor is the best-characterized receptor, and inverse agonists 
commonly referred to as antihistamines have been available for clinical use since 1942. 
There is a strong evidence for their use in the treatment of allergic rhinitis, allergic 
conjunctivitis and urticaria. In contrast, the use of antihistamines for the treatment of 
patients with atopic dermatitis is not currently recommended, based on their limited 
clinical efficacy and the risk of side-effects. [76-79] mHDC is expressed by epidermal 
keratinocytes, and its expression is significantly elevated in the skin of patients with 
atopic dermatitis. [79] mHDC expression by keratinocytes is also increased in response 
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to T-helper 2 cytokines and exogenous factors that play a role in triggering and 
exacerbating atopic dermatitis, including house dust mite allergens and bacterial 
lipopolysaccharide. Keratinocytes also have the ability to respond to histamine, 
expressing H1, H2 and H4 receptors, which together orchestrate changes in the 
expression of over 4000 genes, including those involved in inflammation, proliferation 
and differentiation. [80] 
 
Chronic Allergic Contact Dermatitis 
Histamine can also facilitate the creation of eczematous lesions in the chronic 
allergic contact dermatitis murine model because of its ability to reduce the regulatory T 
cell population in the lesion. Consequently, the tissue lacks the cell population that is 
responsible for the attenuation and control of the inflammatory response. [81] mHDC 
could, therefore, be an interesting pharmacological target to treat chronic allergic contact 
dermatitis.  
 
Allergies 
Basal expression of mHDC is higher in neutrophils from patients with allergies 
than from healthy donors. This evidence shows that neutrophils could be a relevant 
source of histamine in allergic patients, causing this pathology. [5] 
 
Allergic Rhinitis 
Certain polymorphisms in the mHDC gene are associated with various histamine-
related diseases and were presumed to affect the enzyme activity. Recently, it has been 
described a polymorphic difference in the mHDC gene, where the homozygous 
substitution of a glutamic acid at the position 644 by an aspartate increases the risk of 
developing allergic rhinitis. [82] 
 
Gastric Ulcer 
Histamine production and release has been implicated in the pathogenesis of 
gastric ulcers produced by restraint and pylorus ligation. [83, 84] The important role of 
histamine in the gastric ulcer pathology was essential for the research about mHDC as 
well as allergies and mastocytosis. [85] 
Gastrin stimulation of ECL cells led to an elevated mHDC activity and increased 
secretion of histamine the major gastric acid secretagogue. The gastrin-stimulated 
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increase in mHDC activity has been shown to result in part from an increase in mHDC 
gene transcription in the gastric corpus and isolated ECL cells. [86, 87] 
Bile acid secretion also increases the expression of mHDC as well as FXR 
(farnesoid X receptor), CDX1 (caudal-type homeodomain transcription factor) and SHP 
(small heterodimer partner). SHP was also found to be a primary regulatory transcription 
factor for bile acid-induced mHDC expression. [88] 
 
Diabetes 
A recent study has shown, recurring to a murine model of type-1 diabetes, that 
HDC knockout (KO) can decrease the incidence of diabetes when compared with wild-
type mice. The HDC KO maintains the proportion of regulatory T cells and myeloid-
derived suppressive cells in contrast with the increased levels of immature macrophages 
observed in KO mice. This study supports the idea that histamine is involved in the 
pathogenesis of diabetes. [89] 
  
Age at Natural Menopause 
Some HDC gene polymorphisms are likewise significantly associated with age at 
natural menopause (AANM) in Caucasian women. However, no pattern or explanation 
was described to justify this phenomenon. [90]  
 
Chronic Heart Failure 
Histamine release has also been described as a crucial role in the chronic heart 
failure (CHF), putting together the idea that the production of histamine inhibitors could 
be used to treat arrhythmias, sudden cardiac death, myocardial ischemia, and 
congestive heart failure. [91, 92] 
The HDC role in the CHF pathology was also depicted, because a specific HDC 
allele (rs17740607) is associated with a decreased risk for CHF, as a result of the HDC 
activity decreasing and lower endogenous histamine levels in cells. [93]  
 
Cancer 
Histamine biosynthesis has been detected in a number of different tumors, 
including human small cell lung carcinomas [94], pancreatic tumors [95], colonic cancer 
cells [96], and human melanoma cells [97]. Moreover, in breast cancer, whereas 
histamine N-methyltransferase and histamine H3 receptor appeared to be irrelevant in 
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the context of this cancer, a certain HDC allele (T allele of rs7164386) showed a 
significantly decreased of the incidence risk. On the other hand, rs7164386-rs7182203 
alleles were more frequent among breast cancer patients. Polymorphisms of HDC gene 
could be significantly associated with breast cancer. [98] 
A study about human colorectal cancer revealed that mHDC is highly expressed 
in the tumor microenvironment. Human colorectal cancer patients with lymph node 
invasion had a higher expression of mHDC than control. These results suggest that 
histamine expressed in microvessels could be an additional cellular source and involved 
in the cancer invasion through promoting angiogenesis in human colorectal cancer. [99] 
An autocrine loop, consisting of enhanced histamine synthesis by mHDC, 
sustains cholangiocarcinoma growth is described, indicating HDC inhibitors as a 
promising treatment for cholangiocarcinoma patients. [100] 
 
2.5.2. HDC inhibitors 
Due to the pathologies described above, there has been a great interest in the 
development of HDC inhibitors to preclude undesired effects of histamine under certain 
circumstances. In clinical practice, there are only three types of approaches to inhibit the 
histamine effects, and none of them involved the inhibition of mHDC. Instead, the 
inhibitors prevent the degranulation of basophils and mast cells, blocking histamine 
release; behave as antagonists or inverse agonists of the histamine receptors; or act as 
antagonists that promote opposite effects without interfering with the normal histamine 
pathways. Nonetheless of these strategies, a better choice would be the usage of 
compounds that would inhibit mHDC directly, decreasing the effect of histamine more 
efficiently. In fact, several inhibitors have been studied, but none of them has turned out 
to be suitable to be used in clinical practice. 
The first studies regarding the direct inhibition of mHDC in vitro were devoted to 
norepinephrine (Fig. 17) and several structurally related compounds. These compounds 
are reversible inhibitors of HDC that compete with the natural substrate to form similar 
EA. All of those compounds share a structural pattern of an m-hydroxyl-phenethylamine 
(Fig. 17) with a terminal primary amine. This amine group can form an EA with the PLP 
cofactor, but they could easily unbind the PLP again leading to a reversible competitive 
type of inhibition. When a substitution of either a methyl or a carboxyl group on the α-
carbon is made, the inhibitory potency slightly changes. However, the simultaneous 
substitution leads to a complete inactivation of the mHDC. This irreversible inhibition is 
caused by the decarboxylation of the inhibitor and the consequent greater stabilization 
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of the resulting QI. Authors suggested that the inhibitors condensation with PLP was 
crucial to an efficient inactivation of the enzyme. [101] 
4-bromo-3-hydroxybenzyloxyamine dihydrogen phosphate (NSD-1055) (Fig. 17) 
is also a potent inhibitor of mHDC and it can reduce histamine excretion in the urine after 
oral administration. Once again, NSD-1055 can form an EA with the cofactor and prevent 
the natural substrate bind. [102] Following studies assessed the potency of aliphatic and 
benzyl aminooxy amines (NSD-1055 derivatives) into the inhibition of mHDC and all of 
them were tested and showed at most 100-fold less potency compared with NSD-1055. 
[16] Although less potent, these inhibitors helped new searches to find new inhibitors 
capable to reduce mHDC activity in a selective manner, because NSD-1055, for 
example, also exhibited the capability to inhibit dopamine-β-hydroxylase. [103] 
Fewer years late rhodanine (Fig. 17) is described as a potent inhibitor of gastric 
rat HDC in vitro and the mechanism of inhibition involves the reaction of this compound 
with the PLP cofactor and the condensation reaction between 5-methylene carbon of 
rhodanine and enzyme-bond PLP, once rhodanine can inhibit only the holoenzyme and 
not the apoenzyme. [104] These data also corroborate the idea that efficient inhibitors 
should bind the PLP cofactor. 
An inhibitor must be not only potent but also specific. However, the inhibitors 
described above are not so specific as desired. In 1978, the 4-imidazolyl-3-amino-2-
butanone (McN-A-1293) (Fig. 17) was produced with the intent to be the first specific 
inhibitor of mHDC. [105] Indeed, McN-A-1293 can inhibit mHDC in vitro but not AADC, 
and it is also a weak inhibitor of DAO and HNMT, which are enzymes that degrade 
histamine when it is released. [106] This high specificity is due to a great similarity with 
the natural substrate. Nevertheless, McN-A-1293 is a weaker inhibitor of mHDC and 
researchers tried to synthesize other histidine derivatives to interfere more efficiently with 
mHDC activity. [107] These compounds contain different substituents in the α-carbon 
or/and adding different ester groups. Consequently, a good inhibition was achieved with 
the methyl ester of L-histidine (HME) (Fig. 17) with an inhibition of 50% at 4×10-6 M 
concentration with a Ki = 1,8×10-6. Analogous esters with ethyl and other alkyl groups 
were tried, but it caused a significant decrease of the inhibitor efficiency. Also, no 
substitution in the α-carbon evidenced a powerful modification to increase the inhibition 
of mHDC. Moreover, amide derivatives did not reveal a capability to inhibit mHDC. [107] 
At this moment, HME is the most specific and efficient inhibitor of the mHDC activity, and 
only requires an esterification of the carboxylate group with a methyl group.  
Later on, a new work showed the ability of some histidine derivative peptides to 
inhibit mHDC with a potency about 100-fold greater than the previous HME. It was 
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observed that histidine-phenylalanine dipeptide (Fig. 17) was the most effective peptide 
inhibitor, closely followed by histidine-tyrosine dipeptide (Fig. 17). These dipeptides can 
form the EA and block the binding pocket for the natural substrate. Furthermore, both 
peptides are unable to inhibit AADC as well as HME, presenting a similar specificity 
comparatively with HME. [108] This data indicates that the increase of hydrophobicity of 
an inhibitor increases their potency toward mHDC. [109] 
3-Methoxy-5,7,3',4'-tetrahydroxyflavan (ME) (Fig. 17) was reported as gastric 
anti-ulcer drugs because it is also able to inhibit specifically the mHDC in rats and guinea-
pigs. Results showed a real capability of ME to inhibit mHDC and reduce the amount of 
histamine produced in the stomach. [85] The mechanism of inhibition is not known, but 
it is believed that the high hydrophobicity places the inhibitor at the binding pocket, 
hindering by this way the substrate binding. 
The most powerful mHDC inhibitor that is known is (S)-α-fluoromethyl-histidine 
(FMH) (Fig. 17). The inhibitory mechanism of this compound was extensively studied 
because FMH can irreversibly inactivate mHDC [110, 111] and the bacteria form from 
Morganella morganii [112, 113] but had no effect on pyruvyl-dependent HDC such as 
that from Lactobacillus 30a. [110, 114] Many groups have shown that mHDC inhibition 
by FMH is accompanied by the decarboxylation of the inhibitor and consequent fixation 
to the enzyme. [111, 115] The fixation occurs by β-elimination of fluoride. Unfortunately, 
biological assays showed several undesired side effects when FMH is used to inhibit 
mHDC, such as sympathetic facilitations, arterial hypertension and tachycardia. [116]  
The development of FMH, and HME, as new mHDC inhibitors have been very 
useful for basic research on mHDC enzymology, histamine physiology, and molecular 
biology, but they are not suitable drugs for human therapy. One of the problems is that 
these two analogs are also able to inhibit the gram-negative bacterial enzyme giving rise 
to important secondary effects because of their presence in the intestinal track. [67] 
Another important inhibitor of mHDC is an abundant catechin in green tea, i.e., 
epigallocatechin-3-gallate (EGCG). EGCG has been shown to target histamine-
producing cells and to promote anti-inflammatory, antitumor and anti-angiogenic effects. 
Some experimental works have demonstrated that EGCG has a direct inhibitory effect 
on both mHDC and AADC. [117-125] EGCG is able to inhibit mHDC by partially occlusion 
of substrate entrance and establishes several hydrogen bonds with the highly conserved 
residue of the active site, namely His-194A and several other residues in a functional 
loop of the opposite monomer (Tyr-334B-conatining loop). As the active site of AADC is 
more exposed to the solvent than the active site of histidine decarboxylase, EGCG can 
make more electrostatic interactions in the binding pocket with His-192 (the equivalent 
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of mHDC His-194A) and Leu-333B in the homologous functional loop and even with the 
cofactor. These first results confirmed that EGCG interacts with the binding pocket, and 
it does not change the dimeric structure of the enzyme. This blockage was confirmed by 
a molecular docking, where L-histidine, HME, and FMH were docked into an mHDC 
previously inhibited with EGCG. The results revealed that none of them were able to bind 
to the mHDC binding site. In conclusion, the mechanism of inhibition of EGCG is based 
on alterations of the chemical environment at the active site and physical occlusion of 
the substrate entrance. So, no distortion of the quaternary structure or dimerization 
surface is induced by EGCG and other polyphenols. [126] The effect of EGCG was 
tested in an animal (guinea pig) allergic conjunctivitis model in combination with cetirizine 
(H1 receptor antagonist) The combination of catechin and cetirizine showed a statistically 
significant effectiveness in the management of allergic conjunctivitis when compared 
with the standard disease control and catechin and cetirizine individual groups. [127] 
 
 
Fig. 17 – Overview of the structure of all inhibitors described above.  
 
Other studies pointed out the dimerization surface as the most promising area for 
a specific inhibition of mHDC because the bacterial enzyme seems to differ mainly in its 
quaternary structure from the mammal ones. [128] Especially, the flexible loop, 
comprising residues 331–349 in the rat enzyme, has no homologous counterpart in the 
bacterial enzyme, and it is close to the entry of the catalytic pocket of the enzyme. [129] 
Therefore, a computational alanine-scanning mutagenesis (compASM) study could be 
Norepinephrine m-hydroxyl-phenethylamine NSD-1055 Rhodanine
McN-A-1293 Histidine methyl ester Histidine-phenylalanine Histidine-tyrosine
ME (S)-α-fluoromethyl-histidine EGCG
Cα
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an interesting approach aiming the interface area between the two subunits. The 
identification of relevant amino acid residues for the dimerization could be used as drug 
targets intending the mHDC inhibition. 
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B. Theoretical Background 
 
 
 
 
He who loves practice without theory is like 
the sailor who boards ship without a rudder and a compass and 
never knows where he may cast. 
Leonardo da Vinci 
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Theoretical and computational means are nowadays often used to study several 
aspects of biological systems. This, in part, results from the methodological advances 
that allow simulating with high accuracy aspects of these systems, but also due to the 
technological advances that permit the use of these methods in big and complex 
systems, without a significant computational cost. 
Experimental data reveals important information about the systems however, in 
case of catalysis, they cannot assess data about the cleavage and formation of chemical 
bonds. Nevertheless, they provide very relevant information about complex structures 
and intermediates, which give indispensable clues about the mechanism. Computational 
studies can then be used to unravel the mechanism that leads to the formation of those 
reaction intermediates and provide the complete “movie” of the full catalytic process. 
Currently, there are four theoretical levels of theory that are commonly used to 
study enzymatic mechanism, and their usage has a direct impact on the accuracy of the 
calculation, the number of atoms that can be used and computational cost. They are 
normally classified as ab initio; Density-Functional Theory (DFT), semi-empirical; and 
Molecular Mechanics (MM). 
The ab initio methods are the most reliable ones to describe a molecular system. 
Among the ab initio methods, Hartree-Fock (HF) and Pos-Hartree-Fock (Pos-HF) are the 
most used ones. The Pos-HF methods are the most accurate ones but require high 
computational effort, and, therefore, can only be used with a few dozens of atoms. In this 
work, we only will concern about the HF methods because, although they are not so 
accurate in relation to the Pos-HF methods, they allow the use of a wider range of atoms 
in the calculations. Density-Functional Theory (DFT) approach allowed a description of 
biological and chemical systems almost so accurate as the ab initio methods but 
significantly less computationally demanding. These methods allow therefore to increase 
the complexity of the model systems that are studied. A less demanding approach can 
be achieved through semi-empirical methods. These methods are based on HF 
formalism, but introduce several approximations and parameters that also turn them 
considerably less accurate. Finally, the MM methods are based on classical physics to 
predict atomic interactions and movements. However, these methods do not include 
electrons in their description and consider atoms as non-deformable spheres with 
charges and linked each other by springs. For this reason, they cannot be used to 
simulate chemical reactions and phenomena that involve electronic events. The huge 
advantage of these methods is their ability to be used in systems with many atoms 
(thousands) with an inexpensive computational cost. All these approaches will be 
discussed in the next sections, particularly the methods used in this work. 
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More recently, we have been witnessing the development of hybrid methods 
which are the conjugation of two different types of above theoretical methods. Hybrid 
methods, as QM/QM and QM/MM, emerged from the necessity of study large systems, 
as biological complexes, with a compromise between accuracy and computational cost. 
Later on, these methodologies will also be described in more detail. 
  
  
FCUP 
Computational studies addressed to Histidine decarboxylase 
35 
 
1. Molecular Mechanics 
Molecular mechanics (MM), by definition, is used to refer the use of simple 
potential-energy functions as the harmonic oscillator and Coulombic potentials in 
molecular systems. [130]  
In MM, the smallest particle of the system is the atom, which is treated as a 
charged sphere linked to other atoms by springs representing bonds. All interactions are 
then calculated using simple mathematic approaches. For example, bonded interactions 
are calculated using the Hook’s law, whereas the non-bonded interactions, such as, the 
electrostatic and van der Waals interactions are treated using Coulombic and Lennard-
Jones potentials, respectively. Then, the system energy can easily be calculated based 
on bond stretching, angle bending, dihedral torsion, Coulombic and van der Waals 
interactions. [130] 
We are unable to use MM to study chemical reactions because it involves the 
cleavage and formation of bonds, which requires an electronic description. Therefore, 
MM is a powerful tool to explore the conformational space of a system, for example when 
it is used in simple conformational searches of in more complex Molecular Dynamics 
(MD) or Monte Carlo simulations. [131]  
 
 
1.1. Force Fields 
As we see above, MM does not use wave function into the energy calculation. 
Instead, the energy is calculated based on a simple mathematic equation which requires 
some parameters obtained by experimental works or ab initio calculations. The MM force 
fields allow “to approximate” quantum mechanical energy surface, using less 
computational resources. [132, 133] 
Generally, force fields use a class I additive potential energy function to achieve 
the system energy. In this type of functions, all terms for the bond interactions are added 
to all terms for the non-bonded interactions (Equation 1). [132] 
 𝑉TUTVWX = 𝑉Z[\]W] + 𝑉\[\^Z[\]W] 
Equation 1 - Class I additive potential energy function 
 
 Different force fields have been developed and optimized for particular types of 
systems. AMBER (Assisted Model Building with Energy Refinement) [134] is one of the 
most used software that includes ff99SB and GAFF (General AMBER force field) force 
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fields [135] which is used to protein or nucleic acid-containing systems. Nevertheless, 
there are several other force fields such as CHARMM (Chemistry at Harvard 
Macromolecular Mechanics) [136], OPLS (Optimized Potentials for Liquid Simulations) 
[137] or GROMOS (Groningen Molecular Simulation package) [138]. 
 In this work the AMBER ff99SB and GAFF force fields [135] were used so that it 
will be described below. 
 
1.1.1. Bonded interactions 
Considering the AMBER force fields [135], the bond interactions are divided into 
three categories: the bond stretching terms, the angle bending terms, and the dihedral 
terms (Equation 2). 
 𝑉Z[\]W] = 𝑉Z[\]Z[\]T + 𝑉_\`aW_\`aWT + 𝑉]bcW]d_a]bcW]d_aT  
Equation 2 – Energy function for the bond interactions. 
 
The bond stretching contributions to the potential energy are approximated by a 
harmonic oscillator as a function of the bond length (𝑙) (Equation 3). [133, 135] 
 𝑉Z[\] = 12 𝑘Z(𝑙 − 𝑙=)j 𝑘Z is the force constant; 𝑙 is the bond length; 𝑙= is the bond length at the equilibrium. 
 
Equation 3 – Bond-stretching potential energy (𝑽𝒃𝒐𝒏𝒅) function.  
 
A similar harmonic oscillator approximation is also used to describe the angle 
bending potential energy as a function of the angle between three adjacent atoms (𝜃) 
(Equation 4). [133, 135] 
 𝑉_\`aW = 12 𝑘_(𝜃 − 𝜃=)j 𝑘_ is the force constant; 𝜃 is the angle between three adjacent atoms; 𝜃= is the angle between three adjacent atoms at 
the equilibrium. 
 
Equation 4 – Angle-bending potential energy (𝑽𝒂𝒏𝒈𝒍𝒆) function. 
 
For these two potential energy calculations, only two parameters are needed for 
each one, the force constant (𝑘Z or 𝑘_) and the bond length (𝑙=) or angle value (𝜃=). 
The dihedral angle term, also called torsion angle, corresponds to the energy 
associated with the rotation of atoms separated by three bonds. In other words, 
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considering atoms A, B, C and D bonded each other in this order, the dihedral angle is 
the angle between planes ABC and BCD. The potential energy associated with the 
dihedral angle is given as a cosine function by the Equation 5. [133, 135] 
 𝑉]bcW]d_a = 12 𝑘] 1 + cos 𝑛𝜔 + 𝛾  𝑘] defines the energy barrier for the dihedral rotation; 𝜔 is the dihedral angle and could assume values between 0° and 
360°. 𝛾 corresponds to the dihedral angle value for which the energy is minimum; 𝑛 defines the number of function’s 
minimums. 
 
Equation 5 – Dihedral angle potential energy (𝑽𝒅𝒊𝒉𝒆𝒅𝒓𝒂𝒍) function. 
 
 
1.1.2. Non-bonded interactions 
The non-bonded interactions might be split into electrostatic and van der Waals 
interactions (Equation 6). [133, 135] 
 𝑉\[\	Z[\]W] = 𝑉WaW}V. + 𝑉~_\	]Wd	__aT 
Equation 6 – Energy function for the non-bonded interactions. 
 
 The electrostatic interaction describes non-bonded interaction as a result of 
charges or permanent dipoles. The Coulombic law is used to the analytic calculation 
considering atoms as charged points separated by their interatomic distance (Equation 
7). [133, 135] 
 𝑉WaW}V. 𝑖, 𝑗 = 14𝜋𝜀 𝑞b𝑞𝑟b,  𝑞b and 𝑞 are the atomic charges of the atoms i and j, respectively; 𝑟b, is the distance between atoms i and j; 𝜀 is the 
dielectric constant. 
 
Equation 7 – Electrostatic potential energy (𝑽𝒆𝒍𝒆𝒄𝒕.(𝒊, 𝒋)) function between atoms i and j. 
 
 The van der Waals interaction describes repulsive and attractive non-bonded 
interactions, which are not described by the electrostatic term, such as nuclear repulsion 
(Pauli’s repulsion force), instantaneous and induced dipoles attraction (London forces). 
In the AMBER force fields, the van der Waals potential energy is calculated using a 12-
6 Lennard-Jones potential as a function of the distance between two atoms (Equation 
8). [133, 135] 
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 𝑉~_\	]Wd	__aT 𝑖, 𝑗 = 𝜀b, 𝜎b𝑟b j − 𝜎b𝑟b   𝜀b, is the function minimum; 𝑟b, is the distance between atoms i and j; 𝜀 is the dielectric constant; 𝜎b is the interatomic 
distance for which the energy is zero. 
 
Equation 8 – Van der Waals potential energy (𝑽𝒗𝒂𝒏	𝒅𝒆𝒓	𝑾𝒂𝒂𝒍𝒔 𝒊, 𝒋 ) function between atoms i and j. 
 
 
 
1.2. Molecular Dynamics 
Molecular Dynamics (MD) is a common tool to assess relevant information about 
the conformational space of a chemical system. It can also provide important 
thermodynamic and structural flexibility information.  
Since the first MD simulations made in 50’s [139], they have been used for 
several different purposes, such as protein stability, molecular docking, conformation 
rearrangement studies, protein folding, transport through the cellular membrane, among 
others. 
A critical point when we want to choose a duration time for a MD simulation is the 
commitment between the computational cost and the movements that we want to 
sample. For example, atomic fluctuations occur into the fento and picoseconds time 
scale; loops and terminal regions movements take between nano to microseconds to 
happen, and subunit movements and protein folding could exceed some microseconds. 
In this work, we performed some nanoseconds of MD simulation to assess information 
about protein flexibility and atomic fluctuations.  
A MD simulation predicts the atom movement based on integration of Newton’s 
equation from which results data about velocity and position for each atom. At each time 
point, a differential equation derivative from the Newton’s Second Law (Equation 9) is 
defined for each system’s particle. [133] 
 𝑑j𝑥b𝑑𝑡j = 𝐹𝑚b 
Equation 9 – Differential equation that describes the motion of a particle with mass 𝒎𝒊, along one coordinate 𝒙𝒊 
with a force 𝑭𝒙𝒊. 
 
Due to the difficulties behind the analytical solution for that equation, a finite 
integration step (∆𝑡) is used to numerically calculate the position (Equation 10) and the 
velocity (Equation 11) for each atom in the system. 
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 𝑥 𝑡= + ∆𝑡 = 𝑥 𝑡= + 𝑣 𝑡= ×∆𝑡 + 12	𝑎 𝑡= ×∆𝑡j 𝑥 𝑡=  is the atomic position in the time 𝑡=; 𝑣 𝑡=  is the atomic velocity in the time 𝑡=; and 𝑎 𝑡=  is the atomic 
acceleration in the time 𝑡=. 
 
Equation 10 – Atomic position calculation in the 𝒕𝟎 + ∆𝒕 time point using the finite integration step ∆𝒕. 
 
 𝑣 𝑡= + ∆𝑡 = 𝑣 𝑡= + 𝑎 𝑡= ×∆𝑡 𝑣 𝑡=  is the atomic velocity in the time 𝑡=; and 𝑎 𝑡=  is the atomic acceleration in the time 𝑡=. 
 
Equation 11 – Atomic velocity calculation in the 𝒕𝟎 + ∆𝒕 time point using the finite integration step ∆𝒕. 
 
As the above equations suggest, three different variables must be known at the 
beginning: position, velocity, and acceleration. Atomic positions are obtained, for 
example, by the X-ray crystallography or NMR. The velocity distribution of all atoms in 
the system is done recurring to a random assignment from a Maxwell-Boltzmann 
distribution at the system temperature. The acceleration is gotten by the ratio of the force 
and the atomic mass, once the force could be achieved by the potential energy derivative 
in order to the particle coordinates. [133]  
 
1.2.1. Integration step 
As mentioned above, we need to set an integration step that defines the time 
interval between position and velocity calculations for all atoms. Using the smallest 
integration step is the most desirable situation because it minimizes the errors and 
becomes closely to the analytical solution. However, the smaller is the integration step, 
the highest will be the computational cost.  
To overcome this situation, it is a good practice use a ten times smaller integration 
time comparing to the fastest movement in the system. In our system, as well as other 
biological complexes, the fastest event is bond stretching of the hydrogen bonds and 
occurs with time lapses of approximately 10 fs. Then, an integration time of 1 fs is enough 
and was used in the present work. 
 
1.2.2. Ensembles 
The statistical mechanics is a bridge between the molecular events and the 
macroscopic system properties. A macroscopic system is characterized by α+2 state 
functions, where α is the number of components. A state function is, for example, the 
temperature, volume, pressure, number of particles, among others. [133]  
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A macrostate could be defined as an ensemble of microstates under the same 
thermodynamic conditions. The most common types of ensembles are the canonic 
ensemble (number of particles (N), volume (V) and temperature (T) constants); 
isothermal-isobaric (N, pressure (P) and T constants); microcanonic (N, V and total 
energy (E) constants); and the grand canonic (V, T and chemical potential (μ) constants). 
[133]  
In this project, the canonic (NVT) and the isothermal-isobaric (NPT) ensembles 
were used in the MD simulations for the equilibration and production moments, 
respectively. 
 
1.2.3. Periodic boundary conditions 
Usually, the system dimensions used in MD simulations are small because of the 
computational cost inherent. So, the studied system is composed of the protein inside a 
water box, normally modeled as a cubic box. The small models lead to a problem related 
to surface effects. Water molecules near the box surface are under different conditions 
comparing with water molecules inside the box. These different environments lead to 
additional errors that could be solved ignoring those molecules. However, those 
molecules could represent approximately 40% of the total number of molecules in the 
system, invalidating the ignoring approximation. 
A way to overcome that is recurring to periodic boundary conditions, so the 
system is only a central spot in an infinite cubic network consisted by their cell replicas. 
The motion equations are only calculated for the central unit, and the movements are 
reproduced into all other units.  
Evidently this is not an ideal solution because units are following the same 
oriented movements, but it is a good approximation to fix this pitfall. Nevertheless, we 
have to pay attention to prevent abnormal results, once the solvation box should be big 
enough to prevent protein atoms interact with other protein atoms from the replica units. 
For that, in this work, the solvation box was placed in a way that allows a minimum 
distance of 12.0 Å between the protein atoms and the unit surface, since we used a non-
bonded interactions cutoff of 10.0 Å. The non-bonded interactions are the property that 
imposes a minimum size for the unit because they could be calculated for a non-finite 
number of atom interaction due to the infinite number of units. 
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1.2.4. Non-bonded interactions cut-off 
The non-bonded interactions could be split into short and long range, where the 
first ones are habitually described by Lennard-Jones potentials. In this case, the van der 
Waals potential energy is calculated recurring to a 12-6 Lennard-Jones potential where 
the highest term is r-6 dependent, so not far away atoms have already a little contribution 
for the potential energy. However, the Coulombic interactions have a r-1 interatomic 
distance dependency, so more atoms have a non-neglected influence into the total 
potential energy.  
The non-bonded calculation for all atoms from all replica units is not possible 
because there are an infinite number of interactions. Subsequently, an approximation 
has to be done to reduce the number of interactions calculated, and a truncation radius 
is defined. In this work, we use a cut-off radius of 10.0 Å, so all non-bonded interactions 
between each atom and all atoms that do not distance more than 10.0 Å are calculated. 
This approximation is not pejorative for the van der Waals interactions because after 
10.0 Å they are practically insignificant. Nevertheless, it is desirable the correction factor 
adding to adjust this neglected interactions, once all van der Waals interactions are 
attractive, and a sum of thousands of those interactions could have a significant weight 
in the total energy calculation.  
The Coulombic interactions are an important term indeed for the far interactions, 
but the attractive interactions with farthest atoms could easily cancel out by the repulsive 
ones resulting in a weak contribution for the energy calculation. 
In conclusion, it is desirable the use of a high cut-off radius, but we should choose 
a radius that follows a good commitment between computation cost and accuracy.  
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2. Quantum Mechanics 
When only the macroscopic world was known, the classical physics based on 
thermodynamics, electromagnetism and Newton’s movement laws were able to correctly 
describe and explain those phenomena. Nevertheless, when the atomic and subatomic 
studies started happening, the classical physics equations could not be applied to those 
systems. Thereat, several scientists as Einstein, De Broglie, Planck, Bohr, Schrödinger, 
among others postulated theories about Quantum Mechanics (QM), which is able to 
describe the majority of all particle-containing system. 
In the beginning, QM calculations and theories could only be applied to small 
systems as the hydrogen atom, particle in the box, harmonic oscillator, particle in the 
ring and particle in the sphere. [133] Afterward, the computational developments 
together with some mathematical approximations turn QM able to be set in more complex 
molecular systems.  
The Quantum Theory born when Max Planck published work, in 1901, describing 
the concept of a quantum of matter and electricity, leading to a proportional relation 
between the energy and the radiation frequency (Equation 12). [140] 
 𝐸 = ℎ𝑣 𝐸 is the energy of a photon with a certain frequency 𝑣. ℎ is the Max Plank’s constant and it has the value 6.626069×10^¥¦	J	s. [141] 
 
Equation 12 – Planck-Einstein relation. 
 
This concept allowed Einstein to explain the photoelectric effect [142] (discovered 
by Hertz [143]), considering an electromagnetic wave a set of particles. The 
interpretation of the light as a set of particles was confirmed later on by Compton in 1923. 
[144] Almost at the same time, Bohr presented his theory about the atomic structure, 
showing that electrons are also quantized, and they could only occupy certain energy 
levels in the atom. Consequently, the electron movement within the atom must be 
accomplished by emission or absorption of energy. [145] In 1924, Louis de Broglie 
confirmed the reciprocity of the wave-particle duality of the matter, affirming that any 
body has a wave associated with it, and it depends on its momentum (Equation 13). 
 𝜆 = ℎ𝑝 𝜆 is the wavelength of a certain body with a momentum 𝑝. 
 
Equation 13 – de Broglie wavelength.  
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In 1927, Heisenberg introduced the notions of the “new” QM as the uncertainty 
principle [146], which criticizes the classical limitations of simple observation. The 
uncertainty principle indicates an impossibility to know accurately, for example, both the 
moment and the position of a certain particle at the same time, according to the Equation 
14. 
 𝜎𝜎ª ≥ ℏ2 𝜎 and 𝜎ª are the position and momentum associated errors. ℏ is the reduced Plancks’ constant (ℏ = ℎ/2𝜋). 
 
Equation 14 – Uncertainty principle. 
 
Based on these works and others by Dirac, Fermi, Born, Davisson, Germer, 
Debye and Maxwell, for example, QM acquired the actual five fundamental postulates 
from which the first one can define the system mathematically: [147] 
 
“To every state of a physical system, there is a function Ψ ascribed  
to and defining the state.” 
 
It means that each physical system, observed by a quantum point of view, is 
defined by a wave function depending on the spatial coordinates (x, y and z) and the 
time (t) which can determine all the features that can be known about the system. [147, 
148] It is important to refer that the wave function represents the probability amplitude. 
In other words, if we consider a hydrogen atom from which the proton is the center of a 
reference system, the wave function gives the probability to find the electron as a function 
of the electron position. [147] 
The second postulate defines how we could get information about the system, 
recurring to operators, where a certain operator could be used to assess certain system 
property (Equation 15). [133, 147, 148] 
 𝐴Ψ = 𝑒Ψ Ψ is the wave function; 𝐴 is the operator for a certain system property; and 𝑒 is the eigenvalue for that property. 
 
Equation 15 – Second Quantum Mechanics Postulate. 
 
The Equation 15 is correlated to the third postulate that defines the eigenvalue 
as the only information that can be measured from the system when a certain operator 
is used. It means that each single measurement corresponds to a quantum operator (𝐴) 
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and only the eigenvalues of the operator are measured satisfying Equation 15. [147, 
148] 
 
 
2.1. Schrödinger Equation 
The Schrödinger equation is a derivative equation from the Equation 15 where the 
operator is the Hamiltonian, and the given eigenvalue is the total system energy. 
Whether the time-dependent Schrödinger equations (Equation 16) could be analytically 
solved, then all system time evolution could be predicted. [133, 147, 148] 
 𝐻Ψ 𝑟, 𝑡 = 𝐸Ψ 𝑟, 𝑡  Ψ 𝑟, 𝑡  is the wave function of the particle with respect to the position (𝑟) and time (𝑡); 𝜇 is inertial mass; 𝐻 is the 
Hamiltonian (quantum operator); 𝐸 is the energy of the particle. 
 
Equation 16 – Time-dependent Schrödinger equation. 
 
In Equation 16, the second member could be defined as the product of imaginary 
unit, reduced Planck’s constant and the partial derivative with respect to time of the wave 
function (Equation 17). [133, 147, 148] 
 𝐻Ψ 𝑟, 𝑡 = 𝑖ℏ 𝛿𝛿𝑡 Ψ 𝑟, 𝑡  Ψ 𝑟, 𝑡  is the wave function with respect to the position (𝑟) and time (𝑡);	𝑖 is the imaginary unit;	ℏ is the Plank constant 
divided by 2𝜋. 
 
Equation 17 – Time-dependent Schrödinger equation. 
 
 The Hamiltonian (𝐻) could also be described as the sum of a kinetic operator (𝑇) 
and a potential operator (𝑉) (Equation 18). 
 𝐻 = 𝑇 + 𝑉 
Equation 18 – Hamiltonian is a function of kinetic and potential operators. 
 
 The potential operator 𝑉 could be described as the potential energy (𝑉(𝑟, 𝑡)). For 
example, if we consider a single electron under the potential field of an atomic nucleus 
with Z protons, the time-independent potential energy could be defined by Equation 19. 
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 𝑉 𝑟 = 𝑍𝑒j4𝜋𝜀=𝑟 𝑍 is the number of protons in the atomic nucleus; 𝑒 is the electron charge; 𝜀= is the electric permittivity of vacuum; 𝑟 is 
the distance between the electron and the atomic nucleus. 
 
Equation 19 – Potential energy calculation for an electron under the potential field of an atomic nucleus. 
 
 On the other hand, the kinetic operator is calculated based on the Laplacian 
operator (a divergence of the gradient of a 𝑥, 𝑦 and 𝑧 function — ·¸·¸ + ·¸·U¸ + ·¸·¹¸ ) and 
inertial particle mass. 
Then, we could write the Schrödinger equation in an extended way (Equation 
20). 
 −ℏj2𝜇 𝛿j𝛿𝑥j + 𝛿j𝛿𝑦j + 𝛿j𝛿𝑧j + 𝑉(𝑟, 𝑡) Ψ 𝑟, 𝑡 = 𝑖ℏ 𝛿𝛿𝑡 Ψ 𝑟, 𝑡  Ψ 𝑟, 𝑡  is the wave function with respect to the position (𝑟) and time (𝑡); 𝜇 is inertial mass; 𝑥, 𝑦 and 𝑧 are the Cartesian 
coordinates; 𝑉(𝑟, 𝑡) is the potential energy with respect to the position and time;	𝑖 is the imaginary unit;	ℏ is the Plank 
constant divided by 2𝜋. 
 
Equation 20 – Time-dependent Schrödinger equation. 
 
 If the potential function was time-independent, we could write the Schrödinger 
equation as a function that depends only on the position of the particle (Equation 21). 
[133] 
 𝐻Ψ 𝑟 = 𝐸Ψ 𝑟  
Equation 21 – Time-independent Schrödinger equation. 
 
 The wave function does not decode into a physical property, but its square 
represents the probability density at a certain time. If it is multiplied by a spatial volume, 
the result is the probability to find that particle in that position. [149] 
 
 
2.2. Hamiltonians 
Mathematically operators are used to get information about system properties 
from the wave function. The operator application to a eigenfunction results into a wave 
function multiplied by the correspondent eigenvalue. In this way, the Hamiltonian (𝐻) is 
the mathematical operator for the wave function that gives the total system energy. [133] 
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As described in the Equation 18, the Hamiltonian is the result of the sum of the kinetic 
and the potential energy operators, which can be expanded according to Equation 22. 
[133] 
 𝐻 = 𝑇\ + 𝑇W + 𝑉\W + 𝑉WW + 𝑉\\ 𝑇\ and 𝑇W are the kinetic operators for nuclei and electrons, respectively. 𝑉\W, 𝑉WW and 𝑉\\ are the potential operators for 
the nucleus-electron, electron-electron and nucleus-nucleus interactions, respectively. 
 
Equation 22 – Hamiltonian is a function of kinetic and potential operators. 
 
Considering the two particles system electron-proton, the kinetic energy operator 
(𝑇\ and 𝑇W) could be calculated according to Equation 23. 
 𝑇W = −ℏj2𝜇WaW}Vd[\ 𝛿j𝛿𝑥j + 𝛿j𝛿𝑦j + 𝛿j𝛿𝑧j WaW}Vd[\ ; 	𝑇\ = −ℏj2𝜇\»}aW»T 𝛿j𝛿𝑥j + 𝛿j𝛿𝑦j + 𝛿j𝛿𝑧j \»}aW»T 
Equation 23 – The kinetic energy operator (𝑻) for an electron or a nucleus. 
 
Additionally, the potential operator is given by the attractive energy associated 
with the attraction between the nucleus and the electron. If we take in consideration more 
than one atom, this term is also affected by the repulsion interactions between different 
electrons and between different atomic nuclei (Equation 24). The potential operators 
are calculated using a Coulombic-like potential as the MM calculations. [133] 
 
𝑉\\ = 𝑍½𝑍¾𝑟½¾¿½^¾ ;	𝑉\W = 𝑍½𝑍b𝑟b½
À
b
¿
½ ; 	𝑉WW = 𝑍b𝑍𝑟b
À
b^  𝐴 and 𝐵 are two different atomic nuclei; 𝑖 and 𝑗 are two different electrons; 𝑁 and 𝑀 are the number of nuclei and 
electrons, respectively; 𝑍 is the charge of each particle; 𝑟 is the distance between two particles. 
 
Equation 24 – The potential operator (𝑽) for a multi-atomic system. 
 
The exact analytically solution for a Schrödinger equation within a poli-electronic 
system is mathematically impossible. Therefore, some approximations and 
considerations must be done to make it available to be applied in more complex systems.  
 
 
2.3. Variational Principle 
The variational principle is an approximation aiming a solution to the Schrödinger 
equation, and it uses an arbitrary wave function able to describe the electronic and 
nuclear coordinates appropriately and also being operated upon by the Hamiltonian. It is 
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mathematically possible to prove that the energy value obtained by the wave function is 
always greater or equal to the real fundamental state’s energy (Equation 25). [149] 
 Ψ_𝐻Ψ_	𝑑𝜏Ψ_j	𝑑𝜏 ≥ 𝐸= 
Equation 25 – Variational principle. 𝜳𝒂 is an arbitrary wave function and 𝑬𝟎 is the real fundamental state’s 
energy. 
 
 The relation in Equation 25 is very important because it allows the test of several 
arbitrary wave functions and reveals which ones have the lowest value. The lower is the 
value of the variational integral and closer will be this value to the real one. Consequently, 
the most accurate will be the wave function that will provide the better description of the 
closely “true” wave function. Taking this into account, we do not need to construct the 
wave function using a linear combination of orthonormal wave functions. Instead any 
random wave function could be built and tested. [149] 
 
 
2.4. Born-Oppenheimer Approximation 
Besides the variational principle consideration, the Hamiltonian calculation for 
more complex molecular systems leads to the requirement of some more mathematically 
approximations to make calculations feasible.  
In 1927, the Born-Oppenheimer approximation was described as a manner to 
simplify the wave function calculations with a tremendous relevance for molecular 
systems. Born-Oppenheimer approximation postulates that the motion of the atomic 
nuclei and electrons can be separated. It means that the total wave function could be a 
result of the nuclei wave function product by the electrons wave function (Equation 26). 
[150] 
 ΨÇ[V_a = ψ\»}aW_d×ψWaW}Vd[\b} 
Equation 26 – General Born-Oppenheimer approximation equation. 
 
This is an acceptable approximation taking into account that the proton 
(1.67×10^jÊ	kg) is 1836 heavier than the electron (9.11×10^¥	kg) leading to an almost 
instantaneous electron rearrangement after nuclear movement. [133, 151] 
Then, we could apply this approximation in the Hamiltonian calculation and split 
the total system energy into the nuclear and electronic energies (Equation 27). 
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 𝐻Ç[V_a = 𝐻\»}aW_d + 𝐻WaW}Vd[\b} 
Equation 27 – The Born-Oppenheimer approximation in a Hamiltonian form. 
 
The electronic Hamiltonian is calculated with nuclei positions fixed, considering 
kinetic energy of each electron under the nuclei’s force field (𝑇WaW}.), the potential energy 
involved in the interelectronic repulsion (𝑉WaW}.^WaW}.) and in the nucleus-electron attraction 
(𝑉WaW}.^\»}aW»T) (Equation 28).  
 𝐻WaW}Vd[\b} = 𝑇WaW}. + 𝑉WaW}.^WaW}. + 𝑉WaW}.^\»}aW»T 
Equation 28 – Electronic Hamiltonian following the Born-Oppenheimer approximation. 
 
On the other hand, the nuclear Hamiltonian is calculated by the sum of the kinetic 
energy associated with the nuclear movements (𝑇\»}aW»T) and the potential energy 
related with the internuclear repulsion (𝑉\»}aW»T^\»}aW»T) (Equation 29).  
 𝐻\»}aW_d = 𝑇\»}aW»T + 𝑉\»}aW»T^\»}aW»T 
Equation 29 – Nuclear Hamiltonian following the Born-Oppenheimer approximation 
 
 
2.4.1. Electronic Hamiltonian 
In the study of catalytic mechanism in biological systems, the electronic 
Hamiltonian presents the biggest contribution to the total energy comparing to the 
nuclear contribution. So, the nuclei position is often fixed, and the energy is calculated 
based only on the electronic fraction. Several theories and methodologies were 
developed to calculate the electronic energy contribution in a more accurate and less 
expensive way possible. 
  
2.4.1.1. Wave function-based Theories 
Considering the wave function-based theories, we could distinguish three 
different theories, the Hartree-Fock (HF), the post-Hartree-Fock (pos-HF) and the semi-
empirical theories. All of these theories were developed in order to calculate the 
electronic fraction of the Schrödinger equation, creating a Potential Energy Surface 
(PES) from which we could obtain, for example, equilibrium geometries and vibrational 
frequencies. The HF methodologies result in more exact solutions, but they are 
computational more expensive. The semi-empirical theories are derived from the HF 
models, but these neglect all mathematically integrals involving more than two nuclei in 
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the Fock matrix consideration. The success of the semi-empirical theories usage 
depends on the accurate substitution of the neglect integrals by parameters fitting 
experimental results. Semi-empirical methods are substantially more computationally 
efficient, but their applications are conditioned by the existing parameterization. Each of 
these methods is briefly described in the next sections. 
 
a) Hartree-Fock	
The Born-Oppenheimer approximation is not enough, in a mathematical manner, 
to allow the energy calculation of a chemical system. Then, the Hartree-Fock theory 
(HFT) allowed the wave function calculation for any system, in an exactly manner, 
making the computer resources the major limitation. HFT describes the orbitals where 
the electrons move around, and the total wave function is given as a product of all those 
orbitals. [151] Nevertheless, these theories also introduce an approximation because 
they neglect the electronic repulsion between two electrons, considering the electron 
movement as a consequence of the electrostatic field created by the nuclei and the 
average field of the n-1 electrons (other electrons) in the system. Then, the electron 
movement could also be described by a single-particle function, being implicitly 
dependent on the motion of the other electrons. [152] Each single-particle function is 
assigned to each electron in the system and the wave function could be achieved by the 
product of all those functions (Equation 30). 
 ΨÍ_dVdWW	Îd[]»}V 𝑟, … , 𝑟\ = 𝜙 𝑟 ×…×𝜙\ 𝑟\  
Equation 30 – The Hartree product between the spatial orbitals of each electron in the system. 
 
Due to the Pauli exclusion principle, electrons with the same spin could not 
occupy the same orbital, so a spin orbital is calculated by the product between the spatial 
orbital and the spin function (𝛼 or 𝛽) (Equation 31). 
 𝜒 𝑥 = 𝜙 𝑟 . 𝛼 
Equation 31 – Spin-orbital calculation by the product between spatial orbital (𝝓 𝒓 ) and spin function (𝜶). 
 
The Hartree product is calculated using the spin orbitals instead of the solely 
spatial orbitals (Equation 32). [152] 
 ΨÍ_dVdWW	Îd[]»}V 𝑥, … , 𝑥\ = 𝜒 𝑥 ×…×𝜒\ 𝑥\  
Equation 32 – The Hartree product between the spin orbitals of each electron in the system. 
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This calculation is not general, and it cannot be applied to all systems. Therefore, 
the spin orbitals determinant, called Slater determinant, should be used in order to 
normalize the calculation and define the expression for all systems (Equation 33). 
 
ΨWaW}Vd[\b} = 1𝑁! 𝜒 𝑥 ⋯ 𝜒¿ 𝑥⋮ ⋱ ⋮𝜒 𝑥¿ ⋯ 𝜒¿ 𝑥¿  
Equation 33 – Slater determinant 
 
Due the fact of no many-body system have a totally correct solution, the 
variational principle provides a mechanism that allows HF calculations give an 
approximated solution but always greater than the real value. This is important because 
the better the wave function, the lower is the energy, and consequently the energy 
minimum corresponds to the best wave function. [149] 
Again, we can apply the variational principle to this type of wave function (Slater 
determinant) and obtain the following equation (Equation 34). 
 
𝐸WaW}Vd[\b} = 𝜒b ℎ¿bÚ 𝜒b	𝑑𝜏b + (𝐽b + 𝐾b)
¿
Ýb
¿
bÚ  ℎ = 𝑇WaW}. + 𝑉WaW}.^\»}aW»T 
Equation 34 - Energy calculation using the HF theory. 
 
The last term in Equation 34 corresponds to the bi-electronic interactions, and 
the 𝐽b is the Coulomb operator, which represents the potential energy of an electron 
within the full electronic field distributed among the occupied spin orbitals. 𝐾b is the 
exchange operator and represents the energy variation when two electrons exchange 
between two different orbitals. [152] The Equation 34 is the sum of each spin orbital 
energy 𝜀b obtained through the Fock operator (𝐹) (Equation 35). 
 𝐹𝜒b = 𝜀b	𝜒b 
Equation 35 – HF equation for a spin orbital 𝝌𝒊. 
 
 
b) Hartree-Fock	Self-Consistent	Field	(SCF)	
The Hartree-Fock equations seem to have a problem because we need to know 
all other spin orbitals to calculate the energy of a certain electron in the system. This 
issue is recurrent in this type of calculation, and it could be solved using the iterative 
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calculation to achieve a solution when the solutions are self-consistent. This method is 
called the self-consistent field (SCF). Recurring to this technique, a first trial set of spin 
orbitals is constructed based on the initial molecular structure. Those spin orbitals are 
used to build the Fock operator which is solved using the HF equations. If the 
convergence criterion is satisfied, the calculation ends and the system energy is 
calculated otherwise the new set of spin orbitals is used to construct a new Fock operator 
and the calculation restarts. [152] 
 
c) Linear	Combination	of	Atomic	Orbitals	(LCAO)	
HF calculations were successfully used when applied to atomic systems. 
However, the molecular application is computational inappropriate. Roothaan and Hall 
suggested an approximation that answered this problem, the linear combination of basis 
sets. This method described the molecular orbitals as functions of a solely electron 
centering in the atomic nucleus. The calculation is performed recurring to the linear 
combination of atomic orbitals theory (LCAO) which s mathematically decoded by 
Equation 36. [152] 
 𝜓Àà = 𝑐d𝜒dd  
Equation 36 – Molecular Orbital wave function based on a set of basis set using the spin orbitals (𝝌𝒓) and 
associated coefficients (𝒄𝒓). 
 
Theoretically, we can use an infinite number of basis functions to increase the 
accuracy, but we have to achieve a commitment between accuracy and computational 
cost.  
 
d) Semi-empirical	
The high accuracy inherent to the HF calculations makes their application 
prohibited due to the high associated computational cost. The semi-empirical simplifies 
this issue through the use of a certain number of parameters that make the bi-electronic 
interactions calculation negligible, leading to fast calculations and allow their application 
in large systems. [152] The parameters could be obtained by high accurate 
computational methods or experimental data. However, it is a difficult to obtain these 
values because of the time-consumption of the great accurate methods and because of 
the low accurate results obtained by experimental methodologies. [149] 
Semi-empirical calculations undertake the only explicit consideration of the valence 
electrons, correcting the atomic charge according to the cerne electrons. The major 
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difference between all the semi-empirical methodologies is derived to the neglect of 
differential overlap. The most primitive approach is called complete neglect of differential 
overlap (CNDO) which consider only the valence orbitals using the Slater-type of orbitals 
(STO), one function per orbital, all the two-electron integrals are parameterized and other 
simplifications to the HF theory are considered, reducing the two-electron integrals 
dependency from N4 to N2 and calculating the remaining through algebraic formulae 
instead of explicit integration. However, this formalism carries a non-negligible chemical 
cost leading to an incapable accuracy to predict good molecular structures. The 
intermediate neglect of differential overlap (INDO) was the successor of the CNDO 
formalism, and it aimed a better description of the electron-electron interactions based 
on the spectroscopic transitions. Then, a new formalism was considered, the neglect of 
diatomic differential overlap (NDDO), where the neglect of differential overlap is only 
applied when the basis function of a certain electron belongs to different atoms.  Based 
on this formalism, several methods were developed such as MNDO (Modified Neglect of 
Diatomic Overlap), AM1 (Austin Model 1), PM3 (Parameterized Model 3) and PM6 
(Parameterized Model 6). [149]  
 
i. Parameterized	Model	6	
The PM6 method is a recent NDDO modification that was parameterized for 70 
elements. This method presents an average unsigned error of only 4.4 kcal.mol-1 when 
applied to 1373 compounds containing H, C, N, O, F, P, S, Cl, and Br. It was a significant 
improvement over the AM1 and PM3 methods. [153] Besides the interesting results that 
PM6 revealed, the molecular geometries predicted by this theory are less accurate than 
HF or DFT theories, for example. Nevertheless, the parameterization process itself 
carries an inherent error by the human choice of which parameters and data should be 
used to define the parameters.  
 
2.4.1.2. Density-Functional Theory 
As it was mentioned before, the Schrödinger equation gives an exact solution for 
any system. However, its resolution is impossible for several relevant systems like 
enzymes. The HF considerations to simplify the calculations are also too heavy to be 
used in large poly-electronic systems because the requirement for the spin and three-
dimensional coordinates for each electron. Furthermore, the wave function, per si, is 
hard to understand once it does not culminate in a physical property. [149] The semi-
empirical attempt to solve the problem also does not offer a really good alternative to 
describe the molecular geometries accurately.  
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The Density-Functional Theory (DFT) described another way to predict the 
system’s energy, for example, using easily concepts and mathematically-less complex 
approaches. In a general overview, a Hamiltonian depends only on the position and 
atomic numbers of the nuclei and the total number of electrons. In this manner to look at 
a chemical system, the electron density (𝜌) is an observable physical property whose 
integration over all occupied space gives the total number of electrons (Equation 37). 
[149] 
 𝑁 = 𝜌 𝑟 𝑑𝑟 
Equation 37 – Number of electrons (𝑵) given by the integral of the electron density (𝝆 𝒓 ) over all space. 
 
 The electron density concept was introduced by Thomas and Fermi in the 1920s 
as a manner to simply the mathematical consideration of a function per each electron in 
the system. [154] [155] 
Because the nuclei are in fact point charges, they could be described as local 
maxima in the electron density, appearing as point charges among the system’s space. 
Now, the nuclear atomic number is the unique factor that was not included yet to build 
the Hamiltonian. This system property could then be easily introduced in the electron 
density. A certain nucleus A located at an electron density maximum (𝑟½) could also be 
introduced according to the Equation 38. [149] 
 𝛿𝜌(𝑟½)𝛿𝑟½ dåÚ= = −2𝑍½	𝜌 𝑟½  
Equation 38 – Electron density calculation for an atomic nucleus A with atomic number 𝒁𝑨 and a spherically 
averaged density 𝝆(𝒓𝑨). 
 
 These concepts only make a Hamiltonian build possible using a certain electron 
density function, and it also presents an alternative manner to solve the Schrödinger 
equation. [149] The energy could be therefore calculated, using DFT, as a functional of 
the electron density, denoted 𝐸[𝜌]. It means that the energy is given by a function where 
its arguments are another function, in this case the electron density. [152] 
 Furthermore, the DFT calculations are much faster than ab initio methods, when 
applied to systems with 100 or more atoms. Additionally, DFT calculations on d-block 
elements containing systems present results which agree more closely with experimental 
data comparatively with ab initio methodologies. DFT calculation is also faster than ab 
initio because of its dependency on only three coordinates (x, y and z coordinates of 
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 𝜌 𝑟 ) contrasting with ab initio, which depends on four variables per each electron (x, y 
and coordinates plus the spin value). [152] 
 The DFT energy calculation can be given by the Equation 39 and the energy 
associated with internuclear repulsion is added after, according to Born-Oppenheimer 
approximation. 
 𝐸WaW}Vd[\b} = 𝑇 𝜌 𝑟 + 𝑉\W 𝜌 𝑟 + 𝑉WW[𝜌 𝑟 ] 𝑇 𝜌 𝑟  is the electrons’ kinetic energy. 𝑉\W 𝜌 𝑟  and 𝑉WW[𝜌 𝑟 ] are the potential energy associated with nucleus-electron 
attraction and electron-electron repulsion, respectively. 
 
Equation 39 – Electronic energy calculation according to Thomas and Fermi. 
 
 The potential energy terms are covered by a classical approach following the 
Equation 40 and Equation 41. 
 
𝑉\W 𝜌 𝑟 = 𝑍½|𝑟 − 𝑟_| 𝜌(𝑟) 𝑑𝑟À_Ú  
Equation 40 – Potential energy calculation associated with the nucleus-electron attraction. 
 𝑉WW 𝜌 𝑟 = 12 𝜌(𝑟b)𝜌(𝑟)|𝑟b − 𝑟| 𝑑𝑟b 𝑑𝑟 
Equation 41 – Potential energy calculation associated with the electron-electron repulsion. 
 
 The kinetic energy calculation of a continuous charge distribution is conceptually 
difficult to understand. “Jellium” was introduced to answer this issue, which is a system 
where an infinite number of electrons are moving in an infinite volume of space that is 
characterized by a uniformly distributed positive charge. [149] In 1927, Thomas and 
Fermi projected an equation that allows the kinetic energy calculation for the “jellium” 
system (Equation 42) using fermion statistical mechanics.  
 𝑇 𝜌 𝑟 = 310 3𝜋j j¥ 	 𝜌ì¥ 𝑟 𝑑𝑟 
Equation 42 – Kinetic energy (𝑻 𝝆 𝒓 ) calculation for the “jellium” system. 
 
This was an important historic step in the DFT development, but these 
considerations do not give better results than previous methods. Later on, Dirac 
proposed the addition of an exchange term (Equation 43) to Equation 39. [149] This 
exchange term allows the consideration of the Pauli’s principle. 
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𝐸W}c_\`W 𝜌 𝑟 = −9𝛼8 3𝜋 ¥ 𝜌¦¥(𝑟) 𝑑𝑟 
Equation 43 – Exchange energy. 𝜶 could be 1 if the Slater’s derivation is considered. Some empirical values 
were attributed to 𝜶. 
 
 Still, this correction was not enough to make DFT a better alternative to previous 
methods. 
 
a) Hohenberg-Kohn	Theorems	
 The DFT methodology was established and legitimated by the Hohenberg-Kohn 
theorems, in 1964, from which the first theorem asserts that in a non-degenerated 
system, the ground-state energy could be solely defined by the electron density. [156] 
Considering it, they proved that knowing the nuclei’s positions (the external potential) 
and the number of electrons, the Hamiltonian is known, and consequently the wave 
function associated with the ground-state is also known.  
 The second theorem also called the Hohenberg-Kohn variational theorem, 
proved that the electron density followed the variation principle. Assuming a certain 
candidate density, the energy expecting value can be predicted according to the 
Equation 44. [149] 
 Ψ}_\]b]_VW|𝐻}_\]b]_VW|Ψ}_\]b]_VW = 𝐸}_\]b]_VW ≥ 𝐸= 
Equation 44 – Energy calculated through a candidate density function is always greater than or equal to the 
ground-state energy. 
 
 As described before, we could choose several density functions, and those that 
provide lower energies are closer to the real ground-state energy.  
 Besides the excellent assumptions of these two theorems, they do not give a real 
idea about the criteria that should be used to achieve the best density functions. [149] 
 
b) Kohn-Sham	Self-Consistent	Field	(SCF)	
 In 1965, Kohn and Sham presented a way to achieve the system’s energy 
calculation recurring to the density function. They proposed a hypothetical system where 
the electrons do not interact with each other whose Hamiltonian could be given by the 
sum of mono-electronic operators. According to this assumption, the electron density of 
the system is identical to the ground-state density and the energy could be given by the  
Equation 45. [157] 
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 𝐸 𝜌 𝑟 = 𝑇\b 𝜌 𝑟 + 𝑉\W 𝜌 𝑟 + 𝑉WW 𝜌 𝑟 + ∆𝑇 𝜌 𝑟 + ∆𝑉WW 𝜌 𝑟  𝑇\b 𝜌 𝑟  is the kinetic energy of the non-interacting electrons. ∆𝑇 𝜌 𝑟  is the correction to the kinetic energy deriving 
from the interacting nature of the electrons. ∆𝑉WW 𝜌 𝑟  is all the non-classical corrections to the electron-electron 
repulsion energy. 
 
Equation 45 – Energy calculation according to Kohn-Sham SCF theory. 
 
 
 Considering this non-interacting system, the total kinetic energy is given by the 
sum of all individual electronic kinetic energies. The calculation is difficult since it requires 
the calculation of ∆𝑇 𝜌 𝑟  and ∆𝑉WW 𝜌 𝑟  terms whose sum is commonly referred as 
exchange-correlation energy (𝐸îï). An orbital expression for the density may be written 
as the following equation: 
 
𝐸 𝜌 𝑟 = 𝜒b| − 12 ∇jb|𝜒b − 𝜒b| 𝑍ñ|𝑟b − 𝑟ñ|À_Ú |𝜒b
¿
bÚ + 𝜒b| 12 𝜌(𝑟)|𝑟b − 𝑟| 𝑑𝑟 |𝜒b
¿
bÚ+ 𝐸îï[𝜌 𝑟 ] 
Equation 46 – Energy calculation considering orbitals. 
 
 This equation could be used together with the variational principle to predict the 
best density function to describe the system, in other words, the closest density to the 
ground-state one. As HF equations, the Kohn-Sham equations could be presented in a 
similar way of HF equations (Equation 47). [149] 
 ℎbòó𝜒b = 𝜀b	𝜒b 
Equation 47 – Kohn-Sham equation for the orbitals 𝝌𝒊. 
 
 ℎbòó is the mono-electronic operator and is defined by: 
 
ℎbòó = − 12 ∇jb − 𝑍ñ𝑟b − 𝑟ñÀ_Ú + 𝜌 𝑟𝑟b − 𝑟 𝑑𝑟 + 𝑉îï 𝑉îï = 𝛿𝐸îï𝛿𝜌(𝑟) 
Equation 48 – Kohn-Sham (KS) mono-electronic operator. 𝑽𝑿𝑪 is a functional derivative. 
 
 
c) Exchange-correlation	functionals	
 As described above, DFT is an exact theory which needs a technique to get a 
good exchange-correlation energy approximation (𝐸îï[𝜌 𝑟 ]). This functional may be 
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split into two ones, the exchange functional (𝐸î[𝜌 𝑟 ]) and the correlation functional 
(𝐸ï[𝜌 𝑟 ]). The exchange functional is related to interactions between electrons with the 
same spin whereas the correlation functions are associated with the interaction between 
electrons of the opposite spin. Both functionals could be calculated using one of the two 
existing functionals, the local density approximation (LDA) and the generalized gradient 
approximation (GGA). [149] 
 The LDA is the simplest functional, and the electronic density is treated as a 
uniform distribution of electrons. This functional presented good results for systems 
containing metals, but it is inefficient for systems containing many different molecules 
because LDA requires a well-defined electronic density. LDA considers that each 
electron feels the same field regardless its position. [152] 
 The GGA circumvents this limitation through the density gradient inclusion, which 
takes into account the density variations throughout the system. Almost all GGA 
functionals are based on LSDA (Local spin-density approximation), a LDA-related 
functional which includes the spin. The exchange-correlation energy can be calculated, 
through GGA (𝐸îï 𝜌 𝑟 ), adding a density gradient-dependent term to the LSDA 
(Equation 49). 
 
𝐸îï 𝜌 𝑟 = −2¥𝐶 𝜌÷¦¥(𝑟) + 𝜌ø¦¥(𝑟) 𝑑𝑟 + |∇𝜌 𝑟 |𝜌(𝑟)¦¥  
Equation 49 – Exchange-correlation energy calculation using GGA 
 
 The first widely used exchange functional, named “B”, was developed by Axel 
Becke and his mathematical approach includes only one empirical parameter optimized 
considering the noble gases. A few more exchange functionals were developed based 
on B, such as CAM (Coulomb-attenuating method) [158], FT97 (developed by Filatov 
and Thiel in 1997) [159] and PW (Perdew-Wang) [160]. Other functionals were built using 
no empirical parameter like B88 [161], LG (Lacks and Gordon) [162] and PBE (Perdew–
Burke–Ernzerhof) [163]. 
 The correlation functional could be corrected using B88 [161], P86 (Perdew 86) 
[160] and PW91 [164] which do not include any parameter or LYP (Lee, Yang and Parr) 
[165] which includes four parameters but it is able to totally cancel the self-interaction 
error in one-electron systems.  
 These methods present the advantage of allowing the combination between any 
exchange functional with any correlation functional. BLYP is a popular example of that 
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combination once combines the Becke exchange functional with the Lee-Yang-Parr 
correlation functional. [149] 
 Later on, hybrid functionals were developed recurring to Hartree-Fock exchange 
functionals that are considered together with exchange and correlation DFT functionals, 
according to the following equation. [149] 
 𝐸îïÍUZdb] = 𝑐Íù	𝐸îÍù + 𝑐úùÇ	𝐸îïúùÇ 
Equation 50 – Hybrid exchange-correlation energy calculation. 𝒄𝑯𝑭 and 𝒄𝑫𝑭𝑻 are constants obtained by 
mathematical calculations fitting experimental data. 
 
 B3LYP is the most used hybrid functional and combines the three parameters 
Becke functional (B3) and the LYP functional with some HF terms. The exchange-
correlation energy calculated through the B3LYP functional follows the Equation 51. 
[149] 
 𝐸îï¾¥ýþÎ = 1 − 𝛼 𝐸îýóú½ + 𝑐=	𝐸îÍù + 𝑐	∆𝐸î¾ÿÿ + 1 − 𝑐} 𝐸ïýóú½ + 𝑐}𝐸ïýþÎ 
Equation 51 – B3LYP exchange-correlation energy calculation. 𝒄𝟎, 𝒄𝒙 and 𝒄𝒄 are empirical parameters 
determined by Becke. 
 
 This functional provides the best results comparing with other exchange-
correlation functionals, and the energy calculation error is about 3 kcal/mol when 
compared to true ab initio methods. [149] 
 Recently, in 2005, Minnesota functionals, developed by Truhlar, introduced a 
higher weight for HF exchange energy. The first functional, M05 [166], considered 28% 
of HF exchange energy while the successor M05-2X [167] includes 56%. In 2007, the 
M06 family of functionals [168], M06 including 27% of HF correction and M06-2X with 
54% were published, and they appear as an improvement of the previous M05 
functionals. The mean error of energy calculation decreased comparing with M05 and 
allow a more accurate energy determination. The exchange-correlation energy 
calculation follows: 
 𝐸îïÀ= = 𝑋100 𝐸îÍù + 1 − 𝑋100 𝐸îúùÇ + 𝐸ïúùÇ 𝑋 is equal to 27 for M06 functional and 54 for the M06-2X. 
 
Equation 52 – Exchange-correlation energy calculation used by the M06 family of functionals. 
 
 Unfortunately, M06 methods require highly computational resources that make 
its use inadequate when biological systems are studied. Consequently, in this work, the 
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M06 methods are used to calculate the energies in a more accurate manner, but the 
geometry optimization should be done recurring to the B3LYP functional.  
 
d) Dispersion	corrections	
The major disadvantage of DFT methods is the poor description of the London 
dispersion interactions. These interactions are very important for large systems (e.g. 
enzymes) in order to reach an excellent chemical accuracy. The dispersion correction 
functional (DCF) is an add-on to DFT calculation once it allows an energy calculation 
refinement achieved through a better description of the dispersion interactions. The most 
recent parameterization of DCF is DFT-D3, and it was parameterized by the Grimme’s 
group. [169] The DFT-D3 functional was improved by Becke and Johnson (BJ) through 
the introduction of an extra damping functional. The damping functional does not require 
any pair-specific cut-off radii, and it also cancels all artificial repulsive interatomic forces 
at short distances. Besides the better description, no significant differences were 
observed in the energies calculated using the BJ functional or the original DFT-D3 
functional. [170] Furthermore, there are not parameters to use BJ functional as an add-
on functional of M06 or M06-2X. Consequently, in this work, only the DFT-D3 functional 
was used to correct the London dispersion interactions.  
 
2.4.1.3. Basis Sets  
 Basis sets are sets of mathematical functions used to describe atomic orbitals in 
quantum mechanical calculations as DFT and ab initio, in contrast with parameter-
dependent methods such as semi-empirical and molecular mechanics. The results are 
much better as more accurate are the orbital description by the mathematical functions. 
In the limit, we could use an infinite number of basis sets in order to describe orbitals 
more accurately as possible. However, it has a computational cost, and a compromise 
should be taken into account between accuracy and computational cost. Consequently, 
two main criteria must be considered when a basis set limitation is assigned: the basis 
set must be able to describe the real wave function and generate useful chemical results; 
furthermore, those sets should offer a simple way to solve the exchange-correlation 
functionals without an excessive computational cost. [149] 
 
a) Slater-type	orbitals	(STO)	
 The Slater-type orbitals (STO) functions were the first to be applied, and they 
present an exponential dependence of the nucleus-electron distance, describing the 
60 FCUP 
Computational studies addressed to Histidine decarboxylase 
 
hydrogen atomic orbitals accurately. This exponential approach allows a fast 
convergence process. However, their application is limited to systems with a few number 
of atoms due to the difficulty to calculate their four center integrals. STO orbitals do not 
include the orbital radial nodes, but they could be introduced through the linear 
combination of STOs. [149, 152] 
 
b) Gaussian-type	orbitals	(GTO)	
 Boys introduced, in 1950, an improvement to STO replacing the 𝑒^d dependence 
of the STO functions by a 𝑒^d¸. This was the turning point and the establishment of the 
Gaussian-type orbitals (GTO) defined as: 
 
𝜒"Çà(𝑥, 𝑦, 𝑧; 𝛼, 𝑖, 𝑗, 𝑘) = 2𝛼𝜋 ¥¦ (8𝛼)(b##ñ)𝑖! 𝑗! 𝑘!(2𝑖)! (2𝑗)! (2𝑘)! j 𝑥b𝑦𝑧ñ𝑒^÷(¸#U¸#¹¸) 𝛼 determines the GTO width. 𝑖, 𝑗, 𝑘 are the non-negative integers that define the orbital nature. 𝑥, 𝑦, 𝑧 are the atom 
position coordinates. 
 
Equation 53 – GTO function in atom-centered Cartesian coordinates. 
 
 If all defining-orbital integers are zero, the GTO is an s-type of orbital. In a case 
where one of the integers gets the unitary value, a p-type GTO is defined, and we could 
have three combinations corresponding to 𝑝, 𝑝U and 𝑝¹. The d-type of orbitals are six, 
and they are defined by the 𝑖, 𝑗, 𝑘 sum equal to two, leading to a six Cartesian prefactors 
of 𝑥j, 𝑦j, 𝑧j, 𝑥𝑦, 𝑥𝑧 and 𝑦𝑧. The Schrödinger equation only predicts the first five, being 
the two of the last ones obtained by linear combination of orbitals. In fact, the remaining 
one is an s-type of orbital due to its spherical symmetry. [149] 
 Besides the efficient mathematical calculation allowed by GTO functions, they do 
not reproduce the orbital amplitude accurately along the nucleus-electron distance 
because their 𝑟^j dependence. Consequently, the contracted GTO functions (CGTO) 
were developed through the linear combination of STO and GTO orbitals aiming a correct 
orbital description with a low computational cost achieved with GTO functions. The 
CGTO functions improve the description of the electrons near the atomic nucleus, but 
due to their insignificant role in the chemical process, this approximation does not limit 
the results quality. [149, 152] 
 Later on, Pople introduced the split-valence basis concept where the core orbitals 
are treated under a certain scheme of Gaussian primitives whereas the valence orbitals 
are treated using two or three different schemes of Gaussian contraction. A 
nomenclature method was also suggested to describe this method: n-abcG. n represents 
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the number of primitives used to contract GTO of the core orbitals, and the abc 
represents the division and the treatment assigned to the valence orbitals. For example, 
a common basis set 6-31G is characterized by six primitive GTOs for the core orbitals 
and the valence orbitals are divided into two from which the most internal is described 
through three primitive GTOs and the external ones use only one. [149, 152] 
 CGTOs can describe accurately isolated atoms, but the description is poor when 
molecular systems are considered because they are not polarized and their shape is not 
modulated by the surrounding atoms. Pople also introduces the polarization and diffuse 
functions, which can be combined with previous GTOs, to represent the interactional 
phenomena. [149, 152] 
 The polarization functions are characterized by a higher angular momentum of 
the valence orbitals. Considering the hydrogen atom, a p-type orbital can be used to 
polarize the s-type orbital of the hydrogen atom, distorting their electron cloud defining 
the chemical bond. We could also have d-orbitals polarizing p-orbitals which are an 
extremely relevant consideration for the second-period elements. Pople also defined a 
nomenclature to named this polarization functions. If we have a 6-31G set that uses d-
orbital polarization, they could be written as 6-31G(d) or 6-31G*. Additionally, the s-
orbitals polarization by p-orbitals could be included and the set is named 6-31G(d,p) or 
6-31G**. In this work the 6-31G(d) basis set was used to perform the geometry 
optimization due to their good balance between computational cost and accuracy. [149, 
152] 
 The diffusion functions are essential for the correct description of highly negative 
molecules where the electron cloud is considerable more displaced relatively to the 
nucleus. This functions includes a different exponential and are denoted by “+” or “++” if 
they assigned the diffusion functions to heavy atoms or heavy and hydrogen atoms, 
respectively. Considering a system where the hydrogens and heavy atoms are 
considered using diffusion functions, the basis set is written 6-31G++(d). [149, 152] 
 
2.4.2. Nuclear Hamiltonian 
All the previous calculation methods are able to determine solely the electronic 
energy of a system plus the energy that derives from the interaction between the nucleus 
and the electrons (electronic Hamiltonian). However, in order to obtain the full energy, it 
is necessary to calculate the kinetic and potential energies from the nucleus. This energy 
is calculated using the nuclear Hamiltonian and uses certain approximations to achieve 
its calculation.  
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The calculation of the nuclear Hamiltonian is extremely important when the catalytic 
mechanisms are studied because it provides the activation and reaction ∆G (free Gibbs 
energy variation). Besides the slight effect of the nuclear movement into the global 
system energy, its effect could be a cause of the disagreement between experimental 
determinations and theoretical calculations. Even at 0 K, the nuclear motion is not null, 
and the internal energy of the system is given by the sum of the electronic energy and 
the zero-point energy (ZPE). Further, the thermal corrections are computed and added 
to the electronic energy in order to obtain an energy that fits a certain temperature and 
allows the comparison with experimental data. The internal energy at a certain 
temperature could be calculated by the following equation: 
 𝐸ÇÚjÊ¥.ì	ò = 𝐸WaW}Vd[\b} + 𝐸Vd_\Ta_Vb[\_a + 𝐸d[V_Vb[\_a + 𝐸~bZd_Vb[\_a ÇÚjÊ¥.jì	ò 
Equation 54 – Internal energy calculation at a certain temperature. 
 
 The last three terms of the Equation 54 compose the nuclear Hamiltonian and 
they are calculated classically being the translational energy (𝐸Vd_\Ta_Vb[\_a) calculated 
under the particle in a box model, the rotational energy (𝐸d[V_Vb[\_a), calculated based on 
rigid rotor model and the vibrational energy (𝐸~bZd_Vb[\_a) that is computed for each 
vibrational mode of a molecule. 
 Additionally, the normal mode analysis of the vibrational energies provides the 
values of all the frequencies in the system. These frequencies are calculated through the 
second derivative of the energy. Commonly, when we study a catalytic mechanism, we 
are interested in the minima (reactant and product) and the TS. The normal mode 
analysis allows the TS characterization, once a TS has one and only one imaginary 
frequency. The imaginary frequency must involve the atoms that are related with the 
reaction coordinate. Otherwise, both minima have only positive frequencies.  
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3. Hybrid Methods 
 The previous sections describe different theoretical methods characterized by 
different accuracy and consequently different computational cost. Obviously, the QM-
based methods, as DFT or ab initio, present a high exactness in the chemical geometry 
and energy description. However, their application is limited above a hundred atoms 
because their high computational requirements. When we want to study biological 
systems, such as enzymes, we have to consider a huge number of atoms, habitually 
thousands of them. QM methods cannot be considered, and only MM methods could be 
used to study these systems. Unfortunately, MM does not consider electrons and its 
classical approach is not able to describe chemical reactions involving the bond 
breakage and formation.  
 In last few years, the hybrid methods have been considered and developed to 
assign different theoretical levels to different parts of a certain system. Those hybrid 
methods are commonly called QM/MM because the most considered a small part of the 
system using a QM-based method and the remaining through MM. That approximation 
is acceptable because usually the electron-involving phenomena are constricted to the 
active site. A careful choice of which atoms should be studied using a QM method leads 
to very good results and an accomplishable computational calculation. [149, 151, 152] 
 The present work uses precisely the QM/MM methodology to address the mHDC 
catalytic mechanism, using DFT to describe the active site relevant atoms, being the 
remaining protein treated under MM approach. 
 
 
3.1. Type of methods 
 The first step that should be taken, when a QM/MM methodology is used to study 
a certain system, is the choice of which atoms will be studied using which method. 
Commonly, biological systems are studied considering the relevant active site amino 
acid residues, substrates and/or co-factor in the high-level layer (HL) whose calculation 
is done using a QM method. The current computing power does not allow more than few 
hundreds of atoms in the HL. The remaining entire protein and solvent correspond to the 
low-level layer (LL), and it should be treated by MM methods. The big challenge of this 
hybrid approach is related to the boundary zone and how could the connection between 
layers be made. If the bond-interactions appears to be difficult to consider, the non-
bonding interaction, as van der Walls and electrostatic ones, is much more complicated 
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due to the polarization that atoms from one layer could induce in the other. Techniques 
to address this problem will be explained ahead.  
  The energy system calculation can be done using mainly two types of 
approaches, the additive and subtractive methods, in order to combine the energy 
calculated to each layer. In this work, the subtractive method was used because the 
additive method has not accurate equation and parameters to efficiently calculate the 
coupling term of its energy equation. [171] 
 Considering a two region split system (HL and LL), three calculations should be 
done to calculate the total system energy (𝐸$À/ÀÀ½aa ). According to the Equation 55, first 
all the system is considered under the MM theoretical level (𝐸ÀÀ½aa ). Then, only the HL 
atoms associated energy is calculated using the MM method (𝐸ÀÀÍý ). The LL region 
energy is calculated subtracting this last energy to the first one. Finally, the energy of the 
HL atoms is computed again using the QM theoretical level (𝐸$ÀÍý ) and the resulting 
energy summed. 
 𝐸$À/ÀÀ½aa = 𝐸ÀÀ½aa − 𝐸ÀÀÍý + 𝐸$ÀÍý  
Equation 55 – Energy calculation of a subtractive-type of hybrid method 
 
 The system could be divided into more regions and the total energy calculated is 
using the same type of protocol. 
 
3.1.1. ONIOM 
 ONIOM (our own N-layered integrated molecular orbital molecular mechanics) is 
one of the most used subtractive hybrid methods and allows a multiple system division. 
[172] According to the authors, a protein could be studied using MM to describe the 
external region; a semi-empirical method for the intermediate amino acid residues; and 
the active site region can be calculated using a DFT or ab initio method. ONIOM requires 
an explicit description of charges and spin multiplicities for the different regions. [149] 
 In this work, a two-layer system (Fig. 18) was used, and the HL calculation 
recurred to DFT (B3LYP) method, and LL used MM approach. The energy was 
calculated according to the following equation: 
 𝐸úùÇ/ÀÀ½aa = 𝐸ÀÀ½aa − 𝐸ÀÀÍý + 𝐸úùÇÍý  
Equation 56 - Energy calculation of the two-layered ONIOM method. 
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Fig. 18 – Representation of the ONIOM two-layer method. 
Red spheres represent the high level atoms considered using DFT method. Water molecules (Glass bubble 
representation) and the remaining protein (blue ribbon representation) compose the low level treated by MM. Black 
spheres bonded to the high level atoms represent hydrogen atoms used under the link atoms approach. 
 
 
3.2. Boundary methods 
 The hybrid method raises a problem related with the atom linkage between atoms 
belonging to different layers. The problem is quietly bigger when this interatomic 
interaction is covalent which is commonly founded in protein studies. Two 
approximations were developed in order to overcome this problem: the link atoms 
approach and the frozen orbital approach. [149] 
 
3.2.1. Link atoms approach 
 Link atoms approach allows the structural and energetic correction due to the 
boundary cut between layers. This approach uses hydrogen atoms to bind directly to the 
HL atoms whose bonds were cut in the division of layers (Fig. 18). The hydrogen atoms 
can be replaced by other elements such as halogens or group of atoms. However, the 
added atoms are not considered when the MM calculation is computed because those 
atoms are not part of the system. The energy of the bonds which were cut are evaluated 
by MM method considering the respectively HL atom as a LL one. Some studies neglect 
a few of intramolecular features such as angle and torsional bending. [149] 
 The Gaussian software adds the link atoms through a vector whose direction is 
dictated by the HL atom configuration. The link atom is placed at a certain typical 
distance which depends on the involved elements. [149] 
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 Besides the link atoms approach simplicity, their application introduces some 
geometry and energy related errors due to the link atoms induced polarization on the HL. 
However, this is the most used approach mainly due to the difficulties inherent to frozen 
orbital approach implementation.  
 
3.3. Communication between layers 
 In addition to the bonded atoms description, hybrid methods also present other 
problem related to the electrostatic and van der Waals interactions between atoms 
belonging to different layers. Consequently, polarization effects are neglected, and the 
boundary regions tend to be over polarized. Some methods were developed to transfer 
the polarization effect between layers. Nonetheless, their application could be more or 
less extensive, carrying a high computational cost. The mechanical and electrostatic 
embedding methods are the two most used. [149] 
 
3.3.1. Mechanical embedding 
 The mechanical embedding method is the simplest one, allowing a LL 
polarization induced by the HL atoms. The HL region is calculated using the QM method 
without any concern about the polarization. Then, the LL region is calculated using MM 
method feeling the HL polarization, which is introduced through punctual charges. In fact, 
the charges of HL atoms are calculated in each step, but the system does not undergo 
a new optimization cycle concerning those new charges of HL. Habitually, Lennard-
Jones parameters are not updated along the simulation. Some consequences can arise 
from that approximation, mainly the changes in hybridization states whose influence is 
not accounted for. Fortunately, Lennard-Jones potential is a quite short-range function 
introducing not very significant error.  
 
3.3.2. Electrostatic embedding 
 The electrostatic embedding allows a HL polarization by the LL region, which is 
introduced through an additional mono-electronic term that is added to the QM 
Hamiltonian. This term is calculated from the atomic charge distribution along the LL 
region. Otherwise, the LL polarization due to the HL atoms is neglected in this approach, 
but the results tend to be considerably better than those obtained by mechanical 
embedding approach. In sum, electrostatic embedding scheme adds a new self-
consistent cycle where the MM layer must converge according to the new orbital 
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coefficients determined after each cycle for the QM layer. The main disadvantage of this 
approximation is the computational effort increase.  
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C. Results and Discussion 
 
 
 
 
Everything is theoretically impossible, 
until it is done. 
Robert Heinlein 
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In this work, we studied the catalytic mechanism of mHDC using an atomistic 
perspective. The only crystallographic structure of the hHDC available on the Protein 
Data Bank (PDB) was used to study the catalytic mechanism.  
 
 
1. Structure preparation 
Since the only available structure has an inhibitor in the active site, instead of the 
natural substrate, we modified it accordingly. The following section will depict the 
structure of hHDC, and the procedures that were done to prepare the models. 
The PDB file of hHDC includes three dimers that are co-crystallized with an 
inhibitor (HME), some structural modifications were done in order to get a representative 
model of hHDC with the natural substrate. The present section described the steps used 
to obtain that representative model. 
 
 
1.1. PDB Analysis 
First of all, only one of the dimeric structures of HDC was selected from the PDB 
file (PDB code: 4E1O). It is important to take into account the dimeric structure of hHDC 
since the active site of this enzyme (one in each monomer) is composed of residues of 
both monomers. The dimer that was chosen includes chains A and B even though Gly-
1 is missing. The dimer containing chains C and D was not considered because the chain 
C has a Gly-Pro-Leu tag, which was artificially introduced to help the protein purification. 
The third dimer (including chain E and F) was also discarded because comparatively to 
dimer AB, it provides a worst orientation of the PLP-substrate inside the active site. 
(Supplementary Fig. 1) 
In our models, each subunit of hHDC contains 477 amino acid residues, resulting 
in a total of 956 residues for the active dimer. Each subunit comprises fourteen α-helices, 
nine 310-helices, five β-bridges and eleven β-sheets. [17] Active hHDC has also two 
active sites that are located in the interface region between the two subunits that 
comprise amino acid residues from both monomers, i.e.,  Asp-273A, His-194A, Ser-
151A, Arg-447A, Ser-154A, Thr-248A and Ser-196A from chain A and Tyr-334B and 
Ser-354B from chain B (Fig. 19). 
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Fig. 19 – Amino acid residues at the active site interacting with the external aldimine. 
CPK representation of the external aldimine (top center image) and CPK representation of the side chain of each amino 
acid residue labeled with name, number, and chain; and non-bond interactions (dash line). 
 
 
 
1.2. Model Preparation 
In the co-crystalized structure the HME inhibitor is already bonded to the PLP 
cofactor in the form of an external aldimine (Fig. 20 Left). In order to model the “natural” 
external aldimine (EA-S model), the methyl group was removed from that structure (Fig. 
20 Right).  
 
 
Fig. 20 – External aldimine representation.  
CPK representation of (Left) the hHDC inhibitor (HME) bonded to the PLP cofactor. Structure from original PDB file (PDB 
code: 4E1O) without protonation; and (Right) the hHDC substrate (L-histidine) bonded to the PLP cofactor. Structure 
modified from the PDB file.  
 
Experimental data showed that a quinonoid intermediate (QI) is formed during 
the conversion of L-histidine into histamine by hHDC. [26] Therefore, the QI model (Fig. 
SER354B
SER151A
ASP273A
SER196A
HIS194A
TYR334B
ARG447A THR248A
FCUP 
Computational studies addressed to Histidine decarboxylase 
73 
 
21 Right) was also prepared by removing the carboxylate group from the external 
aldimine of the EA-S model (Fig. 21 Left). 
  
 
Fig. 21 – CPK representation of (Left) the EA-S model and (Right) the QI model.  
An atom designation was assigned to each atom of the external aldimine and quinonoid intermediate. 
 
As mentioned before, two cysteine residues (C180S and C418S) were mutated 
to help the crystallization process of the complex between the enzyme and the inhibitor. 
These residues were mutated to the proper amino acid residue, in the built model, as it 
would be found in wild-type enzyme. [17] 
 
 
2. Molecular Dynamics Simulations 
After the adequate preparation of the structures, MD simulations were run for the 
resulting models (EA-S and QI models). MD simulations allow to equilibrate the structure 
and get an ensemble of conformations from which we could get hints about the catalytic 
mechanism. Furthermore, they also generated relevant structural information such as: i) 
hydrogen bond interactions between the external aldimine or the quinonoid intermediate 
with the residues of the binding site; ii) the flexibility of some amino acid residues from 
the active site; and iii) conformational rearrangements of the external aldimine (PLP 
bonded to the substrate) in contrast with the quinonoid intermediate (PLP bonded to the 
decarboxylated substrate). 
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2.1. Parameterization 
MD simulations use MM, which requires the parameterization of some molecules 
that are not fully parameterized on the available force fields. In this case, the external 
aldimine and the quinonoid intermediate do not have their parameters available in the 
AMBER force fields (ff99SB [135] and GAFF [173]). Therefore, the required atomic 
charges were obtained through an ab initio methodology, the Hartree-Fock (HF), with 
the 6-31G(d) basis set. Additionally, ANTECHAMBER program was used to assign the 
atomic typology of each atom from external aldimine and quinonoid intermediate (Fig. 
22). The determined parameters are summarized in Table 2. 
 
 
Fig. 22 – Wedge-Dash representations of the (Left) external aldimine of EA-S model and (Right) the quinonoid 
intermediate of QI model, and respectively atom designation. 
 
 
Table 2 - Atomic charges (atomic units) assigned to each model. 
Charges were obtained through ab initio (HF/6-31G(d)) calculation. Subscript notation identifies the atom to which a 
certain atom is bonded (e.g. HN4 represents the hydrogen bonded to the nitrogen N4). 
 
Atom designation Model EA-A Model Q-A 
Charges Atom Type Charges Atom Type 
C 0.767276 c -- -- 
C2 0.435869 c 0.238541 c 
C3 0.155984 cc 0.021528 cc 
C3’ -0.385323 c3 -0.228211 c3 
C5 -0.158819 cd -0.076425 cd 
C6 0.024505 cc -0.176716 cc 
C6’ 0.091057 c3 0.243755 c3 
C7 -0.200725 cc 0.153613 cc 
C8 0.295049 c2 -0.217836 cf 
Cα 0.227887 c3 0.136627 c2 
Cβ -0.320786 c3 -0.186391 c3 
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Cγ 0.322029 cc 0.401509 cc 
Cδ -0.300586 cd -0.243540 cd 
Cζ 0.253494 cd 0.224967 cd 
HC3’ 0.110522 hc 0.034076 hc 
HC3’ 0.110522 hc 0.034076 hc 
HC3’ 0.110522 hc 0.034076 hc 
HC5 0.228944 h4 0.131444 h4 
HC6’ 0.040947 h1 -0.010255 h1 
HC6’ 0.040947 h1 -0.010255 h1 
HC8 0.143579 h4 0.104414 h4 
HCα 0.006068 h1 0.075237 h4 
HCβ 0.091222 hc 0.041361 hc 
HCβ 0.091222 hc 0.041361 hc 
HCδ 0.217632 h4 0.247842 h4 
HCζ 0.087502 h5 0.077188 h5 
HN 0.353722 hn 0.375443 ho 
HN4 0.373438 hn 0.308858 hn 
HNε 0.384845 hn 0.353390 hn 
N -0.287710 nh -0.248950 nf 
N4 -0.267891 na -0.512076 na 
Nε -0.348962 nc -0.386777 na 
Nη -0.661535 nc -0.655376 nc 
O1 -0.691859 o -0.748082 o 
O11 -0.907394 o -0.812165 o 
O12 -0.907394 o -0.812165 o 
O13 -0.907394 o -0.689602 oh 
O9 -0.439082 os -0.471133 os 
OC -0.779162 o -- - - 
OC -0.779162 o -- -- 
P10 1.379001 p5 1.206651 p5 
 
 According to the parameterization, the release of carbon dioxide generates a 
negative charge into carbon Cα, which is delocalized along the PLP and accommodated 
by nitrogen N4. This is corroborated by decrease of the charge of nitrogen N4 between 
the EA-S and the QI models. 
 
 
2.2. MD Simulations 
The topology and parameter files required to run an MD simulation were prepared 
and built using the ANTECHAMBER software from the AMBER12 package. The 
parameters were retrieved from the ff99SB [135] and the General AMBER (GAFF) force 
fields [173]. The missing parameters were included taking into account the data that was 
obtained from the previous section. The total charge of each studied system was 
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neutralized with 18 sodium ions (Na+) and solvated using a TIP3P [174] type of water 
molecules distancing at least 12 Å from protein (Supplementary Fig. 2). 
After the structural minimizations, the system was submitted to an equilibration 
stage and subsequently to an MD simulation production, using the SANDER software 
from AMBER12 package [134]. During the 20 ps (integration step = 1 fs) of the 
equilibration stage, the temperature of the system was incrementally increased from 0.00 
K to 310.15 K using the Langevin thermostat [175]. In this step, we considered periodic 
boundaries conditions and a canonical (NVT) ensemble. The non-bond interactions were 
considered up to the distance of 10.0 Å. Subsequently, a production stage of 60 ns was 
done considering an isothermal-isobaric (NPT) ensemble. 
The MD simulation results were afterward visualized in the Visual Molecular 
Dynamics software (VMD) [176] and analyzed with Ptraj software [177] from the 
AMBER12 package [134]. 
 
 
2.2.1. System Equilibration 
During the MD simulations, general physical properties of the system, such as 
kinetic and potential energies, temperature, volume, pressure and density, were 
evaluated for the two model systems. The obtained results indicate that the systems 
were stabilized, and no abnormal behavior is observed. Special attention was given to 
the pressure that showed a high fluctuation. Nevertheless, it is considered a normal 
situation because of the small dimensions of the system, and therefore little atomic 
movements leading to a high pressure oscillation. (Supplementary Fig.3, 
Supplementary Table 1, Supplementary Fig.4 and Supplementary Table 2). 
A further root mean square deviation (RMSd) determination was made to the MD 
simulations concerning about the conformation movements, and structural deformation 
of the protein. RMSd is a measure of atomic spatial displacement relatively to the initial 
position.  
We verified that the MD simulation of the EA-S model did not cause a significant 
deformation of the protein structure, once the global RMSd slightly exceeded 2 Å (Fig. 
23). Evaluating the RMSd values along the simulation, we can consider an equilibrated 
system between 40 and 60 ns. The equilibrated region presents a global RMSd of 1.78 
± 0.21 Å and a backbone RMSd of 1.31 ± 0.22 Å. Considering solely the active site 
residues (Asp-273A, His-194A, Ser-151A, Arg-447A, Tyr-334B, Ser-354B, Ser-154A, 
Thr-248A and Ser-196A) and the EA-S, the RMSd presents an even lower fluctuation, 
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1.06 ± 0.19 Å. Only the structures within the equilibrated system (40 to 60 ns) were 
studied in additional analysis and calculations. 
 
 
Fig. 23 – RMSd values for the MD simulation of the EA-S model.  
The blue line corresponds to the RMSd value of all atoms in the system. The orange line corresponds to the RMSd values 
considering only the α-carbons, corresponding to the protein backbone. The red line corresponds to the RMSd values 
considering the active site amino acid residues and the external aldimine. The system was considered equilibrated during 
the last 20 ns (40 to 60 ns). 
 
 We also looked to the RMSd of each subunit in order to disclose if some abnormal 
fluctuation could be hidden by the overall mean. Nevertheless, no abnormal divergence 
was observed, and both subunits presented a similar behavior along the full simulation 
(Fig. 24). 
 
 
Fig. 24 – RMSd values for the MD simulation of the EA-S model. 
The orange lines correspond to the RMSd values of the amino acid residues of the subunit A. The blue lines correspond 
to the RMSd values of the amino acid residues of the subunit B. The system was considered equilibrated during the last 
20 ns (40 to 60 ns). 
 
Similarly to the EA-S model, the MD simulation of the QI model did not show a 
significant structural displacement along the simulation comparing with the first structure. 
In the same way, the global RMSd values slightly exceed 2.5 Å (Fig. 25).  
Again, we considered the last 20 ns, between 40 and 60 ns, where the structure 
is equilibrated. For that time lapse, the global RMSd value is 2.12 ± 0.30 Å in contrast 
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with RMSd value of backbone which is 1.73 ± 0.31 Å. Considering only the active site 
amino acid residues and the QI, the RMSd is even lower, 1.30 ± 0.25 Å. 
 
 
Fig. 25 – RMSd values for the MD simulation of the QI model. 
The blue line corresponds to the RMSd value of all atoms in the system. The orange line corresponds to the RMSd values 
considering only the α-carbons, corresponding to the protein backbone. The red line corresponds to the RMSd values 
considering the active site amino acid residues and the quinonoid intermediate. The system was considered equilibrated 
during the last 20 ns (40 to 60 ns). 
 
 The RMSd evaluation for each subunit also revealed no significant differences 
between both subunits, showing a similar behavior (Fig. 26).  
 
 
Fig. 26 - RMSd values for the MD simulation of the QI model.  
The orange lines correspond to the RMSd values of the amino acid residues of the subunit A. The blue lines correspond 
to the RMSd values of the amino acid residues of the subunit B. The system was considered equilibrated during the last 
20 ns (40 to 60 ns). 
 
The small difference between the RMSd values of both simulations (EA-S and QI 
models) can be easily explained by the fact that the quinonoid intermediate of the QI 
model does not diverge so much from the external aldimine of the EA-S model. However, 
the EA-S model presents lower RMSd values once it fits more closely with the original 
PDB structure than the QI model which does not have the carboxylate group. The 
carboxylate group elimination induces, in the QI model, a small protein rearrangement 
targeting it to a new energy minimum. This new disposal of the active site requires more 
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movements from the surrounding atoms of the active site, resulting in the obtained 
slightly higher RMSd values for the QI model. 
 Further analysis will only concern the last 20 ns of each MD simulation, 
corresponding to an equilibrated system. 
 
2.2.2. Structural Analysis 
The following analyses will address a detailed evaluation of each model (EA-S 
and QI), concerning: i) their key differences relatively to the original PDB structure; ii) the 
important interactions between the active site residues and the EA-S and QI reaction 
intermediates; and iii) structural patterns.  
 
2.2.2.1. Root-Mean-Square deviation (RMSd) 
Comparing all the structures from the equilibrated time lapse of the EA-S model 
simulation (40 to 60 ns) with the original PDB structure, no significant conformation 
deformation was observed since the RMSd value is 1.86 ± 0.06 Å (Fig. 27 Blue line). 
Considering only the backbone, the RMSd is even lower, 1.37 ± 0.08 Å (Fig. 27 Orange 
line), and much lower if we only consider the active site residues and the external 
aldimine of the EA-S model, 0.83 ± 0.09 Å (Fig. 27 Red line).  
 
 
Fig. 27 – RMSd values for the equilibrated MD simulation of the EA-S model using the original PDB structure as 
a reference.  
The blue line corresponds to the RMSd value of all atoms in the system. The orange line corresponds to the RMSd values 
considering only the α-carbons, corresponding to the protein backbone. The red line corresponds to the RMSd values 
considering the active site amino acid residues and the external aldimine. 
 
Overlapping the two structures, we can verify that no observable changes happen 
during the MD simulation (Fig. 28 Left). The residues from the active site also do not 
present any significant differences, apart from the hydrogen atoms that become 
positioned in positions that promote stronger non-bonded interaction after the MD 
simulation (Fig. 28 Right).  
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Fig. 28 – Comparison of a representative structure from the MD simulation (EA-S model) (orange and gray 
colored) and the original PDB structure (blue and yellow colored). 
(Left) NewCartoon representation of the protein. (Right) CPK and licorice representations of the external aldimine and 
active site amino acid residues, respectively. 
 
 In the QI model, we found higher conformational differences between the 
equilibrated structure and the original PDB once the global RMSd value raises to 2.11 ± 
0.11 Å (Fig. 29 Blue line) and the backbone RMSd value reaches 1.69 ± 0.12 Å (Fig. 29 
Orange line). This difference is mostly due to the absence of the carboxylate group, 
which induces some conformational changes in the active site. This evidence is 
confirmed by a higher RMSd value (1.22 ± 0.15 Å) for the active site of the QI model 
comparatively to the EA-S model (Fig. 27 Red line). 
 
 
Fig. 29 - RMSd values for the equilibrated MD simulation of the QI model using the original PDB structure as a 
reference. 
The blue line corresponds to the RMSd value of all atoms in the system. The orange line corresponds to the RMSd values 
considering only the α-carbons, corresponding to the protein backbone. The red line corresponds to the RMSd values 
considering the active site amino acid residues and the quinonoid intermediate. 
 
 A representative structure from the MD simulation using the QI model was chosen 
to overlap with the PDB structure. Despite the comparatively higher RMSd values, no 
noteworthy conformation disparities were noticed (Fig. 30 Left). However, the amino 
acids residues from the active site present noteworthy differences relatively to the initial 
PDB structure. The most significant ones involve His-194A that no longer established a 
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hydrogen bond with substrate (since the carboxylate group no longer exists). In addition, 
and similar to what was observed with the EA-S model, some hydrogen bonds were also 
optimized, namely the ones involving the quinonoid intermediate and the amino acid 
residues Ser-354B, Ser-151A, Ser-196A, Thr-154A and Thr-248A (Fig. 30 Right).  
 
 
Fig. 30 – Comparison of a representative structure from the MD simulation (QI model) (orange and gray 
colored) and the original PDB structure (blue and yellow colored). 
(Left) NewCartoon representation of the protein. (Right) CPK and licorice representations of the quinonoid intermediate 
and active site amino acid residues, respectively. 
 
 In conclusion, all the MD simulations produce equilibrated structures that do not 
differ too much from the initial ones but promote a better orientation of the involved 
atoms, and therefore a better accommodation of the external aldimine and quinonoid 
intermediate inside the active site of mHDC. 
 
2.2.2.2. Root-Mean-Square Fluctuations (RMSF) 
The root-mean-square fluctuation (RMSF) is a measure of the flexibility of a 
certain atom or amino acid residue, once it is a measure of the deviation between that 
particle and its averaged position during a MD simulation. We could evaluate the RMSF 
of different residues and understand in which extension those residues are flexible. 
We analyze the RMSF values of each amino acid residue of the HL of the EA-S 
model during the MD simulation (Fig. 31 Right). Most of the amino acid residues present 
RMSF values between 3 and 5 Å, but the residues closer to the active site (Fig. 31 Right 
– red sections) have the lowest values. Inherently, the most flexible residues are located 
on the external region where the solvent exposition is greater, especially in the C-
terminal region (Fig. 31 Left). 
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Fig. 31 – RMSF values of each amino acid residue during the MD simulation of the EA-S model. 
(Left) NewCartoon representation of a representative structure from the MD simulation colored by RMSF value. VDW 
representation of the external aldimine colored by orange. (Right) RMSF values of each amino acid residue belonging to 
each protein subunit. Pink and green regions correspond to helices and sheets, respectively. Red regions indicate amino 
acid residues at the active site. 
 
 Concerning the active site residues, we found that most of them exhibit poor 
flexibility. This occurs due to the formation of strong hydrogen bonds between the PLP 
intermediates and some residues of the active site, that turn their position almost 
constant during the equilibrated period of MD simulation. In this regard, the stabilization 
of the phosphate group of the PLP cofactor by Ser-151A and Ser-354B, is particularly 
important, since it behaves as an anchor of the full PLP cofactor inside the active site 
(Fig. 32). In contrast, Tyr-334B is the most flexible amino acid residue (Fig. 32) within 
the active site. Its flexibility has already been observed during the RMSd analysis, once 
this tyrosine residue has a completely different orientation comparing to the one that it 
adopts in the PDB structure (Fig. 28 Right). Such conformational flexibility of Tyr-334B 
was expected since it is known that it belongs to a well characterized flexible loop of the 
enzyme [67]. 
 
 
Fig. 32 – RMSF analysis of the MD simulation using the EA-S model. 
CPK and licorice representations of the external aldimine and relevant active site amino acid residues, respectively, 
colored by RMSF value. The RMSF value of each residue and external aldimine are placed near each structure. 
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Despite the high flexibility of Tyr-334B, this residue is always in close proximity 
to the PLP cofactor. Taking into account that this is highly conserved among the PLP-
dependent decarboxylases [29, 68], this results suggests that it can be important for 
catalysis [66]. 
 Considering now the QI model, the RMSF evaluation revealed a similar profile 
(Fig. 33 Right) relatively to the EA-S model. Once more, the most rigid residues are 
placed in the protein’s core while the most flexible ones establish a direct contact with 
the solvent, mainly the ones from the C-terminal region (Fig. 33 Left). 
 
 
Fig. 33 - RMSF values of each amino acid residue during the MD simulation of the QI model. 
(Left) NewCartoon representation of a representative structure from the MD simulation colored by RMSF value. VDW 
representation of the quinonoid intermediate colored by orange. (Right) RMSF values of each amino acid residue 
belonging to each protein subunit. Pink and green regions correspond to helices and sheets, respectively. Red regions 
indicate amino acid residues at the active site. 
 
 Looking at the active site of QI model, we can verify the same trend that was 
described for the EA-S model. Despite the similarities, Tyr-334B appears to be less 
flexible (Fig. 34) when the quinonoid intermediated occupies the active site, indicating a 
stronger interaction with the quinonoid intermediate when compared with the external 
aldimine of the EA-S model (Fig. 32). 
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Fig. 34 - RMSF analysis of the MD simulation using the QI model. 
CPK and licorice representations of the quinonoid intermediate and relevant active site amino acid residues, respectively, 
colored by RMSF value. The RMSF value of each residue and quinonoid intermediate are placed near each structure. 
 
These results also confirm the role of phosphate as an anchor for the PLP and 
also show up a significant higher flexibility of the Tyr-334B, which may be important for 
the catalysis. 
 
2.2.2.3. Radial Distribution Function (RDF) 
In addition to the flexibility analysis, the solvent exposure of the amino acid 
residues is also a relevant aspect for catalysis. So, radial distribution function (RDF) can 
be used to measure the solvent exposure of a certain atom. Furthermore, the integral of 
this function gives the number of water molecules placed at a certain distance of a given 
atom. This type of analysis becomes interesting when we want to understand the 
exposure of the residues of the enzyme in relation to the solvent and disclose about the 
influence of the solvent in a certain chemical reaction.  
When we carefully observe the active site of mHDC, three main regions are 
clearly more solvent exposed: the region nearby the carboxylate group of the substrate, 
and the regions where Tyr-334B and Asp-273A residues are located at. The RDF 
analysis for the carboxylate group (Fig. 35 Top Left) and the Tyr-334B (Fig. 35 Bottom 
Left) showed a high proximity to the solvent (Fig. 35 Right). In fact, the carboxylate group 
has its first solvation sphere approximately at 4 Å and above that distance, the number 
of surrounding water molecules increases exponentially due to the solvent proximity. The 
solvent exposure is more evident in the case of Tyr-334B, which establishes its first 
solvation sphere with two water molecules, at a lower distance (3.85 Å) (Fig. 35 Right). 
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Fig. 35 – RDF analysis of MD simulation using the EA-S model. 
(Left) RDF values as a function of the distance and the cumulative number of water molecules regarding (Top) the 
carboxylate group of the external aldimine and (Bottom) the hydroxyl group of the Tyr-334B. (Right) Surface and VDW 
representation of the subunit A and water molecules, respectively. CPK and licorice representation of the external aldimine 
and Tyr-334B amino acid residue, respectively. Each dashed circumference represents a different solvation sphere placed 
at a given distance. Colored circles indicate the cumulative number of water molecules at a certain solvation sphere. 
 
Combining RDF and RMSF data about Tyr-334B, we could corroborate the 
flexibility of this tyrosine, which is associated with its position in a very flexible and solvent 
exposed loop. Indeed, the proteolytic susceptibility of the Tyr-338B-containing loop is 
justified by this high flexibility and exposure to solvent.  
An important water interaction was also observed nearby Asp-273A. This 
aspartate residue establishes a hydrogen bond with the nitrogen N4 of the PLP and also 
with two water molecules (Fig. 36 Right and Top Left). Interestingly, besides the solvent 
proximity of this aspartate residue, the first solvation sphere does not contact directly 
with the solvent (Fig. 36 Bottom Left).   
 
 
Fig. 36 - RDF analysis of MD simulation using the EA-S model. 
(Top Left) RDF values as a function of the distance and the cumulative number of water molecules regarding the Asp-
273A. (Bottom Left) Wireframe surface representation of the intermolecular interaction between the water molecules. 
(Right) Surface and VDW representation for the subunit A and water molecules, respectively. CPK and licorice 
representation for the external aldimine and Asp-273A amino acid residue, respectively. Each dashed circumference 
represents a different solvation sphere placed at a given distance. 
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 These results suggested that the protein fosters the presence of water molecules 
nearby Asp-273A, promoting a stable and permanent interaction between those water 
molecules and the aspartate residue. In fact, this could explain the ubiquitous 
conservation of those two water molecules among all PLP-dependent decarboxylases. 
If we look at the PDB file of the original hHDC structure as well as to the structure of the 
AADC, we could confirm the presence of these two water molecules in a similar position 
(Fig. 37). 
 
 
Fig. 37 – Overlapping the PDB structures of (gray) the hHDC (PDB code: 4E1O) (gray) and (yellow) the AADC 
(PDB code: 1JS3) [29]. 
CPK representation of the inhibitor of each enzyme and licorice representation of the aspartate residue. The conservative 
water molecules (oxygen atom) are represented by VDW. 
 
 Considering the QI model, the PLP structure remains highly exposed to the 
solvent, and mainly carbon Cα (Fig. 38 Top Left). Due to the fact that the carboxylate 
group has been released, Tyr-334B cannot establish any intermolecular interaction with 
the quinonoid intermediate. However, despite its more solvent exposure, a lower number 
of water molecules are involved in the solvation spheres of Tyr-354B (Fig. 38 Bottom 
Left and Right) comparatively with the EA-S model (Fig. 35 Right). 
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Fig. 38 - RDF analysis of MD simulation using the QI model. 
(Left) RDF values as a function of the distance and the cumulative number of water molecules regarding (Top) the Cα of 
the quinonoid intermediate and (Bottom) the hydroxyl group of the Tyr-334B. (Right) Surface and VDW representation of 
the subunit A and water molecules, respectively. CPK and licorice representation of the quinonoid intermediate and Tyr-
334B amino acid residue, respectively. Each dashed circumference represents a different solvation sphere placed at a 
given distance. Colored circles indicate the cumulative number of water molecules at a certain solvation sphere. 
 
 In the QI model, Asp-273A establishes considerable more interactions with water 
molecules (Fig. 39 Right) than it was found in the EA-S model (Fig. 36 Right). This 
evidence is supported by the formation of a new solvation sphere at 4.5 Å (Fig. 39 Top 
Left) which is absent on the EA-S model (Fig. 39 Top Left). In sum, Asp-273A requires 
a higher stabilization by the nearby water molecules, when the quinonoid intermediate is 
formed. 
  
 
Fig. 39 - RDF analysis of MD simulation using the QI model. 
(Top Left) RDF values as a function of the distance and the cumulative number of water molecules regarding the Asp-
273A. (Bottom Left) Wireframe surface representation of the intermolecular interaction between the water molecules. 
(Right) Surface and VDW representation for the subunit A and water molecules, respectively. CPK and licorice 
representation for the quinonoid intermediate and Asp-273A amino acid residue, respectively. Each dashed circumference 
represents a different solvation sphere placed at a given distance. 
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2.2.2.4. Hydrogen-bond analysis 
Non-bonded interactions are an important feature in the stabilization of biological 
systems, and typically they change in the active site during catalysis. Consequently, the 
dynamics of these interactions are crucial to understand the catalytic mechanism, in 
particular to unravel the critical amino acid residues that are directly involved in catalysis. 
In this work, a hydrogen interaction analysis along the MD simulations were done, aiming 
a map of the most important interactions. 
Both models (EA-S and QI) present several hydrogen interactions with the 
phosphate group, which is understandable due its higher negative charge and electron 
density. In fact, five (Fig. 40 Orange frame) or four (Fig. 41 Orange frame) hydrogen 
interactions are established and maintained during the entire simulation of the EA-S and 
QI models, respectively.  
The carboxylate group of the external aldimine (EA-S model) is stabilized by two 
hydrogen bonds promoted by Tyr-334B and His-194-A residues (Fig. 40 Red frame). 
This histidine residue (His-194A) also establishes an important interaction with the Ser-
196A, which helps it to become properly positioned in the active site (Fig. 40 Red 
Frame). Those interactions are absent on the QI model, since the QI does not have the 
carboxylate group or any polar atom surrounding that position. 
Nonetheless, both models have a hydrogen bond between Thr-248A and oxygen 
O1 of the PLP, which are preserved during the simulations and it is not disrupted after 
the carboxylate group release (Fig. 40 Red frame and Fig. 41 Red frame).  
The imidazole group from the substrate slightly interacts with Pro-82A through its 
protonated nitrogen (Fig. 40 Green frame). This interaction is even weaker in the QI 
model (lower that 5% of the last 20 ns of the simulation) (Fig. 41 Green frame). 
 Finally, the Asp-273A residue presents a stronger interaction with the protonated 
nitrogen N4 in the EA-S model (Fig. 40 Blue frame). However, the carboxylate group 
release and the consequent quinonoid intermediate formation lead to an increase in the 
distance between that aspartate residue and the hydrogen of the nitrogen N4. This 
increase is accomplished by a higher flexibility of the aspartate residue, comparatively 
to the EA-S model, culminating in a lower timely prevalence of the hydrogen bond (Fig. 
41 Blue frame).  
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Fig. 40 – Analysis of the hydrogen interactions between relevant active site amino acid residues (Licorice 
representation) and the external aldimine (CPK representation) – EA-S model. 
Dashed lines represent the hydrogen interactions, and they are accomplished by the mean distance along the MD 
simulation, in Å; and the respectively time prevalence. 
 
 
Fig. 41 - Analysis of the hydrogen interactions between relevant active site amino acid residues (Licorice 
representation) and the quinonoid intermediate (CPK representation) – QI model. 
Dashed lines represent the hydrogen interactions, and they are accomplished by the mean distance along the MD 
simulation, in Å; and the respectively time prevalence. 
 
This data agrees with the RDF information obtained from the MD simulations of 
the QI model that shows that the weaker interaction of Asp-273A with the PLP cofactor 
is extensively compensated by the stronger interactions provided by the surrounding 
water molecules. 
SER354B
SER151A
THR149A
VAL150A
2.63
97.55 %
2.85
77.75 %
2.61
83.40 %
2.60
99.85 %
2.81
90.20 %
SER196A
HIS194A
THR248A
TYR334B
2.72
81.83 %
2.84
52.95 % 2.67
99.00 %
2.83
77.48 %
2.86
64.85 %
2.83
83.10 %
ASP273A
PRO82A
SER354B
SER151A
VAL150A
2.69
98.22 %
2.84
79.45 %
2.62
99.78 %
2.84
82.05 %
THR248A
PRO82A
ASP273A
2.64
89.08 %
2.88
3.67 %
2.91
1.20 %
2.93
0.55 %
90 FCUP 
Computational studies addressed to Histidine decarboxylase 
 
All of these results gave important hints about the catalytic mechanism, and they 
were also essential for building the QM/MM models. Notwithstanding, we have to be 
careful and understand that MM information cannot be so accurately as desired and it 
can lead to a misinterpretation of the mechanism. 
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3. Catalytic Mechanism 
The main goal of this work was the characterization of the catalytic mechanism 
of a mammal PLP-dependent decarboxylase from family II, called Histidine 
decarboxylase (mHDC), which plays a relevant role in several biological processes. We 
based our first trial for the catalytic mechanism of mHDC on the available experimental 
data [26] that proposes a two-step type of mechanism for the L-histidine decarboxylation. 
The first step is characterized by the decarboxylation of the external aldimine (EA-S) 
and, the consequently formation of a quinonoid intermediate (QI) and release of carbon 
dioxide (Fig. 42 – Step 1).  Afterward, the second step takes place and the quinonoid 
intermediate (QI) is protonated by an amino acid residues from the active site (Fig. 42 – 
Step 2) originating a new external aldimine, but now containing histamine bonded to the 
PLP cofactor (EA-P). Finally, the enzymatic turnover occurs and the concomitant release 
of histamine (product) takes place. In this process, Lys-305A becomes once again 
bonded to the PLP cofactor, making the enzyme ready for a new catalytic cycle. 
 
 
Fig. 42 – Scheme representing the reagent, intermediates and product of the enzymatic reaction catalyzed by 
the mHDC. 
 
In order to studied these two steps of the decarboxylation process, the models 
retrieved from the MD simulation (EA-S and QI) were used to determine a potential 
energy surface (PES) through hybrid ONIOM (QM/MM) calculations performed using 
Gaussian09 software [178]. The most important active site residues together with the 
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PLP cofactor and the substrate (external aldimine or quinonoid intermediate) were 
included in the high-level (HL) layer, whereas the remaining part of the protein and water 
molecules were incorporated in the low-level (LL) layer. According to this scheme, the 
HL layer region was calculated using a QM method, DFT:B3LYP/6-31G(d), while the LL 
layer uses a MM approach considering the ff99SB and GAFF force fields [135, 173].  
Since no significant rearrangements of the overall structure of the enzyme are 
expected during the catalytic process, all the atoms that are located more than 30 Å 
away from the active site were fixed during the geometry optimizations. However, all the 
atoms located below this threshold were maintained free during the geometry 
optimizations in order to accommodate all the conformational changes of the residues 
that are located more closely to the active site. 
In all the geometry optimizations, we first searched for the transition state (TS) 
structure starting from a structure similar to the reactant model. This was generally 
obtained with uni-dimensional scans along the particular reaction coordinate in which we 
were interested in. Once a putative TS structure was located, and thus was fully 
characterized (excepted for the frozen atoms), the reactants and the products associated 
with it were determined after intrinsic reaction coordinate (IRC) calculations. In all cases, 
the geometry optimizations and the stationary points were obtained with standard 
Gaussian convergence criteria. The final energies of the minima and TS structures were 
additionally characterized by single-point energy calculations in the HL layer using the 
B3LYP, M06 and M06-2X functionals along with the 6-311++G(3df,2pd) basis set in the 
HL layer. Dispersion corrections were also included in the final energies. The LL layer 
was always calculated with MM methods. The full characterization of the minima of each 
studied reaction was achieved by the nuclear Hamiltonian calculation. The energy 
contribution of the nuclei is obtained through this calculation. The obtained thermal 
corrections allow the determination of all thermodynamic quantities (∆H, ∆S, and ∆G). 
Additionally, the nuclear Hamiltonian calculation includes a frequency analysis that it is 
particularly important to confirm the TS, which should have solely one imaginary 
frequency. 
 All the energy designations that will be presented in the following sections will 
depend on the type of calculations that were performed. The energy difference between 
two structures will be designated by ∆E when the energies are calculated considering 
only the electronic Hamiltonian. If those energies are between an optimized TS and an 
optimized reactant, the associate ∆E will be presented as an activation energy (Ea). 
Additionally, considering the energy difference between an optimized product and an 
optimized reactant, the ∆E is called reaction energy (Er). Afterwards, the nuclear 
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Hamiltonian was calculated and the enthalpy and entropic variations (∆H and ∆S) could 
also be calculated together with the zero-point energy correction. This allowed to 
compute the Gibbs free energy (∆G) either for the respective Ea or Er. 
In this chapter, the terms exothermic and endothermic will be used when the Er 
is negative or positive, respectively. Otherwise, if we consider the ∆Gr, the adopted 
designation will be exergonic or endergonic for negative or positive values of ∆Gr, 
respectively. 
The manipulation and analysis of the Gaussian files (input and output ones) were 
done using the GaussView 5.0.8. [179]. 
 
 
3.1. Step 1 – Decarboxylation 
The first step of the decarboxylation process was studied using an averaged 
structure from the most representative cluster (among 5 clusters) obtained from the MD 
simulation of the EA-S model. This structure was then used to build the QM/MM models. 
During the study of the first step of the decarboxylation process, several different QM/MM 
schemes of this model were used. In all of these schemes, the same reaction coordinate 
was followed. However, in each one of them, a different number of atoms was included 
in the HL layer and therefore in the LL layer of the QM/MM scheme. The choice of the 
atoms that were included in the HL layer was done in an incremental mode. This means 
that in the first scheme, only a few sets of amino acid residues were included in the HL 
layer together with the external aldimine containing the PLP cofactor bonded to L-
histidine. In the next schemes, the number of amino acid residues included in the HL 
layer increased. The choice of these amino acids was always done interactively based 
on visual inspection, but also on single-point energy calculations that help us to choose 
which amino acid residues could stabilize the charge delocalization of the reaction 
intermediates along the catalysis (that was found to be an important aspect of the 
mechanism).  
As the results were obtained, it was also required to make some structural 
modification of the model system that was retrieved from the MD simulations. These new 
models contain different conformation rearrangement or displacement of some amino 
acid residues or in the structure of the external aldimine. In the majority of these models 
a different QM/MM schemes were also used. 
In order to prevent any misconception along the thesis, in the following sections, 
the QM/MM models that were built will be called as EA-S-Mx or QI-Mx according to the 
step that we are describing: the decarboxylation of the external aldimine or the 
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protonation of the quinonoid intermediate, respectively. The “x” is the number of the 
model, and the models with the number 1 correspond to the ones which were directly 
obtained from the MD simulations (EA-S-M1, QI-M1A and QI-M1B). The subsequent 
models are modified versions of these models, e.g. increase of the size of the HL layer 
or structural modifications in the structure of the external aldimine or some active site 
residues. These models got the numbers 2, 3 and 4. When small modifications were 
done, and it requires a side-by-side comparison with the model that gave rise to it, the “ 
‘ “ symbol was added at the end of the designation (example: EA-S-M1 and EA-S-M1’). 
In other cases, a same model was used to test two different reaction coordinates, 
therefore the letters A and B were added at the end of the designation of each model 
(example: QI-M1A and QI-M1B). 
 
 
3.1.1. Model EA-S-M1: Tyr-334B displacement 
The first QM/MM model (EA-S-M1) came from the MD simulation as mentioned 
before. In this model, 96 atoms were included in the high level (HL) layer belonging to 
the EA-S, together with the side chains of the following amino acid residues: Asp-273A, 
His-194A, Ser-151A, Tyr-334B, Ser-354B, Thr-248A and Ser-196A (Fig. 43). 
 
 
Fig. 43 – Structure of the EA-S-M1 model. 
(Left) Wedge-Dash representation of the external aldimine (reactant) and the HL amino acid residues. Blue dashed lines 
represent relevant non-bonded interactions and respectively distance in Å. Red double arrow line represents the bond 
whose length was increased during the scan, and respectively interatomic distance in Å. (Right) CPK and licorice 
representations of the external aldimine and HL amino acid residues, respectively. 
 
The entire system was optimized using the QM/MM scheme: B3LYP/6-
31G(d):AMBER(ff99SB+GAFF). We first optimized the structure of this model and then 
started the search for the TS structure increasing the bond length between the Cα-C 
atoms through a linear scan, that promote the decarboxylation process. In spite of 
several attempts have been conducted, it was not observed a decrease in the energy of 
the scan. The energy profile of this reaction is also very unfavorable. The energy 
difference between the structure where the interatomic distance between Cα-C atoms 
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was 2.40 Å and the reactant was 41.94 kcal/mol (Fig. 44 Top), indicating that such 
reaction could not be possible under physiological conditions. A closer inspection of the 
model indicated that the reason for the high energies observed in this trial were due to 
the close proximity of Tyr-334B to the carboxylate group that prevents the release of 
carbon dioxide (Fig. 44 Bottom). Consequently, the decarboxylation becomes more 
difficult and even impossible.  
 
 
Fig. 44 – Comparison between reactant and last structure from scan. 
(Top) Wedge-Dash representation of the external aldimine (reactant) and HL amino acid residues. Blue dashed lines 
represent relevant non-bonded interactions and respectively distance in Å. Red double arrow line represents the bond 
whose length was increased in the scan, and respectively interatomic distance in Å. (Bottom) Structural comparison 
between the reactant (lower opacity) and the last structure from the scan (higher opacity). CPK and licorice 
representations of external aldimine and HL amino acid residues, respectively. 
 
 The RMSF analysis of MD simulation for the Tyr-334B residue (Fig. 32) has 
already indicated that this residues is extremely flexible. This means that this residue is 
able to move away from the active site towards the solvent. In fact, this flexibility is 
promoted by its water exposure, which is also corroborated by the RDF profile (Fig. 35 
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Bottom Left). The MD simulation visualization also confirmed this data, since Tyr-334B 
can be highly or less exposed to the solvent whenever it is in close contact to the solvent 
or establishes a hydrogen bond with carboxylate group of EA-S, respectively.  
Bearing in mind these observations, a new model (EA-S-M1’) was built through 
a slight displacement between Tyr-334B and the carboxylate group of EA-S (Fig. 45). 
Again, the structure was optimized using the same QM/MM scheme and the optimized 
complex was used to perform a linear scan where the Cα-C bond length was increased. 
  
 
Fig. 45 - Structure of the EA-S-M1’ model. 
(Left) Wedge-Dash representation of the external aldimine (reactant) and the HL amino acid residues. Blue dashed lines 
represent relevant non-bonded interactions and respectively distance in Å. Red double arrow line represents the bond 
whose length was increased in the scan, and respectively interatomic distance in Å. Gray dashed line represents the 
distance between Tyr-334B and the carboxylate group of the external aldimine. (Right) Comparison between models EA-
S-M1 (lower opacity) and EA-S-M1’ (higher opacity). CPK and licorice representations of the external aldimine and HL 
amino acid residues, respectively. 
 
 
With this new model and considering the same interatomic distance between Cα-
C atoms (2.40 Å), the computed energy for the decarboxylation process was 30.02 
kcal/mol (Fig. 46), which is significant lower than the one that was obtained in the 
previous model (EA-S-M1). However, and despite the energy decrease in the energy 
required for the decarboxylation process, no TS was assessed, indicating, once again, 
that such reaction is not feasible. 
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Fig. 46 - Comparison between reactant and last structure from scan. 
(Top) Wedge-Dash representation of the external aldimine (reactant) and the HL amino acid residues. Blue dashed lines 
represent relevant non-bonded interactions and respectively distance in Å. Red double arrow line represents the bond 
whose length was increased in the scan, and respectively interatomic distance in Å. Gray dashed line represents the 
distance between Tyr-334B and the carboxylate group. (Bottom) Structural comparison between the reactant (lower 
opacity) and the last structure from the scan (higher opacity). CPK and licorice representations of the external aldimine 
and HL amino acid residues, respectively. 
 
 
A new model (EA-S-M1’’) was then built increasing substantially the distance 
between Tyr-334B and the carboxylate group of external aldimine comparatively to the 
previous model (EA-S-M1’) (Fig. 47). 
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Fig. 47 - Structure of the EA-S-M1’’ model. 
(Left) Wedge-Dash representation of the external aldimine (reactant) and the HL amino acid residues. Blue dashed lines 
represent relevant non-bonded interactions and respectively distance in Å. Red double arrow line represents the bond 
whose length was increased in the scan, and respectively interatomic distance in Å. Gray dashed line represents the 
actual distance between Tyr-334B and the carboxylate group. (Right) Comparison between models EA-S-M1 (lower 
opacity), EA-S-M1’ (intermediate opacity) and EA-S-M1’’ (higher opacity). CPK and licorice representations of the 
external aldimine and HL amino acid residues, respectively. 
 
 
The scan was repeated using the same QM/MM scheme and increasing the 
interatomic distance Cα-C. However, the energy profile of the reaction decreases only 
by ~5 kcal/mol comparing with model EA-S-M1’ (decreases to 25.22 kcal/mol) (Fig. 48). 
Unfortunately, no TS was obtained once again, confirming an impossible reaction under 
the current conformation.  
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Fig. 48 - Comparison between reactant and last structure from scan. 
(Top) Wedge-Dash representation of the external aldimine (reactant) and HL amino acid residues. Blue dashed lines 
represent relevant non-bonded interactions and respectively distance in Å. Red double arrow line represents the bond 
whose length was increased in the scan, and respectively interatomic distance in Å. Gray dashed line represents the 
actual distance between Tyr-334B and the carboxylate group. (Bottom) Structural comparison between the reactant (lower 
opacity) and the last structure from the scan (higher opacity). CPK and licorice representations of the external aldimine 
and HL amino acid residues, respectively. 
 
 
These results indicate that the displacement of the Tyr-334B from the carboxylate 
group is an important aspect for the catalysis, since the increase of the distance between 
Tyr-334B and the carboxylate group from the external aldimine leads to a decrease of 
∆E (Fig. 49). Nevertheless, this displacement is not enough to make the reaction 
possible, once no TS could be characterized under this structural arrangement. 
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Fig. 49 – Energy variation (∆E) for each model EA-A-M1, EA-A-M1’ and EA-AM1’’. 
Black, red and blue bars correspond to the energy of all the system, HL layer and LL layer, respectively. The energy 
difference was calculated between the optimized reactant and a structure from the scan where the distance between the 
Cα-C was 2.40 Å. The green dashed line represents the Ea predicted by the experimental kcat. 
 
 
3.1.2. Model EA-S-M2: Improvement of the hydrogen bond interactions 
The analysis of the RDFs and hydrogen bond interactions from the MD simulation 
using the EA-S model revealed the presence of two important water molecules close to 
Asp-273A. The same water molecules are also present in the original structure of the 
PDB file, indicating that their presence might be important for catalysis. One of them is 
placed between Asp-273A and Ser-196A and closes a network of hydrogen bonds that 
also include His-194A and the external aldimine (Fig. 50). This result suggests that this 
water molecule might be important to stabilize, among the active site residues, the 
charge that is formed once the decarboxylation takes place. 
 
 
Fig. 50 - Hydrogen interactions between the carboxylate group and Asp-273A. 
Dashed lines represent hydrogen interactions. CPK and licorice representation of the external aldimine and HL amino 
acid residues. 
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Based on this previous analysis, we built a new model (EA-S-M2 model), 
contemplating this water molecule in the HL layer, using the model EA-S-M1’’ as starting 
point, where the Tyr-334B is displaced from its original location. However, in this model, 
Tyr-334B was not considered in the HL layer because it is far away from the external 
aldimine and should not participate on the reaction, taking into account the results 
obtained with previous models. In this new EA-S-M2 model, we have also included Thr-
154A in the HL layer due to its close interaction with the water molecule. Then, the 
system was optimized, and the resulting structure (Fig. 51) was used as the new reactant 
in which the Cα-C bond length was increased likewise in the previous calculations, 
through a linear scan. 
 
 
Fig. 51 - Structure of the EA-A-M2 model.  
(Left) Wedge-Dash representation of the external aldimine (reactant), the HL amino acid residues and the structural water 
molecule. Blue dashed lines represent relevant non-bonded interactions and respectively distance in Å. Red double arrow 
line represents the bond whose length was increased in the scan, and respectively interatomic distance in Å. CPK and 
licorice representations of the external aldimine, HL amino acid residues and water molecule, respectively. 
 
 This model allowed us, for the first time, to obtain a TS that was confirmed by a 
solely imaginary frequency at 101.0160i cm-1 (Fig. 52). The calculated activation energy 
was however too high (Ea = 28.85 kcal/mol) (Fig. 52) which exceeds considerably the 
predictable and suitable energetic barrier. Comparing with the experimental value (Ea = 
18 kcal/mol), the calculated Ea is too elevated [17]. This would lead to an increase in the 
half-life time of catalysis from 578 ms (based on experimental kcat) to more than 2.5 
years, making it impossible to occur under physiological conditions. Additionally, the 
product is also marginally stabilized relatively to the TS, leading to a very endothermic 
reaction (Er = +28.44 kcal/mol) (Fig. 52). 
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Fig. 52 – Structure of reactant (P), transition state (TS) and product (P), and energy profile for the 
decarboxylation step. 
(Top and Bottom Left) Wedge-Dash representation of the external aldimine and HL amino acid residues. Blue dashed 
lines represent relevant non-bonded interactions and respectively distance in Å. Red double arrow line represents the 
bond whose length was increased in the scan, and respectively interatomic distance in Å. (Bottom Right) Energy profile 
comparing reactant, transition state and product. The green dashed line represents the energy barrier predicted by kcat. 
 
 A closer look to the Ea and Er considering the contribution of each QM/MM layer, 
revealed a major contribution of the HL layer. In other words, the energy variation 
between TS and reactant (Fig. 53), as well as, the difference between product and 
reactant (Fig. 53) are mainly affected by the atoms considered under the HL layer. 
Consequently, the high activation and reaction energies are due directly to the atoms 
involved in the HL model.  The contribution of the LL layer for these energies is very 
small and below 1 kcal/mol. These results indicate that perhaps more amino acids from 
the active site need to be included in the HL layer or that these energies reflect some 
problems related with the position and orientation of the external aldimine and/or 
surrounding amino acid residues.   
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Fig. 53 – Activation (Ea) and reaction (Er) energies. 
Energies values considering all atoms of the system system (black), the HL layer (red) or the LL layer (blue). The green 
dashed line represents the activation energy predicted by the kcat. 
 
 A closer look to the relevant interactions between the external aldimine and the 
amino acid residues of active site revealed a weakening of the interaction between His-
194A and the carboxylate group of the external aldimine in the TS structure (Fig. 52). 
This indicates that the carboxylate group of external aldimine became less negative, 
which turns the reaction less favorable (Table 3). In the same way, the hydrogen bond 
between the proton bonded to nitrogen N4 and Asp-273A also becomes weaker, since 
the distance increases 0.08 Å from the reactant to the TS (reactant: 1.60 Å vs TS: 1.68 
Å) (Fig. 52). This suggests that during the reaction there is a possible charge distribution 
along the PLP leading to a less positive charge on nitrogen N4, culminating into a less 
strong interaction with Asp-273A. The charge decrease at Asp-273A (Table 3) justifies 
this previous observation, once a weaker interaction between these residues promotes 
a higher charge concentration on the aspartate residue.  
 
Table 3 - Mulliken charges (atomic units) assigned to external aldimine, carboxylate group/carbon dioxide and 
Asp-273A for each reactional state (reactant, transition state and product). 
 
Structure Charge (a.u.) 
Reactant (R) Transition State (TS) Product (P) 
External Aldimine -1.737490 -1,733655 -1,733655 
Carboxylate Group/Carbon Dioxide -0.082569 -0,052407 -0,052407 
Asp-273A -0.764877 -0,766671 -0,766671 
 
 
 Based on these results, we conclude that the present model does not represents 
accurately the active site during the mHDC catalysis, once the activation energies 
exceeds the predicted experimental value and are not acceptable under physiological 
conditions. 
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 Fig. 54 shows a comparison of the energy profiles of the models presented 
before. Only in the last model (EA-S-M2 model), it was possible to obtain a TS albeit the 
high activation and reaction energies that were obtained. 
 
 
Fig. 54 – Energy profile comparison between models. 
Black, red and blue bars correspond to the energy of all the system, HL layer and LL layer, respectively. The green dashed 
line represents the Ea predicted by the experimental kcat. 
 
 
3.1.3. Model EA-S-M3: Imidazole group protonation 
A closer look at the imidazole group of L-histidine (substrate) revealed a lack of 
any interaction between its protonated nitrogen (Nε) and an amino acid residue within 
the active site. To overcome this situation, we rotate the imidazole group by 180° and 
changed the nitrogen that was protonated. Consequently, the resulting model (EA-A-
M3) enabled a strong hydrogen interaction between the protonated nitrogen (Nη) and 
the Ser-354B (Fig. 55). 
 
 
Fig. 55 - Hydrogen interaction between the imidazole group from substrate and Ser-354B after its rotation and 
the change of the protonated nitrogen atoms. 
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 This new model (EA-A-M3) was built through the modification of previous model 
(EA-A-M2) and subsequent optimization. The resulting structure (Fig. 56) was then used 
to search for the reactant, TS and product of the reaction. The search for the TS was 
once again pursuit through linear scans involving the increase of the C-Cα bond length. 
 
 
Fig. 56 - Structure of the model EA-A-M3. 
(Left) Wedge-Dash representation of the external aldimine (reactant), the HL amino acid residues and a water molecule. 
Blue dashed lines represent relevant non-bonded interactions and respectively distance in Å. Red double arrow line 
represents the bond whose length was increased in the scan, and respectively interatomic distance in Å. (Right) CPK and 
licorice representations of the external aldimine; HL amino acid residues and water molecule, respectively. 
 
 The TS was assessed and confirmed by a unique imaginary frequency at 
90.6370i cm-1 (Fig. 57). The reactant and the product of the reaction were optimized from 
the optimized TS resulting in an activation energy of 29.19 kcal/mol (Fig. 57) which is 
indeed very similar to the one that was obtained with the previous model (EA-S-M2). 
However, if we consider only the energetic barrier associated to the HL model, 22.55 
kcal/mol (Fig. 58), the energy is significant lower that the one obtained using the EA-A-
M2 model (Fig. 53). It means that the HL layer of the EA-A-M3 model describes more 
accurately the active site during the decarboxylation step than the EA-A-M2 model.  
 However, the activation and reaction barriers are being severely penalized in 
about 6 kcal/mol by the enzyme (LL layer) (Fig. 58). This means that somehow the 
enzyme is not helping to catalyze the reaction. In spite of this negative trend, this model 
confirmed the observations done considering the EA-S-M2 model, where the distance 
between the nitrogen N4 and Asp-273A increased during the reaction (Fig. 57). This 
conformational change is a consequence of an electronic delocalization along the PLP 
cofactor, decreasing the hydrogen donor effect of nitrogen N4. At the same time, the 
water molecule placed nearby Asp-273A became closer to this residue, helping to 
stabilize the negative charge (Table 4 and Fig. 57).  Considering an overall view of entire 
active site, the intermolecular interactions tend to become stronger to stabilize the 
negative charge introduced after the carbon dioxide release (Fig. 57). 
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Fig. 57 - Reactant (R), transition state (TS) and product (P) structures and energy profile. 
(Top and Bottom Left) Wedge-Dash representation of the external aldimine, structural water molecule and the HL amino 
acid residues. Blue dashed lines represent relevant non bonded interactions and respectively distance in Å. Red double 
arrow line represents the bond whose length was increased in the scan, and respectively interatomic distance in Å. 
(Bottom Right) Energy profile comparing reactant, transition state and product. The green dashed line represents the 
activation energy predicted by the turnover number (kcat). 
 
 
Fig. 58 - Activation (Ea) and reaction (Er) energies. 
Energies values considering all atoms of the system system (black), the HL atoms (red) or the LL atoms (blue). The green 
dashed line represents the Ea predicted by the kcat. 
 
Table 4 - Mulliken charges (atomic units) assigned to external aldimine, carboxylate group/carbon dioxide and 
Asp-273A for each reactional state (reactant, transition state and product). 
 
Structure Charge (a.u.) 
Reactant (R) Transition State (TS) Product (P) 
External Aldimine -1.712884 -1.705630 -1.697700 
Carboxylate Group/Carbon Dioxide -0.110189 -0.074334 -0.023766 
Asp-273A -0.762634 -0.762357 -0.765171 
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Comparing the energies obtained with this new model and the previous ones, we 
can conclude that the modification endorsed to the initial structure, that was retrieved 
from the MD simulation, has improved the description of the active site and external 
aldimine to promote catalysis (Fig. 59). In this last model, a great improvement of the 
energies in the HL layer have been observed and the total energy is only penalized by 
the unfavorable energies that are obtained by the LL layer. 
 
 
Fig. 59 - Energy profile comparison between models. 
Black, red and blue bars correspond to the energy of all the system, HL layer and LL layer, respectively. The green dashed 
line represents the Ea predicted by the experimental kcat. 
 
 
3.1.4. Model EA-S-M4: N-H bond rotation 
We should emphasize, at this point, that the conformation of the imine linkage 
used in the previous models is what is observed in the PDB structure that contains an 
inhibitor bonded to the PLP cofactor.  However, such conformation is not common in the 
PLP-dependent enzymes that have the N-H pointing towards the opposite direction.  
The results of the previous models indicate the imine linkage in such orientation 
is not efficient for catalysis under physiological conditions, and therefore it can be an 
outcome of the inhibition process. In order to prove this idea, we have built a new model 
(EA-S-M4), in which the N-H bond orientation of the imine linkage of the external 
aldimine was changed. The re-orientation of the NH group was done through the 
opposite rotation, by 180°, of the two adjacent dihedrals in order to point the N-H bond 
to O1 oxygen (Fig. 60). 
 
EA-S-M1 EA-S-M1' EA-S-M1'' EA-S-M2 EA-S-M3
-5.00
0.00
5.00
10.00
15.00
20.00
25.00
30.00
35.00
40.00
45.00
∆E
 (k
ca
l/m
ol
)
Total High Level Low Level
∆E Ea
108 FCUP 
Computational studies addressed to Histidine decarboxylase 
 
 
Fig. 60 – N-H bond rotation through the rotation of its adjacent dihedral angles in opposite directions. 
The model EA-A-M4 was obtained from the model EA-A-M3 according to the described rotations and subsequently 
optimization. 
 
 Regarding this new model and analyzing their suitable resonance structures (Fig. 
61), we understand that the EA-S-M4 model originates a quinonoid intermediate with 
less punctual charges. The previous model (EA-S-M3) presents two possible resonance 
structures for reactant, but when the carboxylate group is released, the resulting 
quinonoid intermediate presents two more punctual charges than the model EA-S-M4. 
This evidence shows up a lower capability of the EA-S-M3 model to spread the charge 
along PLP, whereas when the N-H bond is rotated in the EA-S-M4 model, the formed 
quinonoid intermediate does not have any punctual charge in addition to the phosphate 
ones.  
 Since the active site environment is predominantly hydrophobic, avoiding the 
formation of punctual charges leads to a better stabilization of the full complex. 
Therefore, the new model (EA-S-M4) comprises a better configuration of the full system 
that should favor the decarboxylation reaction. However, this requires a previous 
reaction that promotes the proton transfer from nitrogen N to oxygen O1. We have done 
this calculation and show that this reaction has a very low activation barrier (0.26 
kcal/mol), which is also confirmed by the spontaneous proton passage during the 
optimization procedure. 
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Fig. 61 – PLP structures along the decarboxylation step considering models EA-S-M3 or EA-S-M4. 
Wedge-dash representation of external aldimine, respective resonance hybrid and intermediates along the first step. 
 
 The new model EA-A-M4 was then optimized and using the same approach used 
in the previous sections. The energy profile of the reaction was assessed through a linear 
scan where the bond length C-Cα was progressively increased (Fig. 62). 
 
 
Fig. 62 - Structure of the model EA-A-M4. 
(Left) Wedge-Dash representation of the external aldimine (reactant), the HL amino acid residues and a water molecule. 
Blue dashed lines represent relevant non-bonded interactions and respectively distance in Å. Red double arrow line 
represents the bond whose length was increased in the scan, and respectively interatomic distance in Å. (Right) CPK and 
licorice representations of the external aldimine; HL amino acid residues and water molecule, respectively. 
 
 The energy profile of the linear scan revealed that the energy required to obtain 
the TS decreases substantially when compared with the previous model (23.70 kcal/mol 
vs 29.19 kcal/mol). This barrier has a significant contribution from the LL layer, once 
those atoms are responsible by an energy penalization of 5.84 kcal/mol, while the HL 
layer contributes only by 17.86 kcal/mol for the activation barrier (Fig. 64). This 
penalization was not expected since the enzyme should promote the stabilization of the 
TS and therefore have favorable contribution during catalysis. Consequently, these 
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results indicate that the energies of this step are still too high when compared to the 
experimental value.  Based on this fact, instead of characterizing the reactant, TS and 
product for this reaction we tried to search for the motives for this energetic profile in this 
new model. 
 We then realized that this penalization could be caused by the non-inclusion of 
certain amino acid residues in the HL layer, which could be essential to stabilize the 
external aldimine and promote the reaction. To provide some insight about this matter, 
a single-point energy (SP) calculation were done with an extended HL layer where more 
amino acid residues were included in the HL layer and considered under the high 
theoretical level. The new model (EA-S-M4’) includes some amino acid residues from 
the active site that surround specifically the phosphate group of PLP cofactor (Fig. 63). 
 
 
Fig. 63 – Structure of EA-S-M4’ model. 
Wedge-Dash representation of the external aldimine (reactant), the HL amino acid residues and a water molecule. Blue 
dashed lines represent relevant non-bonded interactions and respectively distance in Å. Green dashed lines represent 
new non-bonded interactions promoted by adding amino acid residues (green colored) to the HL layer comparatively to 
the EA-S-M4 model. 
 
 We should note that these calculations did not include the optimization of the 
atoms of the new QM/MM scheme. The structures were just retrieved from the linear 
scan, one resembling the TS (the highest energy structure) and two other for the adjacent 
minima, one for the reactants and another for the product of the reaction. The results of 
these calculations with the EA-S-M4’ model revealed a significant decrease in the Ea 
(Fig. 64). This indicated a higher stabilization of the TS when the phosphate group of 
PLP is surrounded by more amino acid residues. These calculations also revealed that 
the enzyme is also able to decrease the activation barrier by 3.41 kcal/mol. 
Notwithstanding, the energy associated with the HL layer increased comparatively to the 
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EA-S-M4 model, but this increase can be overcome with the optimization of the system. 
Therefore, EA-S-M4’ model was optimized using the same QM/MM scheme (B3LYP/6-
31G(d):AMBER[GAFF+ff99SB]) and the resultant reactant, TS and product of the 
reaction characterized (Fig. 65). 
 
 
Fig. 64 – Activation energies (Ea) assigned to each model. 
Energies values considering all atoms of the system system (black), the HL atoms (red) or the LL atoms (blue). The green 
dashed line represents the Ea predicted by the kcat. 
 
 
 
Fig. 65 - Structure of the model EA-A-M4’. 
(Left) Wedge-Dash representation of the external aldimine (reactant), the HL amino acid residues and a water molecule. 
Blue dashed lines represent relevant non-bonded interactions and respectively distance in Å. Red double arrow line 
represents the bond whose length was increased in the scan, and respectively interatomic distance in Å. (Right) CPK and 
licorice representations of the external aldimine; HL amino acid residues and water molecule, respectively. 
 
 The EA-S-M4’ model confirmed that an extensive stabilization of the phosphate 
group decreases the activation barrier, once the Ea decreased from 23.70 kcal/mol to 
17.12 kcal/mol. This energy has, as predictable, a major contribution of the HL atoms, 
17.47 kcal/mol, while the remaining enzyme (LL layer) slightly decreases the activation 
barrier by 0.35 kcal/mol. As observed with previous models, we confirmed a highly 
endothermic step since the Er is 16.90 kcal/mol. (Fig. 66) 
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Fig. 66 - Activation (Ea) and reaction (Er) energies. 
Energies values considering all atoms of the system system (black), the HL atoms (red) or the LL atoms (blue). The green 
dashed line represents the Ea predicted by the kcat. 
 
The TS of this reaction is characterized by an imaginary frequency at 87.2080i 
cm-1. A careful analysis of the reaction reveals that the break of the bond between Cα-C 
atoms is triggered by the electronic density withdrawing mediated by the PLP cofactor. 
The oxygen O’2 from substrate and the protonated nitrogen of His-194A establish a 
hydrogen bond that orientates the carboxylate group of substrate during the 
decarboxylation. During the decarboxylation reaction, this interaction becomes weaker 
once the negative charge of the carboxylate group is transferred to PLP (Fig. 68ab) and 
the carbon dioxide molecule becomes non-polar (Fig. 68c) (interaction length increases 
from 1.63 Å to 2.18 Å (Fig. 67)). The released carbon dioxide molecule presents a charge 
of -0.06 a.u., which is practically neutral in contrast with the original charge of carboxylate 
group, -0.62 a.u. (Fig. 68c and Table 5). Consequently, the negative charge is 
accommodated by the PLP ring (Fig. 68a), since its global charge varied from +0.73 to 
+0.34 and it is dispersed along all ring (Table 5). Notwithstanding, the nitrogen N4 
presents the highest charge variation (reactant: -0.35 a.u. vs product: -0.53 a.u.) 
indicating a major role in the PLP capability to withdraw the electronic density from Cα-
C bond. This data is corroborated by a decrease in the bong length of N4-H (reactant: 
1.10 Å vs product: 1.06 Å (Fig. 67)) and a consequently distancing from Asp-273A 
(reactant: 1.52 Å vs product: 1.62 A (Fig. 67)). Therefore, the negative charge of Asp-
273A became less stabilized and the intermolecular interaction with the closer water 
molecule became stronger (interaction length decreases from 1.81 Å to 1.77 Å (Fig. 67)). 
Subsequently, all the hydrogen bonds established with Ser-196A and His-194A becomes 
weaker once all intermolecular interactions distances became higher. 
With respect to the upper region of PLP (Fig. 68a), we can disclose the formation 
of double bonds between Cα-N and C6-C7 atoms, since their length decreased from 
1.45 Å and 1.48 Å to 1.32 Å and 1.41 Å, respectively (Fig. 67). Simultaneously, the 
double bond between C8-N atoms was converted into a single bond (bond length 
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increased from 1.29 Å to 1.36 Å (Fig. 67)). These results indicate an electronic 
delocalization along those atoms but the negative charge formed due to the 
decarboxylation reaction is not accommodated here once the charge for that region did 
not varies significantly between the reactant and the product of the reaction (charge 
increases 0.06 a.u.) (Table 5). 
Concerning about the interactions between the amino acids close to the 
phosphate group of PLP cofactor, no significant differences were observed during the 
reaction, indicating its major role on anchoring PLP during the catalytic process. (Fig. 67 
and Fig. 68) 
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Fig. 67 - Reactant (R), transition state (TS) and product (P) structures and energy profile. 
(Left) Wedge-Dash representation of the EA-S, water molecule and the HL amino acid residues. Blue dashed lines 
represent relevant non-bonded interactions and respectively distance in Å. Red double arrow line represents the bond 
whose length was increased in the scan, and respectively interatomic distance in Å. (Top Right) CPK and licorice 
representations of the EA-S, water molecule and HL amino acid residues at the TS. (Bottom Right) Energy profile 
comparing reactant, TS and product. The green dashed line represents the Ea predicted by the kcat. 
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Fig. 68 – Electrostatic map of reactant and product. 
Electrostatic maps were built based on Merz-Singh-Kollman charges. Red regions correspond to more negative regions 
whereas blue ones correspond to more positive regions. Green regions are related to neutral regions. The electrostatic 
map was built considering 1.76 points/Bohr3. 
 
 
Table 5 – Merz-Singh-Kollman charges (atomic units) assigned to EA-S, respective regions a and b, carboxylate 
group/carbon dioxide (region c), phosphate group of PLP and Asp-273A for each reactional state (reactant, 
transition state and product). 
 
Structure Charge (a.u.) 
Reactant (R) Transition State (TS) Product (P) 
EA-S -1.180714 -1.666394 -1.722829 
Carboxylate Group/Carbon Dioxide -0.623646 -0.123422 -0.055462 
PLP – Region a +0.732749 +0.354325 +0.339217 
PLP – Region b -0.568023 -0.510279 -0.507979 
Phosphate Group -1.653409 -1.686586 -1.678557 
Asp-273A -0.852647 -0.868528 -0.868990 
 
 
 This model (EA-S-M4’) provided for the first time an energy profile that suites 
very well to what is obtained with the experimental kinetic studies. Comparing with the 
previous models (Fig. 69), we have now a model that presents an activation barrier for 
the first step that is slightly lower than the one that is predicted by experimental studies. 
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Fig. 69 - Energy profile comparison between models. 
Black, red and blue bars correspond to the energy of all the system, HL layer and LL layer, respectively. The green dashed 
line represents the Ea predicted by the experimental kcat. 
 
 
Until now, all the presented calculations only contemplate the electronic 
Hamiltonian, therefore a subsequent set of calculations were done aiming the nuclear 
Hamiltonian determination.  
Frequency calculations on the EA-S-M4’ model, using Gaussian09, were done 
using the obtained and optimized structures of reactant, TS and product. Results indicate 
a great increase of entropy when the TS is achieved, being even greater when the 
product is formed. This increase of entropy considerably decreases the energetic barrier 
by 3.63 kcal/mol and stabilizes the product by 5.01 kcal/mol. These results are in 
agreement with what was expected, since during the first step one molecule (external 
aldimine) is broken to generate two molecules (quinonoid intermediate and carbon 
dioxide). When this thermal correction is considered, we can talk about ∆G‡ and ∆Gr, the 
free Gibbs energy of activation and reaction respectively.  Then, the ∆G‡ for the first step 
is 13.48 kcal/mol and the ∆Gr is 10.88 kcal/mol, unraveling an exergonic step (Fig. 70). 
As described before, DFT based methods have some difficulties in describing 
accurately intermolecular interactions, especially van der Waals forces. In order to 
overcome this situation, a complementary calculation using a dispersion correction 
functional (GD3) were done to get a better accounting of those intermolecular 
interactions. Considering the GD3 corrections, ∆G‡ decreased to 13.38 kcal/mol and ∆Gr 
also decreased to 11.78 kcal/mol after GD3 corrections (Fig. 70). In this particular case, 
GD3 corrections only affect ∆G‡ and ∆Gr by less than 1%, indicating a very acceptable 
description of non-bond interactions by the B3LYP functional. 
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Fig. 70 – Energetic profile of the first step of catalytic mechanism. 
 
 In order to improve the theoretical description of the system, a benchmark of 
basis sets was performed to compare its influence on the final energies. To this end, 
different basis set from 6-31G(d) to a more complete 6-311++G(3df,2dp) were tested. 
Furthermore, a benchmark of functionals was also made in order to get the influence of 
the functionals used in the DFT calculations of the electronic energy. To this end, single-
point energy (SP) calculations with hybrid functional that include a percentage of HF 
exchange were also done. In this case, M06 and M06-2X were used, and they have 27% 
or 54% of HF exchange term, respectively. 
  
 
Fig. 71 – Benchmark of functionals and basis sets for the first step, using EA-S-M4’ model.  
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 The results from the benchmark calculations (Fig. 71) showed that the effect of 
the basis set do not provide an important variation on the calculated energies for the first 
step using the EA-S-M4’ model. The energies calculated by the different functionals 
have however provided different results. Interestingly, no major differences on the 
calculated energies computed with the B3LYP and the M06 functionals are observed. In 
fact, the M06 functional provided better results, lowering down either the activation 
energy and the reaction energy. This can in part be explained taking into account the 
strong delocalization effect of the electrons that is observed in this reaction Therefore, 
the inclusion of the additional HF exchange by the M06 functional provided a better 
description of the system.  Interestingly a major increase on the activation and reaction 
energies are observed when using the M06-2X functionals. This functional is 
characterized by adding more 27% of HF exchange in relation to M06. We believe 
therefore that the introduction of this “extra” effect is having a negative impact on 
calculated energies.  The results would become similar to the ones provided by B3LYP 
and M06 functionals if the reactant, TS and product of the reaction were re-optimized 
with this functional. However, this would lead to extremely high computational cost that 
was not feasible due to disk and memory problems on the available hardware. 
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3.2. Step 2 – Intermediate protonation 
As mentioned above, the available experimental data suggest that the catalytic 
mechanism of mHDC is a two-step type of mechanism where the second step involves 
the protonation of the product from the first step, i.e., the quinonoid intermediate (QI 
model) by an unknown proton-donor.  Based on the site-directed mutagenic experiments 
two amino acid residues from the active site can play such role and they are Tyr-334B 
or/and His-194A. [66] 
When Tyr-334B is mutated by glycine the enzyme becomes inactive. [66] This 
fact indicates that this amino acid residue is important for the catalytic process and can 
play a crucial role either in the first step or in the second step of the mechanism. Since 
the theoretical results from the previous section indicate that Tyr-334B is not required for 
the first step, it is therefore evident that it must be somehow involved in the second step 
of the mechanism. The MD simulations made in this work, reinforce this idea since this 
residue can be found very near to carbon Cα of the quinonoid intermediate, and therefore 
can be a good candidate to protonate this carbon. 
Site directed mutagenesis of His-194A indicate that when this residue is mutated 
by glycine the enzyme is still active but the catalytic process is very slow. [66] This result 
shows that this residue may not be directly involved in catalysis as Tyr-334B but, might 
be important to assist the proton transfer or be important for the correct orientation or 
stabilization of the reaction intermediates inside the active site. The theoretical results 
obtained in the last section reveal that in the first step of the catalytic mechanism, this 
residue establishes an important hydrogen bond with the carboxylate group of the 
external aldimine that was shown to be important for the correct orientation of the 
carboxylate group during the decarboxylation process. However, this role does not fully 
justify the results obtained with the site-directed mutagenesis of this residue and 
therefore another role maybe played by His-194A in the second step of the catalytic 
process. The MD simulations show that this residue can also be found very near to 
carbon Cα of the quinonoid intermediate, and behave as a proton donor or behave as a 
proton switcher that facilitates the proton transfer from Tyr-334B, that is locate very close 
to His-194A. Taking into account the pKa of histidine, it can be disclosed the participation 
of this residue as a direct proton donor, and therefore its role as a proton switcher gains 
more credibility. 
Based on the results obtained by the MD simulations, and taking into account 
these two mechanistic alternatives, two structures were selected and subjected to 
QM/MM protocol that have similar time prevalence along the MD simulation. The first 
model, QI-M1A, was used to test if the protonation of the quinonoid intermediate could 
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be made by Tyr-334B and mediated by His-194A. The second one, QI-M1B was used 
to test if the proton transfer occurs directly through Tyr-334B, without the participation of 
His-194A. Unfortunately, these models were built based on the MD simulations that were 
modeled accordingly to the initial structure available in the PDB file. Consequently, both 
models have the N-H bond pointing to the phosphate group of PLP instead to O1 oxygen 
as it was shown to be important in the first step described on the previous sections. 
Therefore, the calculations that were performed with the two mechanistic alternatives 
(QI-M1A and QI-M1B) will be briefly described without an extensive analysis. It should 
be noted here that these calculations were done at the same time that the ones from the 
first step were conducted. Therefore, at that time it was not known if the effect of rotating 
the NH group of the imine linkage would interfere with the catalysis or not. Nevertheless, 
the description of these calculations will be important to calculate the effect of the imine 
linkage rotation on the energies of the second step. 
In order to simulate the second step with the imine linkage rotated, two other 
models were created. These models were built based on the product of the reaction from 
the EA-S-M4’ model. These models were called QI-M4A and QI-M4B. They both have 
the same structural disposition of the EA-S-M4’ model, but the protonation by Tyr-334B 
of the quinonoid intermediate was tested with the mediation of His-194A or without it, 
respectively. 
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3.2.1. Model QI-M1A: His-194A protonates the QI 
This first model (QI-M1A) has the NH group of His-194A pointing towards carbon 
Cα of quinonoid intermediate. The hydroxyl group of Tyr-334B is also aligned with the 
other nitrogen atom of the imidazole ring of His-194A.  The model has 93 atoms in the 
HL layer, and includes the quinonoid intermediate and the following amino acid residues: 
His-194A, Tyr-334B, Thr-248A, Asp-273A, Ser-151A, Ser-196A and Ser-354B (Fig. 72). 
 
 
Fig. 72 - Structure of the model QI-M1A. 
(Left) Wedge-Dash representation of the quinonoid intermediate (reactant) and the HL amino acid residues. Blue dashed 
lines represent relevant non-bonded interactions and respectively distance in Å. Red double arrow line represents the 
bond whose length was decreased in the scan, and respectively interatomic distance in Å. (Right) CPK and licorice 
representations of the quinonoid intermediate and HL amino acid residues, respectively. 
 
The theoretical results that were obtained with the QI-M1A model revealed that 
His-194A can behave as a proton switcher in the protonation of the carbon Cα of 
quinonoid intermediate by Tyr-334B. The reaction has a Ea of 7.74 kcal/mol and the 
reaction is very exothermic (Er of -26.08 kcal/mol). The major contributions for the 
activation and reaction energies came from HL atoms, once the contribution of LL layer 
is +2.61 kcal/mol for the activation barrier and -1.18 kcal/mol for the energy of reaction. 
(Fig. 73) 
 
 
 
Fig. 73 - Activation (Ea) and reaction (Er) energies. 
Energies values considering all atoms of the system system (black), the HL atoms (red) or the LL atoms (blue). The green 
dashed line represents the Ea predicted by the kcat. 
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The TS of this reaction was confirmed by a unique imaginary frequency at 
1431.24 cm-1 (Fig. 74). During the protonation step, the proton from His-194A migrates 
to carbon Cα of the quinonoid intermediate and the opposite nitrogen of imidazole group 
of His-194A receives a proton from the hydroxyl group of Tyr-334B. At the end of the 
reaction, His-194A recovered its initial protonation state and the negative charge 
migrates from the quinonoid intermediate to Tyr-334B (Fig. 74). As seen before, Tyr-
334B belongs to a very flexible and solvent-exposed loop which allows an easy 
stabilization of the generated negative charge and also promotes a quickly re-protonation 
by the solvent. 
During this step, the N4-H bond length increased from 1.07 Å (reactant) to 1.11 
Å (product) (Fig. 74), indicating the recovery of the positive charge of N4 nitrogen. This 
was a consequence of the protonation of carbon Cα of PLP by His-194A. Consequently, 
N4-H bond became weaker and this proton got a higher acidic character. Therefore, the 
interaction between this proton and the oxygen of Asp-273A became stronger, a 
phenomenon that is corroborated by a decrease of the interaction distance (reactant: 
1.63 Å vs product: 1.51 Å) (Fig. 74). 
 
FCUP 
Computational studies addressed to Histidine decarboxylase 
123 
 
 
Fig. 74 - Reactant (R), transition state (TS) and product (P) structures and energy profile. 
(Left) Wedge-Dash representation of the quinonoid intermediate and the HL amino acid residues. Blue dashed lines 
represent relevant non-bonded interactions and respectively distance in Å. Red double arrow line represents the bond 
whose length was decreased in the scan, and respectively interatomic distance in Å. (Top Right) CPK and licorice 
representations of the quinonoid intermediate and HL amino acid residues at the TS. (Bottom Right) Energy profile 
comparing reactant, TS and product. The green dashed line represents the Ea predicted by the kcat. 
 
 Although this model (QI-M1A) is inaccurate, it showed that His-194A can 
protonate the quinonoid intermediate but it requires Tyr-334B to re-protonate His-194A 
simultaneously. We disclose here a key role of Tyr-334B in the protonation of quinonoid 
intermediate mediated by the His-194A. The next model (QI-M1B) describes a direct 
protonation of quinonoid intermediate exclusively promoted by the Tyr-334B. 
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3.2.2. Model QI-M1B: Tyr-334B protonates the QI 
The next model (QI-M1B) describes a direct protonation of quinonoid 
intermediate exclusively promoted by the Tyr-334B. As mentioned before this model was 
built using a structure from the MD simulation and it is faithful to the original structure 
available in PDB file. The QI-M1B model has exactly the same amino acid residues in 
the HL layer comparatively as the previous model (QI-M1A). The difference lies in the 
reaction coordinate that was tested. In this case, the distance between carbon Cα and 
the proton of Tyr-334B was incrementally decreased, simulating the protonation of 
quinonoid intermediate by Tyr-334B. The structure used as reactant (Fig. 75) was 
obtained through an optimization using the QM/MM scheme B3LYP/6-
31G(d):AMBER(ff99SB+GAFF). 
 
 
Fig. 75 - Structure of the QI-M1B model. 
(Left) Wedge-Dash representation of the quinonoid intermediate (reactant) and the HL amino acid residues. Blue dashed 
lines represent relevant non-bonded interactions and respectively distance in Å. Red double arrow line represents the 
bond whose length was decreased in the scan, and respectively interatomic distance in Å. (Right) CPK and licorice 
representations of the quinonoid intermediate and HL amino acid residues, respectively. 
 
 The theoretical results obtained with this model confirmed that the protonation of 
the quinonoid intermediate by Tyr-334B is possible and that the process is kinetically 
more favorable than the previous model (QI-M1A) where His-194A mediates the proton 
transfer. The activation barrier for this step is 0.38 kcal/mol (Fig. 76) and it is significantly 
lower than the barrier imposed to the protonation mediated by His-194A (7.74 kcal/mol 
(Fig. 73)). Nonetheless, this step is thermodynamically less favorable since the Er is -
19.77 kcal/mol (Fig. 76), which makes the reaction less exothermic by 6.31 kcal/mol 
comparatively to the protonation catalyzed by His-194A (-26.08 kcal/mol (Fig. 73)). 
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Fig. 76 - Activation (Ea) and reaction (Er) energies. 
Energies values considering all atoms of the system system (black), the HL atoms (red) or the LL atoms (blue). The green 
dashed line represents the Ea predicted by the kcat. 
 
 The TS of this step was confirmed by an imaginary frequency at 563.7731i cm-1 
(Fig. 77). During the protonation step, the Cα of the quinonoid intermediate was 
protonated by Tyr-334B with a very low activation barrier. During the reaction, the 
negative charge, that was initially located in the PLP cofactor, is delocalized to the Cα in 
the TS a fact that help the proton transfer from Tyr-334B. We can confirm this 
delocalization, since the N4-H bond length increased (reactant: 1.06 Å vs product: 1.08 
Å) (Fig. 77) indicating a more positive N4 nitrogen. Accordingly, Asp-273A established 
a stronger non-bond interaction with the proton bonded to N4, once the interaction 
distance decreases from 1.70 Å to 1.64 Å  (Fig. 77). With respect to the phosphate group, 
no significant changes were observed, corroborating the phosphate role as an anchor of 
PLP. 
 These results confirm the key role played by Tyr-334B in the protonation step of 
the quinonoid intermediate through a reaction that is very exothermic and also very fast 
(low activation energy). In the next models, this hypothesis was tested with models that 
accurately describe the quinonoid intermediate, once they correspond to the product of 
the first step, and they have the correct orientation of N-H bond.  
Ea Er
-30.00
-25.00
-20.00
-15.00
-10.00
-5.00
0.00
5.00
∆E
 (k
ca
l/m
ol
)
Total High Level Low Level
0.38 0.11 0.27
-19.77 -19.42
126 FCUP 
Computational studies addressed to Histidine decarboxylase 
 
 
Fig. 77 - Reactant (R), transition state (TS) and product (P) structures and energy profile. 
(Left) Wedge-Dash representation of the quinonoid intermediate and the HL amino acid residues. Blue dashed lines 
represent relevant non-bonded interactions and respectively distance in Å. Red double arrow line represents the bond 
whose length was decreased in the scan, and respectively interatomic distance in Å. (Top Right) CPK and licorice 
representations of the quinonoid intermediate and HL amino acid residues at the TS. (Bottom Right) Energy profile 
comparing reactant, TS and product. The green dashed line represents the Ea predicted by the kcat. 
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3.2.3. Model QI-M4A: His-194A protonates the QI (N-H bond rotated) 
As mentioned above, this model (QI-M4A) was built using, as initial structure, the 
product from the first step (EA-S-M4’ model). The HL layer had the same amino acid 
residues of QI-M1A model plus Tyr-334B that has an important role for the quinonoid 
intermediate protonation. The complex was optimized and the resulting structure (Fig. 
78) was used to run the linear scan of the reaction coordinate that involves the proton 
migration from His-194A to the carbon Cα of the quinonoid intermediate. 
 
 
Fig. 78 - Structure of the QI-M4A model. 
(Left) Wedge-Dash representation of the quinonoid intermediate and the HL amino acid residues. Blue dashed lines 
represent relevant non-bonded interactions and respectively distance in Å. Red double arrow line represents the bond 
whose length was decreased in the scan, and respectively interatomic distance in Å. (Right) CPK and licorice 
representations of the quinonoid intermediate and HL amino acid residues, respectively. 
 
 The TS of this step was achieved using this model (QI-M4A) and confirmed by a 
unique imaginary frequency at 1517.7971 cm-1 (Fig. 80). The activation barrier for the 
protonation of quinonoid intermediate by His-194A is 13.84 kcal/mol (Fig. 79). This 
barrier is similar to the one that was obtained using the QI-M1A model, but the N-H bond 
rotation induces an energy penalization in the QI-M4A model. The increase of the energy 
barrier is a consequence of the difficulties in protonation the Cα of the quinonoid 
intermediate, once His-194A is worst orientated to promote that reaction. Similarly to 
what was found in the QI-M4A model, the reaction is very exothermic with the QI-M4A 
model (Er = -16.80 kcal/mol) (Fig. 79). 
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Fig. 79 - Activation (Ea) and reaction (Er) energies. 
Energies values considering all atoms of the system system (black), the HL atoms (red) or the LL atoms (blue). The green 
dashed line represents the Ea predicted by the kcat. 
 
 
 In this model, His-194A donates its proton to the quinonoid intermediate, and it 
becomes negatively charged (Fig. 80). The negative charge of His-194A is promptly 
stabilized by the Tyr-334B, which is corroborated by a decrease in the hydrogen 
interaction between Tyr-334B and His-194A (reactant: 2.75 Å vs product: 2.44 Å) (Fig. 
80). When the protonation of the quinonoid intermediate occurs, PLP ring loses the 
negative charge that was accommodated during the first step. This evidence is confirmed 
by a strong interaction between nitrogen N4 and Asp-273A (reactant: 1.65 Å vs product: 
1.53 Å), which results in a more positively charges nitrogen N4 (Fig. 80). Consequently, 
the water molecule nearby Asp-273A becomes more apart (reactant: 1.75 Å vs product: 
1.80 Å) and the interaction of that water with other amino acid residues, Thr-154A and 
Ser-196A, becomes stronger (Fig. 80). 
 As all previous models have already showed that the phosphate group of PLP 
does not undergo significant changes in its interactions profile with the nearby amino 
acid residues (Fig. 80). 
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Fig. 80 - Reactant (R), transition state (TS) and product (P) structures and energy profile. 
(Left) Wedge-Dash representation of the quinonoid intermediate and the HL amino acid residues. Blue dashed lines 
represent relevant non-bonded interactions and respectively distance in Å. Red double arrow line represents the bond 
whose length was decreased in the scan, and respectively interatomic distance in Å. (Top Right) CPK and licorice 
representations of the quinonoid intermediate and HL amino acid residues at the TS. (Bottom Right) Energy profile 
comparing reactant, TS and product. The green dashed line represents the Ea predicted by the kcat. 
 
 
 The QI-M4A model describes a possible mechanism for the protonation of 
quinonoid intermediate. However, the activation of this step is very high taking into 
account that the first step of the mechanism that requires 13.48 kcal/mol for the first step. 
This would turn the full mechanism not feasible under physiological conditions and 
therefore the direct protonation of the quinonoid intermediate by Tyr-334B is more likely 
to occur. Mutagenesis studies confirm these results, once the His-194A mutants kept 
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their catalytic activity, besides the lower rate. It means that His-194A is important for the 
catalysis, but it is not involved in a major role during the reaction. 
 
 
3.2.4. Model QI-M4B: Tyr-334B protonates the QI (N-H bond rotated) 
Similar to the previous model (QI-M4A), the model (QI-M4B) was built having as 
reference, the product from the first step retrieved from the model EA-S-M4’ model. This 
means that this model is equal to the previous one, but, in this case, we studied the direct 
protonation of carbon Cα of the quinonoid intermediate by Tyr-334B. The complex was 
optimized and the resulting structure (Fig. 81) was used to run the linear scan to follow 
the reaction coordinate that is involved in the proton migration from the hydroxyl group 
of Tyr-334B to carbon Cα of the quinonoid intermediate. 
 
 
Fig. 81 - Structure of the QI-M4B model. 
(Left) Wedge-Dash representation of the quinonoid intermediate (reactant) and the HL amino acid residues. Blue dashed 
lines represent relevant non-bonded interactions and respectively distance in Å. Red double arrow line represents the 
bond whose length was decreased in the scan, and respectively interatomic distance in Å. (Right) CPK and licorice 
representations of the quinonoid intermediate and HL amino acid residues, respectively. 
 
 
 Unfortunately, the full characterization of the TS and respective adjacent minima 
(reactant and product) for this reaction are still not completely characterized. Currently, 
the full convergence of the TS structure has not been fulfilled, but frequency calculation 
of the structure closest to the TS shows only one imaginary frequency at 25.8653i cm-1 
and coincides with the reaction coordinate that is being followed. This means that is just 
a matter of time to gather the full characterization of the TS of this step. Several 
structures of the reactant and the product of this reaction have already been obtained, 
but in order to obtain the ones that are truly connected to the TS structure, we need to 
wait for the full characterization of the TS and obtain them through IRC calculations. At 
this point only global energies regarding the activation and reaction energies can be 
presented with the B3LYP/6-31G(d) level of theory. However, we do believe that the final 
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energies using the same level of theory will not change significantly to the ones that are 
presented here.  
Analogously to what happenned to the QI-M1B model, we confirmed a very fast 
reaction for the protonation of the quinonoid intermediate, since the activation barrier is 
very low (Ea = 2.87 kcal/mol). Moreover, this model also confirmed a high exothermic 
reaction (Er = -26.02 kcal/mol), something that has already been observed with the QI-
M1B model. These results demonstrate that Tyr-335B is the proton donor that protonates 
carbon Cα of the QI intermediate. This result goes in line with the mutagenic experiments 
that reveal that if this residue is mutated by a glycine the enzyme becomes inactive. His-
194A has a secondary role in this process and is not directly involved in the protonation 
step. However, it plays a very important role to guide Tyr-334B nearby carbon Cα of the 
quinonoid intermediate, and, at the same time, to stabilize the negatively charged that is 
kept by Tyr-334B after the protonation step. Such stabilization also helps, in the product 
of the reaction, to move Tyr-334B towards the solvent, in order to become re-protonated 
by the water molecules, and by this way promote enzymatic turnover. The role played 
by His-194A in the reaction is, therefore, not so innocent has it was previously thought.  
The obtained results so far also indicate some insight about the electronic 
delocalization along the PLP cofactor during this step. As we observed in the first step 
(EA-S-M4’), the decarboxylation process produces a negative charge at carbon Cα, that 
is deeply stabilized by the PLP ring, (region a). Since the product of the first step is the 
reactant of the second one, we confirmed the same phenomenon in the reactant of this 
step (QI-M4B model) (Fig. 82). When the proton, donated by Tyr-334B, moves towards 
carbon Cα, the electronic density is withdrawn from the PLP ring (region a) to the carbon 
Cα (region c) in order to promote the nucleophilicity of carbon Cα, and, by this way, to 
become protonated (Fig. 82 and Table 6). We observed that in this reaction the PLP ring 
(region a) becomes more positively charged and the atoms surrounding nitrogen N 
(region b) also becomes less negative. This results into an increase of the global charge 
of the new external aldimine that is formed after the protonation step (reactant: -1.786819 
vs product: -1.045458).  
In sum, the PLP cofactor is very important to stabilize the transient negative 
charge that is formed after the decarboxylation step. Afterward, the quinonoid 
intermediate is generated, and the PLP cofactor recovers its initial electronic stage. 
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Fig. 82 - Electrostatic map of reactant and product. 
Electrostatic maps were built based on Merz-Singh-Kollman charges. Red regions correspond to more negative regions 
whereas blue ones correspond to more positive regions. Green regions are related to neutral regions. The electrostatic 
map was built considering 1.76 points/Bohr3. 
 
 
Table 6 - Merz-Singh-Kollman charges (atomic units) assigned to QI, respective regions a and b, carboxylate 
group/carbon dioxide (region c), phosphate group of PLP and Asp-273A for reactant and product). 
 
Structure Charge (a.u.) 
Reactant (R) Product (P) 
QI -1.786819 -1.045458 
Region c +0.333209 +0.527512 
PLP – Region a +0.341382 +0.717479 
PLP – Region b -0.5983585 -0.300780 
Phosphate Group -1.738189 -1.702650 
Asp-273A -0.857459 -0.858841 
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D. Conclusions and Future Perspectives 
 
 
 
 
Science never solves a problem 
without creating ten more. 
George Shaw 
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 HDC is currently an important drug target that can be used in the treatment of 
several diseases, such as atopic dermatitis, allergies, CHF and cancer. This enzyme 
requires the presence of the PLP cofactor that is necessary for the catalytic process. 
Currently, there is only one structure of mHDC available on the PDB, and it was co-
crystallized with an inhibitor bonded to the PLP cofactor.  This structure together with 
other experimental studies generated several proposals about the catalytic mechanism 
of this enzyme. 
There is a general consensus that the mechanism involves two steps. The first 
step involves the decarboxylation of the natural substrate and the concomitant release 
of carbon dioxide. The second step involves the protonation of the quinonoid 
intermediate by an active site residue. The available site-directed mutagenic studies also 
reveal that several active site residues are essential for catalysis: Asp-273A, Lys-305A, 
Tyr-334B, His-194A, Ser-304A, Thr-248A, Asn-302A, Tyr-80A, Ser-354B and Ala-83A. 
[66] The mutation of any of these residues either turns the enzyme inactive or decreases 
considerable the catalytic process. In spite of these results, it is still no fully understood 
how the catalytic mechanism takes place. For instance, nothing is known about which 
amino acid residue from the active site is involved in the last protonation step. It is also 
unknown the role played by His-194A, Tyr-334B and Asp-273A on catalysis that have 
been shown to be detrimental for the catalytic process. In addition, the only PDB 
structure that is available for this enzyme, includes the PLP cofactor bonded to substrate 
analogue with an unusual conformation of it that has never been found in other PLP-
dependent enzymes.  Either this conformation is an artifact generated by the 
crystallization process or from the inhibitory process. Otherwise this structure can also 
suggest that this enzyme employs a different type of mechanism that has never been 
observed in other PLP-dependent enzymes. 
All of these questions remain unanswered and required further explanations. This 
is important since HDC is an important drug target and there is an urgent need to develop 
new inhibitors targeting this enzyme. In addition, understanding the catalytic mechanism 
of this enzyme will allow to understand the specificity of this enzyme in relation to the 
other enzymes of the same family. This is particularly important since AADC (another 
enzyme of this family) share many similarities to this enzyme but accepts a different type 
of substrates. Taking into account that AADC is another important drug target, the 
understanding of the differences related to their substrate specificity will help to develop 
new and more specific inhibitors targeting each of these enzymes. 
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 In this work, theoretical and computational means were used to shade some light 
to each of these questions and also to describe with atomic detail the full catalytic 
mechanism of mHDC. 
Since there is only one structure of mHDC available on the PDB, our first task 
focused on modeling the wild-type enzyme with the natural substrate bonded to it. This 
was particular important since the inhibitor adopts a different conformation in relation to 
the PLP cofactor that is not common among the other PLP-dependent enzymes. The 
generated model was then subjected to a MD simulation in order to optimize the structure 
of the full complex and accommodate all the changes that were introduced manually. 
This initial task was particular important to achieve all the milestones that were 
highlighted before since it allowed to sample several conformations of the PLP cofactor 
together with the substrate bonded to it, as well as the conformation of several active 
site residues and surrounding water molecules that were later one identified as crucial 
for the catalytic process. 
 
Several models were then taken from the MD simulation, and the QM/MM models 
were built and used to study the catalytic mechanism of mHDC, using the ONIOM 
subtractive scheme and the DFT-B3LYP/6-31G(d):AMBER(ff99SB + GAFF) level of 
theory. In this process, several reaction coordinates were followed for each step that 
were used to explore different mechanistic proposals. It is worth mentioning here that 
the first step of the catalytic mechanism was calculated with a higher theoretical level of 
theory and with a more complete basis set (DFT-M06/6-311+G(d,p)/GD3 
:AMBER(ff99SB + GAFF). However, since the final calculations of the second step are 
still not complete, we opted to just present in the conclusion of this thesis the energies 
that were obtained with lower theoretical level of theory. However, the results from the 
first step indicate that the results obtained with the higher theoretical level and a more 
complete basis set does not influence dramatically the energies that are presented in 
this section. 
The QM/MM calculations revealed that the decarboxylation was impossible under 
physiological conditions using the complex of the wild-type enzyme with the natural 
substrate bonded to the PLP cofactor in the unusual conformation, similar to what is 
found in the PDB structure with the code 4E1O [17] (Ea > 20 kcal/mol).  Several 
modifications to the complex were introduced to explore different conformations of the 
active site residues, as well as different QM/MM schemes but with no success. These 
results clearly indicated that the unusual disposition of the natural substrate in relation 
to the PLP cofactor is not feasible for catalysis.  
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The wild-type enzyme model was then modeled with the substrate bonded to the 
PLP cofactor in a similar conformation that is observed in the majority of the PLP-
dependent enzymes. This new configuration allows the best orientation of the imine 
bond, and allows the formation of an important hydrogen bonds between nitrogen N4 
and the carbonyl groups of the PLP cofactor. In addition, such configuration promotes 
the positioning of the imidazole group of the substrate in a manner that endorses a 
hydrogen bond formation with Ser-354B that noticeably affects the decarboxylation 
process.  In addition, in such model, His-194A becomes parallel aligned to the PLP 
cofactor and establishes an important hydrogen bond with the carboxylate group that 
was found to be important for the correct orientation and accommodation of the external 
aldimine inside the active site. In addition, His-194A also becomes aligned with Tyr-334B 
that was found to be important for the second step of the mechanism. 
The QM/MM calculations of this model system showed that the catalytic 
mechanism is complete in two steps. The computed energies reveal that the 
decarboxylation is the rate-limiting step. It also indicates that the energetic profile for the 
catalytic mechanism of mHDC is highly endothermic reaction in the decarboxylation 
process, and highly exothermic reaction in the second step that involves the protonation 
of the quinonoid intermediate (Fig. 83 black line).  
The final energies of the energetic profile present in Fig. 83 were computed with 
the DFT-B3LYP/6-31G(d):AMBER(ff99SB + GAFF) level of theory, including the thermal 
correction calculated with the DFT-B3LYP/6-31G(d):AMBER(ff99SB + GAFF) level of 
theory and the dispersion effect of the DFT calculations with the GD3 basis set. 
The thermal corrections provide a good overview about the entropic contribution 
for the total energy along the calculated energetic pathway. The entropy contribution 
lowers either the activation barrier by 2.21 kcal/mol and the reaction energy by 4.16 
kcal/mol of the first step (the entropic effects on the second step are still not available). 
The entropic effect observed in the first step can be explained by the fact that during the 
decarboxylation process, two molecules (quinonoid intermediate and carbon dioxide) are 
formed from only one molecule, the external aldimine. Consequently, the stabilization of 
the product from the first step is significantly more stabilized when the entropic 
contributions are considered (Fig. 83 dark blue line).  
The light blue line at the Fig. 83 corresponds to the activation and reaction 
energies (∆E) for the second step, since the full characterization of the TS and minima 
were not achieved yet in this step, as explained before. 
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Fig. 83 – Energetic profile of all reaction catalyzed by mHDC. 
 
 The obtained results go in line with the experimental free energy that indicate that 
the rate-limiting step should be below 18 kcal/mol and in our results the rate-limiting step 
requires an activation energy of 13.48 kcal/mol.  
 
The computed energies also provide interesting results regarding the different 
contribution of HL and LL layers in the QM/MM scheme that was used, in the activation 
and reaction energies of the decarboxylation step. The energetic profile for the first step 
(Fig. 84) reveals that the LL layer slightly stabilizes the TS and product as we expected. 
The major contribution for the energies are assigned to the HL layer that includes all the 
amino acids players involved in the decarboxylation process. 
 
 
Fig. 84 – Energetic profile of the decarboxylation process catalyzed by mHDC. 
Energies values considering all atoms of the system (black), the HL atoms (red) or the LL atoms (blue). The green dashed 
line represents the Ea predicted by the kcat. 
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The computed mechanism is also in good agreement with the available 
experimental data [66] that points Lys-305A, Asp-273A, Tyr-334B and His-194A as 
important residues for catalysis. 
Lys-305A is crucial for the catalysis because it establishes an imine bond with 
the PLP cofactor, originating the internal aldimine. If the Lys-305A is not present, the 
internal aldimine is not formed, and, consequently, the decarboxylation of L-histidine is 
blocked [51, 52]. 
The computed catalytic mechanism has shown that when Tyr-334B is directly 
involved in the protonation step of the second step of the catalytic mechanism the 
reaction is about one hundred million times faster than when His-194A is used to mediate 
the proton transfer. This explains why the mutation of Tyr-334B by a glycine turns the 
enzyme inactive whereas the mutation of His-194A by glycine only decreases the 
catalytic activity of the enzyme, but does not prevent the reaction to occur. 
The role played by His-194A in the mechanism has also been disclose. His-194A 
is important to guide the tyrosine residue during its approximation to the carbon Cα of 
the quinonoid intermediate, and to guide Tyr-334B back to the solvent in order to be re-
protonated. In addition, this residue is important in the first step of the mechanism to 
align the carboxylate group and the PLP ring along the decarboxylation process. 
The mutagenesis studies also point Asp-273A as important for catalysis. The 
results obtained in this work revealed that this residue stabilizes the positively charged 
nitrogen N4 of the PLP cofactor, which promotes the charge withdrawing along the PLP 
cofactor and that helps the catalytic process (Fig. 85). However, such stabilization is not 
so straight as initial it can be thought. Indeed, when we mutated this residue by an 
alanine and repeated the first step of the catalytic mechanism (results not shown in this 
thesis), we found that the reaction is much faster and the reaction is not so endothermic 
as it was obtained when Asp-273A is present in the active site. This indicates that Asp-
273A is not favoring the decarboxylation process, and this is an important feature for the 
full catalytic process. Indeed, if the negative charge was fully stabilized along the PLP 
cofactor, it would no longer be available for the protonation step of the second step that 
is required for the enzymatic turnover. In sum, we have a commitment that allows an 
overall faster reaction that allows the decarboxylation and protonation processes, 
besides the penalization of the first one. 
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The role played by Asp-273A is also helped by the network of hydrogen bonds 
that it established with the neighbor water molecule, Ser-196A and His-194A. When the 
external aldimine is formed, His-194A has also an important role because it establishes 
a hydrogen bond with the carboxylate group of the external aldimine. This interaction is 
important to orientate the carboxylate group, and to stabilize its negative charge. 
Consequently, the strong interaction between His-194A and the carboxylate group of 
PLP drags all the hydrogen bond network that is established between Asp-273A and 
His-194A, that includes a serine residue (Ser-196A) and a water molecule. In the 
reactants of the first step, the water molecule nearby Asp-273A is moved away and 
interacts weakly with the aspartate residue. This scenario is inverted after the 
decarboxylation process because His-194A loses its interaction with the carboxylate 
group, and it interacts weakly with Tyr-334B, which is not negatively charged. The water 
molecule placed nearby Asp-273A starts to interact with it in a stronger manner, 
stabilizing the negative charge of Asp-273A. This phenomenon is a consequence of 
weakening of the hydrogen bond between Asp-273A and nitrogen N4, which becomes 
much more negative than in the initial structure.  
 
 
Fig. 85 – Importance of the hydrogen bond network established between the carboxylate group and Asp-372A. 
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Fig. 86 – Dihedral analysis of all tested model for the first step. 
 
As we saw, His-194A has several minor roles during catalysis, and one of them 
is to correct the orientation of the carboxylate group of the external aldimine during the 
decarboxylation process. This evidences the dihedral angle of the carboxylate group 
relatively to the PLP cofactor as an important feature for the catalysis. Dunathan [60, 61] 
have already proposed that during the decarboxylation process, the bond that is broken 
should be held at 90° to the plane in the relation the extended conjugated system. 
Accordingly, this positioning helps a faster catalysis for the decarboxylation step. [60, 61] 
We compare the dihedral angles of each model that was built to describe the 
decarboxylation step (Fig. 86) to disclose about the main differences. The model that 
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actually describes accurately the first step (EA-S-M4’) has the carboxylate group in 
almost perpendicular plane to the extended conjugated system of PLP (77.82°). If we 
look to the TS structures, we can confirm this trend, since EA-S-M4’ model presents the 
carboxylate group closer to 90° comparatively to the other models. In this comparison, 
we cannot include the EA-S-M1 models because they did not allow a TS characterization 
and the reaction was block by the proximity of Tyr-334B. In conclusion, Dunathan’s 
theory was confirmed based on our models, but the carboxylate group does not need to 
be necessarily perpendicular to the conjugated system of PLP. Moreover, the correct 
orientation of the bond that is broken is not the only requirement to become the 
decarboxylation possible. Ser-354B is another amino acid residue that plays an 
important role in anchoring the phosphate group of PLP, but it is also crucial for the 
specificity of mHDC. If we overlap the active sites of AADC and mHDC, we can only 
disclose the absence of this serine residue in the AADC. In this work, we showed that 
Ser-354B establishes a strong hydrogen bond with the imidazole group of the substrate, 
and it gives the specificity of mHDC to L-histidine. For example, one of the substrates of 
AADC, L-DOPA, cannot bind the active site of mHDC due to the bigger side chain ring 
(dihydroxybenzene) that cannot be accommodate inside the active site because of 
stereochemical impediments. Then, we confirmed the role of Ser-354B in the substrate 
specificity of mHDC, and we can also predict a similar catalytic mechanism for AADC, 
since the players and their arrangement inside the active site is identical to those who 
have been identified in mHDC. 
 
To finalize this conclusion, the complete description of the entire catalytic 
mechanism of mHDC will be presented (Fig. 87). The initial steps that are common to 
every PLP-dependent enzyme have already been described [51, 52], and the specific 
steps of the catalytic mechanism of mHDC were disclosed with this work.  
The decarboxylation of L-histidine by the mHDC involves three major stages: i) 
the activation of mHDC by internal aldimine formation; ii) the transimination reaction, 
where the substrate binds the PLP cofactor; and iii) the decarboxylation reaction, where 
the substrate is decarboxylated and, then, protonated.  
 In the first stage, the PLP cofactor binds the ε-amino group from Lys-305A, 
originating an internal aldimine. The internal aldimine is the structure where the Lys-
305A is linked to the PLP cofactor through an imine bond. When the enzyme has the 
internal aldimine formed in its binding pocket, it is ready to receive the substrate. Then, 
in the second stage, the internal aldimine binds the L-histidine (substrate) to form a gem-
diamine intermediate. At this point, both Lys-305A and the substrate are bonded to the 
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PLP cofactor. Afterward, the Lys-305A releases the PLP cofactor, and this originates an 
external aldimine. The external aldimine is formed through the imine linkage between 
the substrate and the PLP cofactor. Since the external aldimine is formed, PLP ring 
withdraws the electronic density, and the bond that links the carboxylate group to the 
substrate becomes weaker. Consequently, carboxylate group is released in the form of 
carbon dioxide, and the resulting carbanion is stabilized by the PLP cofactor, originating 
a quinonoid intermediate. The quinonoid intermediate is, then, protonated by the 
hydroxyl group of Tyr-334B at the same position from where the carboxylate group was 
removed. Consequently, a new external aldimine is formed, and it consists in the product 
(histamine) bonded to the PLP cofactor. This new external aldimine enters again in the 
transimination stage, where the enzymatic turnover takes place. At this time, the 
histamine is released through the binding of Lys-305A and the internal aldimine is 
recovered for a new catalytic cycle.  
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Fig. 87 – Schematic representation of the proposal catalytic mechanism of mHDC.   
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1. Detailed information about the molecular dynamics simulations 
CHAIN A:    -SMEPEEYRERGREMVDYICQYLSTVRERRVTPDVQPGYLRAQLPESAPEDPDSWDSIFGDIERIIM 
CHAIN B:    -SMEPEEYRERGREMVDYICQYLSTVRERRVTPDVQPGYLRAQLPESAPEDPDSWDSIFGDIERIIM 
CHAIN C: GPLGSMEPEEYRERGREMVDYICQYLSTVRERRVTPDVQPGYLRAQLPESAPEDPDSWDSIFGDIERIIM 
CHAIN D:    GSMEPEEYRERGREMVDYICQYLSTVRERRVTPDVQPGYLRAQLPESAPEDPDSWDSIFGDIERIIM 
CHAIN E:    GSMEPEEYRERGREMVDYICQYLSTVRERRVTPDVQPGYLRAQLPESAPEDPDSWDSIFGDIERIIM 
CHAIN F:    GSMEPEEYRERGREMVDYICQYLSTVRERRVTPDVQPGYLRAQLPESAPEDPDSWDSIFGDIERIIM 
       70               80               90              100             110             120             130                                                                   
CHAIN A: PGVVHWQSPHMHAYYPALTSWPSLLGDMLADAINCLGFTWASSPACTELEMNVMDWLAKMLGLPEHFLHH 
CHAIN B: PGVVHWQSPHMHAYYPALTSWPSLLGDMLADAINCLGFTWASSPACTELEMNVMDWLAKMLGLPEHFLHH 
CHAIN C: PGVVHWQSPHMHAYYPALTSWPSLLGDMLADAINCLGFTWASSPACTELEMNVMDWLAKMLGLPEHFLHH 
CHAIN D: PGVVHWQSPHMHAYYPALTSWPSLLGDMLADAINCLGFTWASSPACTELEMNVMDWLAKMLGLPEHFLHH 
CHAIN E: PGVVHWQSPHMHAYYPALTSWPSLLGDMLADAINCLGFTWASSPACTELEMNVMDWLAKMLGLPEHFLHH 
CHAIN F: PGVVHWQSPHMHAYYPALTSWPSLLGDMLADAINCLGFTWASSPACTELEMNVMDWLAKMLGLPEHFLHH 
       140             150              160             170             180              190             200                                                                   
CHAIN A: HPSSQGGGVLQSTVSESTLIALLAARKNKILEMKTSEPDADESSLNARLVAYASDQAHSSVEKAGLISLV 
CHAIN B: HPSSQGGGVLQSTVSESTLIALLAARKNKILEMKTSEPDADESSLNARLVAYASDQAHSSVEKAGLISLV 
CHAIN C: HPSSQGGGVLQSTVSESTLIALLAARKNKILEMKTSEPDADESSLNARLVAYASDQAHSSVEKAGLISLV 
CHAIN D: HPSSQGGGVLQSTVSESTLIALLAARKNKILEMKTSEPDADESSLNARLVAYASDQAHSSVEKAGLISLV 
CHAIN E: HPSSQGGGVLQSTVSESTLIALLAARKNKILEMKTSEPDADESSLNARLVAYASDQAHSSVEKAGLISLV 
CHAIN F: HPSSQGGGVLQSTVSESTLIALLAARKNKILEMKTSEPDADESSLNARLVAYASDQAHSSVEKAGLISLV 
       210             220              230             240             250              260             270                                                                   
CHAIN A: KMKFLPVDDNFSLRGEALQKAIEEDKQRGLVPVFVCATLGTTGVCAFD?LSELGPICAREGLWLHIDAAY 
CHAIN B: KMKFLPVDDNFSLRGEALQKAIEEDKQRGLVPVFVCATLGTTGVCAFD?LSELGPICAREGLWLHIDAAY 
CHAIN C: KMKFLPVDDNFSLRGEALQKAIEEDKQRGLVPVFVCATLGTTGVCAFD?LSELGPICAREGLWLHIDAAY 
CHAIN D: KMKFLPVDDNFSLRGEALQKAIEEDKQRGLVPVFVCATLGTTGVCAFD?LSELGPICAREGLWLHIDAAY 
CHAIN E: KMKFLPVDDNFSLRGEALQKAIEEDKQRGLVPVFVCATLGTTGVCAFD?LSELGPICAREGLWLHIDAAY 
CHAIN F: KMKFLPVDDNFSLRGEALQKAIEEDKQRGLVPVFVCATLGTTGVCAFD?LSELGPICAREGLWLHIDAAY 
       280             290              300             310             320              330             340                                                                   
CHAIN A: AGTAFLCPEFRGFLKGIEYADSFTFNPSKWMMVHFDCTGFWVKDKYKLQQTFSVNPIYLRHANSGVATDF 
CHAIN B: AGTAFLCPEFRGFLKGIEYADSFTFNPSKWMMVHFDCTGFWVKDKYKLQQTFSVNPIYLRHANSGVATDF 
CHAIN C: AGTAFLCPEFRGFLKGIEYADSFTFNPSKWMMVHFDCTGFWVKDKYKLQQTFSVNPIYLRHANSGVATDF 
CHAIN D: AGTAFLCPEFRGFLKGIEYADSFTFNPSKWMMVHFDCTGFWVKDKYKLQQTFSVNPIYLRHANSGVATDF 
CHAIN E: AGTAFLCPEFRGFLKGIEYADSFTFNPSKWMMVHFDCTGFWVKDKYKLQQTFSVNPIYLRHANSGVATDF 
CHAIN F: AGTAFLCPEFRGFLKGIEYADSFTFNPSKWMMVHFDCTGFWVKDKYKLQQTFSVNPIYLRHANSGVATDF 
       350             360              370             380             390              400             410                                                                   
CHAIN A: MHWQIPLSRRFRSVKLWFVIRSFGVKNLQAHVRHGTEMAKYFESLVRNDPSFEIPAKRHLGLVVFRLKGP 
CHAIN B: MHWQIPLSRRFRSVKLWFVIRSFGVKNLQAHVRHGTEMAKYFESLVRNDPSFEIPAKRHLGLVVFRLKGP 
CHAIN C: MHWQIPLSRRFRSVKLWFVIRSFGVKNLQAHVRHGTEMAKYFESLVRNDPSFEIPAKRHLGLVVFRLKGP 
CHAIN D: MHWQIPLSRRFRSVKLWFVIRSFGVKNLQAHVRHGTEMAKYFESLVRNDPSFEIPAKRHLGLVVFRLKGP 
CHAIN E: MHWQIPLSRRFRSVKLWFVIRSFGVKNLQAHVRHGTEMAKYFESLVRNDPSFEIPAKRHLGLVVFRLKGP 
CHAIN F: MHWQIPLSRRFRSVKLWFVIRSFGVKNLQAHVRHGTEMAKYFESLVRNDPSFEIPAKRHLGLVVFRLKGP 
       420             430              440             450             460              470              480                                                                   
CHAIN A: NSLTENVLKEIAKAGRLFLIPATIQDKLIIRFTVTSQFTTRDDILRDWNLIRDAATLILSQ--------- 
CHAIN B: NSLTENVLKEIAKAGRLFLIPATIQDKLIIRFTVTSQFTTRDDILRDWNLIRDAATLILSQ--------- 
CHAIN C: NSLTENVLKEIAKAGRLFLIPATIQDKLIIRFTVTSQFTTRDDILRDWNLIRDAATLILSQ--------- 
CHAIN D: NSLTENVLKEIAKAGRLFLIPATIQDKLIIRFTVTSQFTTRDDILRDWNLIRDAATLILSQ--------- 
CHAIN E: NSLTENVLKEIAKAGRLFLIPATIQDKLIIRFTVTSQFTTRDDILRDWNLIRDAATLILSQ--------- 
CHAIN F: NSLTENVLKEIAKAGRLFLIPATIQDKLIIRFTVTSQFTTRDDILRDWNLIRDAATLILSQ--------- 
 
Supplementary Fig. 1 - Sequence alignment of the amino acid sequence of all chains from PDB file 4E1O. Red 
boxes highlight a position where an amino acid residue is missing. Yellow boxes highlight the Gly-Pro-Cys tag 
introduced artificially. 
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Supplementary Fig. 2 - New Cartoon representation of the human mHDC protein structure and TIP3P water 
solvation box. Subunit A and B are colored by blue and red, respectively. 
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Supplementary Fig. 3 – Physical general properties during the MD simulation of EA-S model.  
(A) Temperature; (C) Kinetic energy; (D) Potential energy; (E) Total system energy; (F) Pressure; (G) Volume; and (H) 
Density variations along the 60 ns MD simulation. (B) Temperature variation along the first 20 ps MD simulation 
corresponding to the equilibration step. 
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Supplementary Table 1 - Mean values and respective standard deviations for the physical general properties 
during MD simulation of EA-S model.  
Calculations were done considering only 20 ns of the MD simulations between 40 and 60 ns, corresponding to an 
equilibrated region. 
 
Temperature (K) 310.0 ± 5.1  
Kinetic Energy (kcal/mol) (8.27 ± 0.36)x104  Potential Energy (kcal/mol) (-3.89 ± 0.03)x105 
Total Energy (kcal/mol) (-3.06 ± 0.05)x105  Pressure (atm) 1.46 ± 85.69 
Volume (Å3) (1.305 ± 0.003)x106  Density (g/cm3) 1.014 ± 0.002 
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Supplementary Fig. 4 - Physical general properties during the MD simulation of QI model.   
(A) Temperature; (C) Kinetic energy; (D) Potential energy; (E) Total system energy; (F) Pressure; (G) Volume; and (H) 
Density variations along the 60 ns MD simulation. (B) Temperature variation along the first 20 ps MD simulation 
corresponding to the equilibration step. 
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Supplementary Table 2 – Mean values and respective standard deviations for the physical general properties 
during MD simulation of QI model. 
Calculations were done considering only 20 ns of the MD simulations between 40 and 60 ns, corresponding to an 
equilibrated region. 
 
Temperature (K) 310.0 ± 5.1  
Kinetic Energy (kcal/mol) (8.27 ± 0.36)x104  Potential Energy (kcal/mol) (-3.89 ± 0.03)x105 
Total Energy (kcal/mol) (-3.06 ± 0.05)x105  Pressure (atm) 1.31 ± 84.78 
Volume (Å3) (1.305 ± 0.003)x106  Density (g/cm3) 1.014 ± 0.002 
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2. Book chapter 
This book chapter was accepted for publication in the multi-volume set (I-V) 
“Therapeutic Nanostructures” by the Elsevier publisher. 
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Abstract 
The increasing understanding of tumour biology has allowed the identification of 
various cellular characteristics that are more frequently associated with cancer cells than 
with normal cells. These findings have prompt the development of new therapeutics 
specifically designed to exploit these differences. In this context, the amino acid 
depriving enzymes have shown very promising results and proven to be active and very 
specific against various types of cancers. These therapies involve the depletion of 
specific amino acids in the blood stream that cannot be synthesised by tumour cells. This 
happens because these cells have often a defecting enzymatic armamentarium and 
therefore rely on external supply for those amino acids. Decreasing the concentration of 
certain amino acids in blood has thus been shown to impair the development or even 
destroy tumour cells. Normal cells remain unaltered since they are less demanding 
and/or can synthesize these compounds in sufficient amounts by other mechanisms. 
In this chapter, the structure, function, catalytic mechanism and therapeutic 
application of some amino acid depriving enzymes will be reviewed. Particular attention 
will be given to enzymes that have potential or are currently used in the treatment of 
several types of cancer, namely : i) L-asparaginase used for the treatment of acute 
lymphoblastic leukaemia, ii) L-arginase and L-arginine deiminase that are used in the 
therapy of hepatocellular carcinomas and melanomas, two diseases that account 
annually with approximately 1 million of new cases and for which there is currently no 
efficacious treatment and iii) L-Methioninase with potential to be used in the treatment of 
breast, colon, lung and renal cancers. 
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1. Introduction 
Cancer has become the leading cause of death in the developed world and has 
remained one of the most difficult diseases to treat. During the last 5 decades, cancer 
therapy has relied mainly on low molecular weight molecules.  However, this class of 
compounds, very potent in their action, unfortunately lacks tumour specificity and has 
often unacceptable toxicities toward normal cells. All of these factors are often followed 
by side effects, which often undermine the effectiveness of the therapeutic treatment in 
patients (Cantor et al., 2012b). For this reason, the demand for new and improved 
therapeutics against cancer remains high and at the same time a deeper knowledge 
regarding the development of tumours is required.  
The development of tumour cells is still not fully understood, but many advances 
have been made in this area.  Alterations to cellular metabolism seem to constitute a 
nearly universal feature in many types of cancers. For instance, many tumours exhibit 
deficiencies in their enzymatic armamentarium and cannot biosynthesize one or more 
amino acids that are essential for its development, survival and spread. In order to 
overcome these problems, tumours rely on the extracellular pool of these amino acids 
to satisfy protein biosynthesis demands and continue to grow without being affected.  
This means that if the concentration of those amino acids is decreased, the development 
of tumour cells can be impaired or even annihilated.  At the same time, normal cells 
remain unchanged since they are less demanding or can synthesize these compounds 
in sufficient amounts by alternative pathways. 
These observations are the basis of the amino acid deprivation cancer therapy 
that involves the systemic depletion of tumour-essential amino acid. This knowledge is 
not new and was initially suggested over 50 years ago, but only now it is gaining 
popularity with the advances in protein engineering technology and, on more 
sophisticated approaches that enable the study of genetic and metabolic differences 
between tumour and normal cells(Cantor et al., 2012a). 
In these tumours, diet is not enough to achieve a therapeutically relevant level for 
amino acid depletion and therefore enzymes are used instead. Regrettably,  the human 
genome does not encode enzymes with the pharmacological or  catalytic requisites that 
are essential for the pretended therapeutic purpose. For this reason heterologous 
enzymes (from other organisms), recombinant and/or engineered human enzymes are 
used both in animal studies and in clinical trials. Currently the enzymes of bacterial origin 
are the most frequently used. 
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The main function of heterologous or engineered human enzymes used in amino 
acid depletion therapies is to decrease the concentration of a certain amino acid in the 
blood stream (e.g. converting it into another molecule) that is essential for the 
development of a tumour.  Some examples include a large fraction of hepatocellular 
carcinomas (HCC) and metastatic melanomas that become apoptotic under conditions 
where the nonessential amino acid L-arginine (L-ARG) in serum is depleted (Ni et al., 
2008), central nervous system cancers that respond to L-methionine (L-MET) deprivation 
(Tan et al., 2010), and acute lymphoblastic leukaemia (ALL) for which depletion of L-
asparagine (L-ASN) has been shown to significantly reduce cancer growth (Rytting, 
2010b). 
In this review, the structure, function, and catalytic mechanism of therapeutic 
heterologous enzymes involved in L-ARG, L-MET and L-ASP degradation will be 
revised. Particular attention will be given to the heterologous enzymes L-arginase, L-
arginine deiminase, L-methioninase and L-asparaginase taking into account their current 
therapeutic potential.   
 
 
2. Amino Acid deprivation enzymes 
At least 20 amino acids have been identified in cells and from these the human 
body cannot manufacture de novo (from scratch) nine which, consequently need to be 
obtained from the diet.  These amino acids are normally denominated as essential and 
include L-phenylalanine, L-valine, L-threonine, L-tryptophan, L-methionine, L-leucine, L-
isoleucine, L-lysine, and L-histidine. Six other amino acids are termed conditionally 
essential. This means that their synthesis can be carried out by humans but their 
synthesis can be limited by a variety of factors, such as prematurity in the infant or 
individuals in severe catabolic distress.  These amino acids are L-arginine, L-cysteine, 
L-glycine, L-glutamine, L-proline and L-tyrosine. The remaining five amino acids are 
dispensable in humans (also denoted as non-essential), meaning they can be 
synthesized in the body, e.g., L-aspartic acid, L-asparagine, L-glutamic acid, L-alanine 
and L-serine. 
The optimal conditions for amino acid depletion therapies occur when the 
tumours are sensitive to one of the non-essential or conditionally essential amino acids.  
This will ensure that only tumour cells will be affected by the therapy whereas the normal 
cells remain unaltered since they can synthesize these compounds in sufficient amounts 
by their own means.  The most notable example of target enzymatic amino acid depletion 
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in cancer therapy is illustrated by the remarkable success of L-asparaginase, in the 
treatment of childhood ALL, and to a lesser extent, non-Hodgkins lymphoma. Another 
examples involve the use of arginine deiminase in the HCC, melanoma, and other urea 
cycle-deficient cancer cells that have a high demand for L-arginine. The essential amino 
acids can also be used in amino acid depletion therapies, but it is not very common. This 
only happens in tumours where the normal metabolism of one essential amino acid is 
disrupted or when there is some sort of defect in the ability to use a certain amino acid. 
This is for example the case of L-methionine that has been shown to be detrimental for 
the survival of a variety of tumour tissues, including colon, breast, prostate, ovary, lung, 
brain, kidney, stomach and bladder cancers as well as larynx melanoma, sarcoma, 
leukaemia and lymphomas.  In this case the action of methionine-γ-lyase has been 
shown to be successfully used in the treatment of these types of cancers. 
Taking into account the therapeutic potential of these enzymes in cancer 
therapies, they have been deeply studied in the last two decades. These therapies have 
been showing promising results, but also some problems in clinical trials. In the following 
sections a detailed analysis of each of these enzymes is done based on the amino acid 
that they metabolize.   
 
2.1. L-asparagine 
L-asparagine (ASN) is a non-essential amino acid that is involved in the metabolic 
control of cell functions in nerve and brain tissue. This amino acid is important in the 
synthesis of a large number of proteins and plays an important role in the biosynthesis 
of glycoproteins where it provides key sites for N-linked glycosylation.  ASN also plays 
an important role in the metabolism of ammonia, which is toxic in the human body.  
Since L-asparagine is a non-essential amino acid, it can be easily synthesized by the 
cells. The precursor in the biosynthesis of ASN is oxaloacetate which reacts with L-
glutamate to form L-aspartate and α-ketoglutarate, in the presence of a transaminase 
enzyme. The L-aspartate then reacts with L-glutamine to form L-asparagine in an ATP-
dependent reaction that is catalysed by L-asparagine synthetase (Richards and Kilberg, 
2006). 
Certain types of tumours, such as leukemic cells, cannot synthesize ASN 
because they lack or have deficient expression of the enzyme L-Asparaginase synthase. 
This means that the proliferation and survival of these tumour cells are dependent on the 
external supplies of this amino acid. As normal cells can synthesise ASN, this means 
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that L-asparagine deprivation therapies would mainly interfere with tumour cells that are 
ASN deficient. 
L-Asparaginase (ASNase) is a bacterial enzyme that has been used with great 
success in leukaemia treatment regimens for four decades. This enzyme performs the 
opposite reaction of L-asparagine synthetase by hydrolysing ASN to L-aspartic acid and 
ammonia. By reducing the levels of plasmatic L-asparagine,  ASNase starves leukemic 
cells and promotes tumour cell apoptosis. 
The therapeutic role of ASNase was first note by Kidd in 1953,(Kidd, 1953) that 
found that guinea pig serum had antitumor activity against two kinds of   lymphoma in a 
murine model and lymphosarcoma in rats. This fact was, latter on, attributed to the 
enzyme ASNase that was present in the serum (Broome, 1961, Broome, 1963). Later 
on, in 1966, DeLowrey and co-workers using a purified guinea pig serum treated a boy 
with acute lymphoblastic leukaemia, and obtained an objective response (Dolowy et al., 
1966). This turned ASNase into a promissing anticancer drug, and therefore large 
amounts of the enzyme were required to start new studies and large-scale clinical trials. 
However this was not an easy task at that time since the isolation and purification of the 
enzyme was difficult and not all the ASNases possess anti-tumour activity.  
L-Asparaginases (EC 3.5.1.1) is a relatively wide spread enzyme, found in many 
microorganisms such as Aerobacter, Bacillus, Pseudomonas, Serratia, Xanthomonas, 
Photobacterium (Peterson and Ciegler, 1969), Streptomyces (Dejong, 1972), Proteus 
(Tosa et al., 1971), Vibrio (Kafkewitz and Goodman, 1974) and Aspergillus (Sarquis et 
al., 2004).  After intense research ASNases derived from Escherichia coli (Ecoli-
ASNase) and  Erwinia chrysanthemi  (Echry-ASNase) turned out to have the best anti-
cancer capabilities. Ecoli-ASNase has thereby become the main source of ASNase 
because it is easy to produce in large amounts.  Echry-ASNase is typically reserved for 
cases of Ecoli-ASNase hypersensitivity. 
The E. coli expresses two ASNases denoted as Ecoli-ASNase-I and Ecoli-
ASNase-II that are found in different intra or extracellular localizations. Ecoli-ASNase-I 
(cytosolic) has a lower affinity for ASN, while Ecoli-ASNase-II (periplasmic) has a high 
ASN affinity.  Due to the higher affinity of Ecoli-ASNase-II towards L-asparagine, this 
enzyme is the mostly studied enzyme and the one that is used for oncologic therapeutic 
purposes. 
Ecoli-ASNase-II is a tetrameric protein that is composed by four identical 
subunits, each one containing 326 amino acid residues. The binding pocket of this 
enzyme involves residues from both subunits of each dimer, namely, THR12, TYR25, 
SER58, GLN59, THR89, ASP90 and LYS162 from one subunit (Figure 1 - red chain), 
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and ASN248 and GLU283 from the other subunit (Figure 1 - grey chain). All of these 
residues are interconnected by a strong hydrogen bond network, including a water 
molecule that is structurally conserved. The position of the amino acid residues in the 
active site suggests several possible pathways for the catalytic reaction, but the almost 
symmetric location of two threonine residues, THR12 and THR89, observed in the X-ray 
structure 3ECA above and below carbon C2 of the substrate, suggests that one of them 
must be directly involved in the reaction (Figure 1) (Swain et al., 1993). 
 
 
Figure 1 | New Cartoon representation of the co-crystalized structure of ASNase with L-Asparagine (PDB Code: 3ECA). 
Each subunit is represented with a different colour (blue, grey, red and green) and the substrate in ball and sticks and 
coloured by CPK.  In the close-up of the active site the residues of the active site that are important for the catalytic 
process as well as the substrate are represented in licorice. 
 
The first step of the mechanism involves the formation of a tetrahedral 
intermediate (Figure 2a) that results from the nucleophilic attack of the water molecule 
to ɑ-carbon of the substrate. In the course of this reaction, LYS162 receives the proton 
from the water molecule and becomes positively charged. The second step (Step 2) of 
the reaction involves a concerted double proton transfer from LYS162 to THR89 and 
from THR89 to the substrate, from which results the formation of ammonia and aspartic 
acid. However, the ammonia molecule is still weakly bound to the substrate at this stage 
and its dissociation requires an additional step (Step 3). At the end of this process (Step 
4), the enzyme is ready for the next turnover (Gesto et al., 2013). 
Ecoli-ASNase-II and Echry-ASNase have been established as a general 
treatment for acute lymphoblastic leukaemia for nearly 40 years.  It is used for remission 
induction and intensification treatment in all paediatric regimens and in the majority of 
adult treatment protocols.  Currently, it is estimated that these enzymes have contributed 
to significant improvements of therapy outcomes and to achieve complete remission of 
leukaemia in about 90% of patients. 
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Notwithstanding its high therapeutic efficacy, the administration of Ecoli-ASNase-
II for long periods produces acute allergic reactions and silent immunity, a condition that 
is characterised by circulating antibodies and rapid clearance of the enzyme from the 
blood (Henriksen et al., 2015, Avramis et al., 2002, Woo et al., 1998). In order to 
overcome this problem, a modification of Ecoli-ASNase-II with 5-kDa units of 
monomethoxypolyethylene glycol was introduced (PEG-Ecoli-ASNase-II) (Rytting, 
2010a). The modified enzyme preserves enzyme activity, but decreases immunogenicity 
of the protein and extends elimination half-life (5 times longer then native enzyme) 
(Keating et al., 1993).  
 
Figure 2 | Schematic representation of the ASNase catalytic mechanism. Each blue circle represents a different reaction 
intermediate. The black arrows indicate the reaction steps and the red ones the reactions that occur in each step of the 
mechanism.  The important reaction intermediates are labelled with letters (a). 
 
Currently, three L-Asparaginase agents are available.  Either these are derived 
from E. coli in its native form (Ecoli-ASNase-II) or as a pegylated enzyme (PEG-Ecoli-
ASNase-II) or extracted from Erwinia chrysanthemi (Echry-ASNase). Due to the unique 
anticancer mechanism of action, PEG-Ecoli-ASNase-II and  Echry-ASNase have already 
been approved by US Food and Drug Administration (FDA) for the treatment of several 
cancers such as acute lymphoblastic leukaemia (Hill et al., 1967), lymphosarcoma (Story 
et al., 1993) and a few subtypes of non-Hodgkin’s lymphoma (Kobrinsky et al., 2001).  
Ovarian carcinomas and other solid tumours have also been proposed as additional 
targets for ASNase, with a potential role for its glutaminase activity (Covini et al., 2012).  
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2.2. L-arginine 
L-arginine (ARG) is a precursor/mediator of a series of biological pathways, some 
of them involved in important cellular functions such as in nitrogen metabolism (Rogers 
and Visek, 1985), creatine, agmatine and polyamine synthesis (Klein and Morris, 1978). 
In addition, ARG is the major substrate for the production of nitric oxide (Billiar, 1995), 
stimulates anabolic hormone release, and it is immunostimulatory and thymotrophic 
(Barbul et al., 1977, Barbul et al., 1983). 
The enzyme Argininosuccinate synthetase (ASS) catalyses the condensation of L-
Citrulline and L-Aspartic acid to Argininosuccinate which is subsequently converted to 
ARG and Fumaric acid by Argininosuccinate lyase (ASL)  (Figure 3-A) (Haines et al., 
2011).  
 
Figure 3 | Schematic representation of the enzymes involved in ARG metabolism and degradation. The enzymes available 
on the cell have grey background. Recombinant enzymes or from bacterial sources are represented with red background. 
 
In healthy adults the level of endogenous synthesis is sufficient to make ARG a 
non-essential dietary amino acid (Castillo et al., 1993). However under catabolic stress 
(e.g. inflammation, infection, etc.), the levels of endogenous synthesis may not be 
sufficient to meet metabolic demands and ARG becomes an essential amino acid. For 
this reason, this amino acid is often denoted as a semi-essential amino acid instead of 
non-essential (Reeds, 2000).  
Certain tumour cells such as metastatic melanoma, prostate carcinomas, HCC 
(Dillon et al., 2004), non-Hodgkin's lymphoma, Hodgkin's lymphoma, pancreatic 
carcinoma, osteosarcoma and malignant pleural mesothelioma and some breast 
tumours (Qiu et al., 2015) have an elevated requirement for ARG due to the deficient 
expression of ASS. This causes ARG autotrophy and therefore these tumours rely only 
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on exogenous sources of ARG for growth and proliferation. Deprivation of this amino 
acid is, for this reason, investigated as a novel strategy for cancer therapy and has been 
showing promising efficacy against the ARG-auxotrophic tumours mention above (Feun 
et al., 2015, Shen et al., 2003, Wheatley and Campbell, 2003).  
ARG can be degraded by several mechanisms, either using enzymes available 
on the cell, such as L-Arginase (ARGase) (Figure 3-B) or L-arginine decarboxylase 
(ADC) (Figure 3-C), using human recombinant ARGase-I (Figure 3-D), or using parasite-
enzymes from a bacterial source such as Arginine deiminase (ADI, Figure 3-E).  From 
these enzymes, ARGase-I and ADI are the most promising ones since they have 
therapeutic potential. L-arginine decarboxylase is relatively toxic to normal cells and 
therefore it is not used for therapeutic purposes (Savaraj et al., 2010).  
 
2.2.1. L-Arginase	
ARG can be degraded directly to L-Ornithine by ARGase (EC 3.5.3.1), an enzyme 
of the urea cycle (Figure 3-B).  Thus the insertion of ARGase on the extracellular moiety 
could be used to decrease the levels of ARG in cells.  However, under salvage 
conditions, higher concentration of L-Ornithine (product of the reaction of ARGase) can 
be converted back to L-Citrulline by Ornithine transcarbamyl transferase and then 
recycle back to ARG by ASS/ASL (Figure 3-A). This feedback mechanism makes normal 
cells and many tumours resistant to ARGase inhibition. Fortunately, there are many 
tumours that present  deficient expressions of OCT and/or ASS enzymes and in these 
cases ARGase can be efficiently used to decrease ARG intracellular levels and therefore 
tumour growth (Cheng et al., 2007). 
ARGase is found in organisms from the five kingdoms (Reczkowski and Ash, 
1992).  In most mammals, two isoforms of this enzyme exist and are denoted as types I 
and II. They share approximately 60% amino acid sequence homology and differ in their 
expression regulation, tissue distribution, subcellular locations, immunologic reactivity, 
physiologic function and certain enzymatic properties (Vockley et al., 1996, Spector et 
al., 1983, Jenkinson et al., 1996, Herzfeld and Raper, 1976, Dizikes et al., 1986). 
ARGase-I is a cytosolic enzyme located predominantly in the liver (Krebs, 1973). 
ARGase-II is a mitochondrial enzyme that does not appear to function in the urea cycle 
and is more widely distributed in numerous tissues (Morris et al., 1997). 
In mammals, ARGase-I is present in the liver and it is one of the most important enzymes 
involved in nitrogen metabolism. It is involved in the principal route for disposal of excess 
nitrogen resulting from amino acid and nucleotide metabolism. The flux of nitrogen 
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through this pathway is considerable, given that the average individual excretes about 
10 kg of urea per year (Ash et al., 1998). 
In humans, h-ARGase-I is an oligomer of 107 kDa and shows optimum pH at 9.3 
and has a Km for ARG about 10.5 mM (Beruter et al., 1978) . The key structural features 
of mammalian ARGase-I include a binuclear Manganese cluster (Mn), and an S-shaped 
tail composed by 19 amino acids at the C terminus of each monomer. The S-shaped 
tails are located at the subunit-subunit interface, and 54% of the inter-subunit interactions 
are mediated by this region of the protein (Lavulo et al., 2001). 
The catalytic mechanism of this enzyme is still not fully understood but several 
suggestions have already been proposed, some of them more consensually accepted 
(Christianson and Cox, 1999, Cox et al., 2001, Leopoldini et al., 2009) than others 
(Khangulov et al., 1998). Among the active site residues, GLU277 is apparently 
implicated in the substrate binding through the establishment of electrostatic interactions 
with the guanidium group of the substrate. This interaction appears to orientate the 
subtract in a favourable position with respect to the metal-bound hydroxide anion with 
whom it must react with (Cavalli et al., 1994, Kanyo et al., 1996, Scolnick et al., 1997). 
Both Manganese ions are coordinated to a hydroxide anion and with two Aspartates 
(ASP232 and ASP128) and one Glutamate (GLU277). These structural features can be 
observed in the  crystallographic structure  with the PDB code 3GMZ, where the human 
ARGase is in complex with L-ornithine.  (Figure 4) (Ilies et al., 2011).  
 
Figure 4 | New Cartoon representation of the co-crystalized structure of h-ARGase with L-Ornithine (PDB Code: 3GMZ). 
Each subunit is represented with a different colour (blue and grey) and the substrate in ball and sticks and coloured by 
CPK.  In the close-up of the active site are represented: the residues of the active site that are important for the catalytic 
process in licorice and, the oxygen atom from the hydroxide ion and the two magnesium ions in VDW. 
 
According to (Leopoldini et al., 2009) the hydrolysis of ARG mediated by 
ARGase-I is kinetically favoured when the ASP128 residue is deprotonated. The 
hydrolysis starts with the binding of ARG to the Mn(II) ions through the gaunidium groups. 
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These interactions place the substrate in a good position to undergo nucleophilic attack 
by the bridging hydroxy anion to carbon Cζ (Step 1) from which results a tetrahedral 
intermediate (Figure 5a). In the second step of the mechanism, ASP128 acts as an 
acid/base catalyst, abstracting a proton from the hydroxyl group and shuttling it to the 
nitrogen Nε of the substrate (Step 2). This step is then followed by the bond break 
between nitrogen Nε and carbon Cζ of the substrate from which results L-ornithine and 
urea (Step 3). In the following step (Step 4), a water molecule enters to bridge the 
binuclear Mn(II) cluster, causing the urea product to move to a terminal coordination site 
on Mn(II). HIS141 appears to facilitate product release by serving as a proton shuttle 
from bulk solvent to nitrogen Nε of ornithine and regenerating the nucleophilic metal-
bridging hydroxide anion (Step 5). Once this step is complete ornithine dissociates, the 
enzymatic turnover takes place and the enzyme is ready for a new catalytic cycle (Step 
6). 
 
Figure 5 | Schematic representation of the ARGase catalytic mechanism. Each blue circle represents a different reaction 
intermediate. The black arrows indicate the reaction steps and the red ones the reactions that occur in each step of the 
mechanism.  The important reaction intermediates are labelled with letters (a-c). 
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h-ARGase-I has been tested with success in experimental animals since 1950, 
and showed promising activity in vitro conditions(Simon-Reuss, 1953, Wiswell, 1951). 
However, the therapy failed to produce major responses when tested  in vivo conditions. 
The reason for this failure was related with the low affinity of this enzyme for ARG with 
the consequent requirement of a large quantity of enzyme in order to obtain the expected 
therapeutic results. In addition, this enzyme has a short circulatory half-life (only a few 
minutes) (Savoca et al., 1979) and its optimal pH is very high (9.5) that cannot be 
achieved under physiological conditions.  All of these drawbacks declined the use of h-
ARGase-I as an antitumor agent in the last decades (Currie et al., 1979).  In spite of 
these drawbacks it was shown, in 2010 that a pegylated recombinant human arginase I 
(PEG-r-h-ARGase-I) impairs the proliferation of malignant T cells in acute lymphoblastic 
T cell leukaemia in vivo and in vitro studies (Hernandez et al., 2010).    
Later on, a pegylated cobalt-modified enzyme was developed and showed that 
the substitution of the Mn(II) metal center in h-ARGase-I by Co(II) (Co-r-h-ARGase-I)  
turns the enzyme more efficient for ARG hydrolysis and lowers the IC50 in a variety of 
malignant cell lines, including melanomas and hepatocellular carcinomas in vitro assays 
(Stone et al., 2010). The onlysame group also reported a modification of Co-r-h-ARGase-
I with PEG-5K esters that shown an increase  retention of the enzyme in circulation by 
about 2 orders of magnitude. The use of PEG(5K)-Co-h-ARGase-I was later on  be found 
to be effective in the treatment  of hepatocellular and pancreatic carcinomas in xenograft 
models (Glazer et al., 2011). 
 
2.2.1. L-arginine deiminase. 
L-arginine deiminase (ADI, EC 3.5.3.6) is widely distributed among prokaryotic 
organisms and some anaerobic eukaryotes, but has never been identified in humans or 
other higher eukaryotes (Figure 3-E). The organisms that employ this pathway use ADI 
to convert ARG to L-Citrulline and ammonia (Horn, 1933). L-Citrulline is then degraded 
further, forming ATP (Adenosine Tri-Phosphate), carbon dioxide, and L-ornithine (Arena 
et al., 1999). The ADI pathway is thus used by these organisms to get energy, carbon, 
and nitrogen. In addition, it has also been suggested that this pathway can also protect 
some bacteria from acidic conditions, by the production of ammonia (Casianocolon and 
Marquis, 1988). 
The interest in ADI for therapeutic purposes began in the 90s when Takaku and 
co-workers successfully used this enzyme to inhibit the growth of several murine and 
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human tumour cell lines in vitro and in vivo, by exhausting the supplies of ARG (Takaku 
et al., 1995, Takaku et al., 1992).  From there one, several studies confirmed the potential 
of  ADI, purified from Mycoplasma, as an anti-tumour agent in different types of tumours 
(Takaku et al., 1992) (Sugimura et al., 1992) (Ashikaga et al., 1994).  Later on, it was 
also found that beyond the anti-tumour activity, ADI has an anti-angiogenic activity via 
suppression of nitric oxide generation (Beloussow et al., 2002, Park et al., 2003, Yoon 
et al., 2007). The cooperative anti-proliferative and anti-angiogenic activities of ADI are 
believe to be the key assets that turn ADI very effective in the treatment of several 
tumours and other diseases.  
ADI has been structurally and pharmacologically characterized from various 
bacteria, but the most studied enzyme is ADI from Mycoplasma arginini take into account 
its therapeutic potential (Zhang et al., 2015). ADI from M. arginini has 410 amino acids 
and is composed of two identical subunits with a molecular weight of 45 kDa each and 
has a isoelectric point of 4.7. Its Vmax value and Km value for ARG is estimated to be 
50 units/mg protein and 0.2 mM, respectively. It exerted maximal enzyme activity at pH 
6.0-7.5 and at 50 °C (Takaku et al., 1992). 
 
Figure 6 | New Cartoon representation of the co-crystalized structure of ADI homodimer structure with a tetrahedral 
reaction intermediate (PDB Code: 1S9R). Each subunit was represented with a different colour (blue and grey) and the 
reaction intermediate in ball and sticks and coloured by CPK. In the close-up of the active site the residues of the active 
site that are important for the catalytic process are represented in licorice as well as the reaction intermediate that should 
be formed after the first step of the mechanism. 
 
  A proposal for the catalytic mechanism of ADI from M. arginini was published by 
Das and co-workers in 2004 (Das et al., 2004). The crystallographic structures available 
on the protein databank show that the active site is deeply buried on the protein surface 
and the substrate binds with the guanidium group pointing towards two aspartates 
(ASP161 and ASP271). These interactions endorse a specific orientation of the 
substrate that becomes aligned with HIS296 and CYS398, two residues that play an 
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important role in the catalytic process . These structural features are represented in 
Figure 6 (PDB code 1S9R) (Das et al., 2004). The importance of the CYS398 in the 
catalytic reaction is well established since it has already been demonstrated trough 
structural studies, mutagenesis and thiol modifying agents (Das et al., 2004) (Smith et 
al., 1978, Lu et al., 2004) (Lu et al., 2006, Galkin et al., 2005). 
 
Figure 7 | Schematic representation of the ADI catalysis mechanism. Each blue circle represents a different reaction 
intermediate. The black arrows indicate the reaction steps and the red ones the reactions that occur in each step of the 
mechanism.  The important reaction intermediates are labelled with letters (a-d). 
 
In the first step of the mechanism there is a nucleophilic attack of CYS398 to 
carbon Cζ of the substrate. Simultaneously the proton from CYS398 migrates to nitrogen 
Nη2 of the substrate. At the same time, one proton from the same nitrogen migrates to 
HIS296  and the proton from HIS296 is transferred to GLU213. In the end of the first 
step, a tetrahedral intermediate (Figure 7a) is generated with carbon Cζ of the substrate 
covalent bonded to CYS398. 
In the second step of the catalytic mechanism occurs the formation of ammonia 
through the migration of one proton from HIS296 to Nη2 of the substrate. Simultaneously, 
one proton is transferred from GLU213 to HIS296. In the end of this reaction, the reaction 
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intermediate (Figure 7b) remains covalently bonded to CYS398 and one molecule of 
ammonia is released from the active site. 
The next steps of the mechanism (Figure 7: step 4-6) involve the release of the 
product of the reaction (L-Citrulline) and the enzymatic turnover. This requires three 
sequential steps and involves the reaction of one water molecule that is in close proximity 
to ASP271 and HIS296.  In the forth step of the catalytic mechanism occurs the 
nucleophilic attach of the water molecule to carbon Cζ of the reaction intermediate 
(Figure 7c). At the same time one proton from the water molecule is transferred to 
HIS296 and one proton migrates from HIS296 to GLU213. The reaction is endorsed by 
the close proximity of ASP161 that establishes two hydrogen bonds with the NH groups 
of the intermediate that turns carbon Cζ more electrophilic.  In the end of this reaction, 
another tetrahedral intermediate is generated (Figure 7d) still bonded to CYS398 but 
now with a hydroxyl group attached to carbon Cζ instead of an amino group that was 
found after step 1. Step 5 involves the cleavage of the covalent bond between CYS398 
and the substrate. This requires the proton transfer from hydroxyl group of the reaction 
intermediate to CYS398. Simultaneously, occurs the proton transfer from GLU213 to 
HIS296. In the end of this reaction, L-Citrulline is generated and it is ready to leave the 
active site. The final step of the reaction (Step 6) involves the enzymatic turnover that 
requires HIS398 to lose a proton to the solvent or any neighbor active site residue. 
In recent years there has been an increased interest in ADI as a potential 
antineoplastic therapy since various studies have demonstrated disturbances in both 
ARG synthesis and metabolism in malignant processes.  To date several types of cancer 
have already been shown to be sensitive to arginine deprivation via ADI, such as 
melanoma, lung cancer, renal cell carcinomas, and HCC (Liu et al., 2014).  These 
tumours do not express ASS and are therefore highly sensitive to ARG deprivation and 
optimal targets for ADI chemotherapies. In spite of the promising results, the application 
of these treatments presents some limitations. The therapeutic efficiency of ADI is limited 
to tumours that do not express ASS and/or have an inactivated L-Citrulline to ARG 
recycling pathway (Ensor et al., 2002, Qiu et al., 2014).  In addition, ADI has a short 
serum half-life and when used in prolonged treatments is highly immunogenic. In order 
to overcome some of these limitations a pegylated form of ADI was formulated, PEG(20)-
ADI (Molecular weight: 20 kDa), that serves to reduce the immunogenicity of the enzyme 
while greatly improving its pharmacokinetic half-life in serum (Ni et al., 2008, Feun and 
Savaraj, 2006, Feun et al., 2008). This enzyme revealed a similar efficiency in vitro 
assays with melanomas and HCC, comparing with native ADI, however, it shows a much 
more effectiveness in vivo assays (Ensor et al., 2002). Currently, the anti-tumour activity 
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of PEG(20)-ADI has been also observed in pancreatic (Bowles et al., 2008), prostate 
(Kim et al., 2009), small cell lung (Kelly et al., 2012), head, neck (Huang et al., 2012) and 
breast cancers (Qiu et al., 2014), lymphoma  (Delage et al., 2012, Huang et al., 2012), 
myxofibrosarcomas (Huang et al., 2013), melanoma (Feun et al., 2012) and glioblastoma 
(Syed et al., 2013, Qiu et al., 2014).  
The therapeutic efficacy of PEG(20)-ADI has been validated through phase I/II 
clinical trials in advanced HCC (Glazer et al., 2010, Izzo et al., 2004, Yang et al., 2010) 
and melanoma patients (Ascierto et al., 2005, Feun et al., 2012, Ott et al., 2013). 
Additionally, there are several ongoing phase I and/or II clinical trials using PEG20-ADI 
in patients with advanced non-Hodgkin's lymphoma, acute myeloid leukaemia, malignant 
pleural mesothelioma, prostate and non-small cell lung, advanced gastrointestinal, 
HER2 (Human Epidermal growth factor Receptor 2) negative metastatic breast, 
advanced pancreatic, and small cell lung cancers. 
PEG(20)-ADI has also been reported as a potentially better therapeutic agent for 
the treatment of leukaemia than ASNase, which has been used for the treatment of acute 
leukaemia for over 20 years.  ADI can inhibit the growth of cultured leukaemia cells at 
concentrations of 5–10 ng/ml, which are about 20–100 times lower than those of ASNase 
(Feun et al., 2008). In addition, in vivo studies showed that ADI treatment does not have 
serious side-effects such as anaphylactic shock, coagulopathies, and liver toxicity, which 
have been reported for ASNase (Vrooman et al., 2010).  
 
2.3. L-methionine  
L-methionine (MET) is a sulphur containing amino acid that plays many key roles 
in cells (Guedes et al., 2011) (Nozaki et al., 2005).  In every cell, MET is essential for 
protein synthesis and it is the precursor of  many compounds, such as Glutathione (a 
tripeptide that reduces reactive oxygen species, thereby protecting cells from oxidative 
stress),  polyamines spermine and spermidine (which are detrimental on nuclear and cell 
division) and S-adenosylmethionine (the major source of methyl groups in a myriad of 
biological and biochemical events) (Ho et al., 2011) (Cellarier et al., 2003a) (Thivat et al., 
2007, Davis and Uthus, 2004). One of the most relevant biological role of MET in the cell 
is DNA methylation, where it serves as precursor for S-adenosylmethionine synthesis.  
DNA methylation is a common epigenetic signalling tool that cells use to control gene 
expression and has been associated with a number of key processes including genomic 
imprinting, X-chromosome inactivation, repression of repetitive elements, and 
carcinogenesis (Geiman and Muegge, 2010) (Ramani et al., 2010).  
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In spite of its importance in cells, MET is a special essential amino acid as its 
long-term dietary deprivation is still compatible with life. This happens because unlike 
other essential amino acids that must be ingested, MET can be recycled by re-
methylation of homocysteine (de novo synthesis), either by L-methionine synthase 
(MetS) or in the liver by betaine-homocysteine methyltransferase (BHMT) (Cellarier et 
al., 2003a, Hoffman, 1984, Guo et al., 1993a).  In addition, MET can also be obtained by 
a salvage pathway in which MET is generated from 5′-methylthioadenosine towards 
Methylthioadenosine phosphorylase (MTAP). This is true for all normally functioning 
cells, however, numerous malignant cell lines, such as breast, lung, colon, kidney and 
bladder cancers, melanoma and glioblastoma (Breillout et al., 1990, Hoffman, 1985, 
Kokkinakis et al., 2001, Poirson-Bichat et al., 2000, Cellarier et al., 2003b) do not have 
a functional methionine cycle intact. As a result, they cannot synthesize MET and in the 
absence of an exogenous supply they experience growth inhibition or eventually they 
die.   
The mechanisms responsible for MET dependence in malignant cell lines are still 
not fully understood. Several studies have shown that MET dependent tumour cell lines 
presented relatively low amounts of L-methionine synthase or/and have deficient 
methionine synthase activity (Kenyon et al., 2002, Christa et al., 1986, Fiskerstrand et 
al., 1994). Other studies emphasized the importance of the inhibition of the salvage MET 
pathway in which MTAP  is a key enzyme and is also responsible for the production of 
polyamines which are critical for cell proliferation. Indeed, the loss of MTAP activity 
through gene deletion is a common feature in many kinds of human cancers including 
non-small cell lung cancer, glioma, T-cell acute leukaemia, bladder cancer, 
osteosarcoma and endometrial cancer (Nobori et al., 1993, Traweek et al., 1988, Subhi 
et al., 2003, Albers, 2009). In contrast, other studies suggest that MET dependence 
would result not from an enzymatic deficiency but rather on an increased requirement 
for this amino acid. In fact, MET requirements of tumour cells are higher than that of 
normal cells because of increased protein synthesis and DNA trans-methylation 
reactions. This promotes multiple biochemical reactions necessary for fast growth of 
tumour cells, and can change DNA expression. Indeed, in several tumours, a variety of 
growth inhibitory and pro-apoptotic genes are transcriptionally silenced as a result of 
DNA hyper-methylation (Zingg and Jones, 1997) (Baylin et al., 1998). 
The observation that some human tumours are MET dependent in vivo presents 
a therapeutic target for cancer growth control and has been studied in great detail in the 
last two decades (Hoshiya et al., 1995). As MET is sourced mainly from diet, initial 
studies observed that simple methionine dietary restriction caused regression of a variety 
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of animal tumours and inhibits metastasis in animal models (Breillout et al., 1987, 
Breillout et al., 1990, Guo et al., 1993b, Goseki et al., 1987, Millis et al., 1998).  Phase I 
clinical trials of dietary methionine restriction for adults with advanced cancer indicate 
that dietary methionine restriction is safe and provided promising results.  However, 
reduction of methionine levels in humans solely by dietary intervention presents several 
limitations as MET is practically ubiquitous for all food and the price of such diet is about 
US$ 1000 per month. 
A more attractive pharmacological approach to lowering MET levels in vitro and 
in vivo involves the use of MET degrading enzymes. L-methionine-α-amino-γ-
mercaptoethane lyase or methioninase (MGL, EC 4.4.1.11) is an enzyme that 
specifically degrades L-methionine to α-ketobutyrate, methanethiol and ammonia (Kreis 
and Hession, 1973) very efficiently.  In addition, it can also degrade L-homocysteine, a 
key factor that prevents endogenous MET production(Sato and Nozaki, 2009).  
MGL is found in bacterial species and in fungi, but it is absent in mammals. (Sharma et 
al., 2014). This enzyme was originally purified from Clostridium sporogene, but later on 
it was found that MGL from Pseudomonas putida (Pp-MGL) yielded a more stable 
enzyme with a relatively low Km (Esaki and Soda, 1987). Due to problems in purification 
of Pp-MGL, the MGL gene, isolated from P. putida, is now cloned and expressed in great 
quantities from Escherichia coli (r-Pp-MGL) (Hori et al., 1996).  
 
Figure 8 | New Cartoon representation of the co-crystalized structure of the MGL homotetramer structure with the PLP 
cofactor (PDB Code: 2O7C). Each subunit was represented with a different colour (red, green, blue, grey). In the close-
up of the active site it is shown the internal aldimine in ball and sticks, where PLP cofactor covalent bonded to an active 
site LYS. The other active site residues that are important for the catalytic process are represented in licorice. 
 
Pp-MGL has 389 to 441 amino acids, and it is found as a homotetramer with a 
molecular weight of about 149 to 173 kDa (Nakayama et al., 1984). The active site of 
this enzyme is located at the interface of the two neighbouring subunits, each one 
containing one Pyridoxal 5’-phosphate (PLP) cofactor that is required for the catalytic 
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process (Toney, 2005, Motoshima et al., 2000, Kudou et al., 2007a) (Mamaeva et al., 
2005). The cofactor is stabilized by six residues TYR59, ARG61, TYR114, CYS116, 
LYS240, and ASP241 that have been found to be important for catalysis (Figure 8) 
(Kudou et al., 2007a). 
 
Figure 9 | Schematic representation of the MGL catalysis mechanism. Each blue circle represents a different reaction 
intermediate. The black arrows indicate the reaction steps and the red ones the reactions that occur in each step of the 
mechanism.  The important reaction intermediates are labelled with letters (a-h). 
 
MGL is classified into the γ-family of PLP-dependent enzymes. However, it 
possesses a key cysteine (CYS116) in the active site that is not conserved in other PLP 
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γ-family enzymes. Mutagenic studies revealed that this active site CYS is essential for 
substrate speciﬁcity (Sato et al., 2008) (McKie et al., 1998) (Kudou et al., 2008, Kudou 
et al., 2007a) and also for enzymatic activity (Inoue et al., 2000, Kudou et al., 2008). 
The enzymatic mechanism of MGL is proposed based on the knowledge of other 
PLP γ-family enzymes and the enzymological analyses of P. putida wild-type and mutant 
forms (Fukumoto et al., 2012, Kudou et al., 2007a) (Cerqueira et al., 2011, Oliveira et 
al., 2011). Similar to all PLP-dependent enzymes, in the steady state the PLP cofactor 
is covalently bonded to an active site LYS forming what is generally known as an internal 
aldimine (Figure 9a). When MET is available in the active site of MGL it binds to PLP 
(Step 1) generating a geminal diamine (Figure 9b). Afterwards, the cleavage of the 
covalent bond between the PLP cofactor and the active site LYS211 takes place (Step 
2) and the substrate becomes covalent bonded to the PLP cofactor through the primary 
amino group forming an external aldimine (Figure 9c). The next step (Step 3) involves 
the abstraction of one proton from carbon Cα of the reaction intermediate by an active 
site base resulting in the formation of a quinonoide intermediate (Figure 9d). Later on, 
carbon 7 from PLP is protonated by an active site base (Step 4) from which results a 
ketamine intermediate (Figure 9e). An active site base then abstracts a second proton 
from carbon Cβ (Step 5) and an enamine intermediate is generated (Figure 9f) that 
triggers the γ-elimination (Step 6) and the generation of unprotonanted Methanethiol 
(Figure 9g). Methanethiol is subsequently protonated by the active site base and an 
Aminocrotonate intermediate is obtained (Figure 9h)  (Step 7). In the final step of the 
catalytic process (Step 8), a water molecule mediates the α-Ketobutyrate and Ammonia 
generation and the concomitant release of Methanethiol. At the same time, the 
enzymatic turnover takes place recovering the steady state of the enzyme, i.e., internal 
aldimine in which the active site LYS is covalent bonded to the PLP cofactor. (Inoue et 
al., 2000, Toney, 2005, Sato et al., 2008) (Kuznetsov et al., 2015). 
The therapeutic manipulation of r-Pp-MGL to deplete plasma MET has been 
widely investigated in the last two decades (Jeanblanc et al., 2005) with promissing 
results in a number of L-methionine-dependent cancer cell lines including lung, colon, 
kidney, brain and prostate cancers, melanoma and fibrosarcoma (Miki et al., 2000a) 
(Yamamoto et al., 2003) (Tan et al., 1999, Tan et al., 1997, Miki et al., 2000b, Miki et al., 
2001, Tan et al., 1996, Smiraglia et al., 2001). Preclinical studies in animal models have 
also demonstrated the potential of r-Pp-MGL to efficiently inhibited the growth of Yoshida 
sarcomas and a human lung tumour in nude mice xenograft models (Tan et al., 1996). 
Several studies have also shown promising results combining the chemotherapeutic 
effect of r-Pp-MGL with other compounds, such as, cisplatin, 5-fluorouracil (5-FU), 1-3-
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bis(2-chloroethyl)-1-nitrosourea (BCNU), cisplatin, and vincristine (Tan et al., 1999). 
These studies have shown synergic effects in mouse models of colon, lung and brain 
cancers and glioblastoma(Yoshioka et al., 1998, Hu and Cheung, 2009, Kokkinakis et 
al., 2001, Tan et al., 1999, Hoshiya et al., 1997). Other authors have also studied the 
administration of r-Pp-MGL with Selenomethionine (a nontoxic compound). These 
studies have shown that r-Pp-MGL catalyses the conversion of Selenomethionine into 
Methylselenol, and the later compound is able to oxidate thiol groups and generate toxic 
superoxide.  This compound is very toxic to cells and can cause apoptosis via a 
mitochondrial pathway (Guo et al., 1993a, Kim et al., 2007). As the in cancer cells the 
metabolism is faster than in normal cells this approach has the advantage of being target 
specific. 
In spite of the initial success of r-Pp-MGL for cancer therapy it presents some 
problems that precludes an easy manipulation, namely, the instability of r-Pp-MGL in 
plasma caused by immunogenicity, proteolysis, oxidation of the active site residues, 
release of PLP and the instability of the active dimer (Kudou et al., 2007b). Modification 
of this enzyme with polyethylene glycol (PEG) has reduced immunogenicity, lengthen 
the half-life of the recombinant enzyme, and possibly inhibited proteolytic enzymes that 
could degrade MGL (Tan et al., 1998). The intravenous administration of PEG-r-Pp-MGL 
was tested in phase I clinical trials. Patients in these trials experienced no significant 
toxicity, and plasma MET levels fell dramatically. However, the authors did not assess 
the anti-tumour activity of this treatment and to date no other clinical trials have been 
published (Sun et al., 2003a, Yang et al., 2004b, Yang et al., 2004c).  
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3. Conclusions 
A prerequisite for making an effective medication in the treatment of cancer is 
that some fundamental difference between normal cells and cancer cells must be 
defined. An optimal chemotherapeutic agent must thus exploit this cellular difference in 
such a way that normal cells are spared and only cancer cells are injured. In this context, 
the amino acid depriving enzymes are promising anti- cancer drugs that have proven to 
be active and very specific against various types of cancers. Their mode of action is 
simple:  they decrease the concentration of certain amino acids in the blood stream and 
thus impair the development or even destroy tumor cells that are autotrophic for those 
amino acids. Normal cells remain unaltered since they are less demanding and/or can 
synthesize these compounds in sufficient amounts by other mechanisms. 
ASNase is probably the best-known example of amino acid depletion 
chemotherapies using enzymes.  The application of this enzyme in the treatment of 
childhood acute lymphoblastic leukaemia has already been approved by FDA and shows 
very good results. ARG deprivation by ADI is a novel approach to target tumors that lack 
argininosuccinate synthetase (ASS) expression.  ADI showed promising results during 
initial clinical trials for the therapy of HCC and melanomas and has currently been 
granted by FDA and EMEA for the drug Orphan Drug status for the potential treatment 
of these diseases(Shen and Shen, 2006). Some studies also suggest that ADI  has 
potential to become a better therapeutic agent for the treatment of leukaemia than 
ASNase in the treatment of leukaemia(Gong et al., 2000, Muller and Boos, 1998). 
Currently, the major drawback of ADI and ASNase for therapeutic purposes is the 
heterologous origin. As these enzymes are derived from microorganism, they are 
immunogenic in humans and have very short circulating half-life. The chemotherapeutic 
treatments using these enzymes thus require multiple injections to produce the desired 
effect and from which results a variety of adverse effects including hypersensitivity 
reactions, anaphylactic shock, and the inactivation and clearance of the enzyme itself 
(Schellekens, 2002). In order to overcome these problems and allow a safer application 
in cancer treatments, these enzymes have been linked to PEG to improve the 
pharmacokinetic and pharmacodynamic properties.  The therapeutic results of these 
modified enzyme are much safer and have prompted the use of ADI in many clinical 
trials and the approval of ASNase  by FDA and EMEA for the treatment of some types 
of tumours. 
MGL is another heterologous enzyme discussed in this review. Similarly to 
ASNase and ADI, this enzyme presents several immunogenic effects, but contrarily to 
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those enzymes the pegylated form does not seem to overcome this problem. Several 
attempts were made to decrease the toxicity of this enzyme by the co-administration of 
pyridoxal 5-phosphate and oleic acid or dithiothreitol (Cantor et al., 2011) (Sun et al., 
2003b). However, several side effects persist and its utilization in cancer therapies 
continues to be inappropriate(Miki et al., 2001, Yang et al., 2004a). 
From the discussed enzymes, ARGase is the only enzyme that is from human 
origin. This means that it presents low immunogenicity, a great advantage over  ADI in 
the treatment of cancer that are autotrophic for ARG. Indeed, several authors consider 
ARGase a better chemotherapeutic agent for cancer treatment than ADI because apart 
from its low immunogenicity, this enzyme also is effective in tumours for which ADI is 
ineffective (although in these cases OCT cannot be expressed). Its major disadvantage 
when compared with ADI is its high Km and high optimum pH, which requires large 
quantities of enzyme in order to accomplish the expected therapeutic results.  Actually 
this problem may be overcome by the utilization of cobalt-substituted ARGase, but more 
studies are required to acquire its potential in cancer therapy. 
Despite the problems arising from the use of amino acid depleting enzymes in 
amino acid depriving chemotherapies, the recent progresses made in this field will 
undoubtedly facilitate the pursuit of new treatments to combat cancers. ASNase was the 
first enzyme approved by FDA and EMEA for the chemotherapeutic treatment of 
leukaemia with remarkable success. Taking into account the on-going clinical trials made 
with other enzymes such as, ARGase or ADI, and the promising results that are being 
obtained, one might expect that the clinical approval of these enzymes should not be too 
distant in the future and will have undoubtedly a profound influence on human health.  
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3. Conference presentations 
Oral Communication: 
Fernandes, H. S., Cerqueira, N. M. F. S. A., “Computational studies addressed to the 
catalytic mechanism of Histidine Decarboxylase”, IJUP’16 – 9º Encontro de Jovens 
Investigadores da Universidade do Porto, Fundação da Juventude – Palácio das Artes, 
2016 February 17th, Porto 
 
Poster Presentantion: 
Henrique S. Fernandes, Nuno M. F. S. A. Cerqueira, “Computational studies addressed 
to the catalytic mechanism of Histidine Decarboxylase” | Encontro De Jovens 
Investigadores Em Biologia Computacional Estrutural (EJIBCE) – Instituto Pedro Nunes, 
Coimbra – 2015, 18th December 
 
Fernandes, Henrique S., Ramos, Maria J., Cerqueira, Nuno M. F. S. A., “Computational 
studies addressed to the catalytic mechanism of Histidine Decarboxylase”, 5º Encontro 
Português de Jovens Químicos (PYCheM) and 1st European Young Chemists Meeting 
– Guimarães, 2016 April 23th 
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Supplementary Fig. 5 – Poster presented at the “Encontro De Jovens Investigadores Em Biologia 
Computacional Estrutural (EJIBCE)” – Instituto Pedro Nunes, Coimbra – 2015, 18th December 
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Supplementary Fig. 6 – Poster presented at “5º Encontro Português de Jovens Químicos (PYCheM) and 1st 
European Young Chemists Meeting” – Guimarães, 2016 April 23th 
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4. Non-academic work 
During this project, it was also developed an educational software called “Protein 
Wars”. This educational game was available during the “14ª Mostra da Universidade do 
Porto” from 17/03/2016 to 20/03/2016, and its main aim was to show the importance of 
chemistry and drug development to society in a ludic manner. 
“Protein Wars” was developed using the TCL language and it works as a VMD 
plugin. It was also built an arcade-like machine and configured the buttons in order to 
make it ready to work with “Protein Wars” and VMD.  
The game has several levels, and in each level, a protein is presented with a 
short explanation about it and how it is related with a specific disease. The main goal of 
each level is to target relevant regions of those proteins, which culminate into their 
destruction. The main objective was to show that several drugs that are commercially 
available aim the destruction of these enzymes, and this often involves the inactivation 
of their active sites.  
The project will continue to be developed and some improvements and new levels 
will be implemented in the future. 
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Supplementary Fig. 7 – Screenshots of the “Protein Wars” game and photography of the arcade machine 
construction. 
 
 
Supplementary Fig. 8 – “Protein Wars” game was available during the “14ª Mostra da Universidade do Porto 
2016”. 
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 Moreover, two additional scripts were developed. “ONIOM Analysis” (github.com 
/henriquefer/oniomANALYSIS) was developed to allow an easy manner to extract the 
structures from Gaussian output files to PDB or Gaussian input files. The script was 
developed using the TCL language, and it runs in the bash, requiring only the resulting 
.log file from QM/MM calculations using Gaussian09. Additionally, the script is able to 
extract the energies of each layer of the QM/MM model, considering all the structures or 
solely the optimized ones. 
 
 
Supplementary Fig. 9 – Screenshots of the “ONIOM Analysis” script. 
 
 
 A second script, called “ONIOM FROZEN” (github.com/henriquefer/oniom 
FROZEN) was also developed to handle with the freezing state of the atoms in any 
Gaussian input file. The script allows the inversion of the freezing status of each atom, 
unfreezing all atoms of the model, freeze all atoms of the model or freezing the atoms of 
the residues that were selected by the user (and need to be provided in second file). 
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Supplementary Fig. 10 – Screenshot of the “ONIOM Frozen” script. 
 
 
